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Abstract 
The nucleocapsid of Hepatitis B Virus is an icosahedral structure composed of 180 
subunits of the viral Core Antigen (HBcAg). This protein is 183 amino acids in size 
and has a highly arginine-rich carboxy-terminal region. It can be expressed at high 
levels in E. coli, in which it forms nucleocapsid-like core particles which are 
morphologically indistinguishable from nucleocapsids isolated from infected 
individuals. The latter property was utilised in this work, the aim of which was to 
investigate the role of particular amino acids of HBcAg in the determination of the 
structure of the protein monomer and that of the core particle. 
Previous work (Stahl et al., 1982) had suggested the importance of the amino-terminal 
region of the protein in the determination of its structure. This was investigated further 
in this work by the use of site-directed mutagenesis to create a series of deletion and 
substitution mutations within this region. These were expressed in E. coli and the 
importance of amino acid 3 was demonstrated by immunological assay. 
HBcAg contains four cysteines, all of which are completely conserved among 
mammalian hepadnaviruses. The role of these cysteines in HBcAg and core particle 
structure determination and stability was investigated by the use of site-directed 
mutagenesis to create a series of mutants in which cysteine codons were replaced by 
serine codons in several combinations, and in the context of both the full-length 
protein and of a truncated protein lacking the arginine-rich carboxy- terminal region. 
These proteins were produced in E. coli and formed particles indistinguishable from 
wild-type particles in structure, even when no cysteines were present. Their behaviour 
during non-reducing SIDS-polyacrylamide gel electrophoresis indicated the presence 
of different disulphide bond complements in different mutants and allowed a model 
to be deduced for the arrangement of disulphide bonds within the core particle. In 
addition, the stability of the mutant core particles was found to depend on the number 
and nature of the cysteines present. 
Finally, the role of the carboxy-terminal region of the core protein in terms of the 
determination of disulphide bond formation involving the remainder of the protein was 
investigated by the use of a series of proteins with the same amino-terminus but 
different carboxy-terminal regions. Non-reducing SDS-polyacrylamide gel 
electrophoresis of this series of proteins demonstrated a dependence of disulphide 
bond formation on the nature of the carboxy-terminal region of the protein. 
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CHAPTER 1: Introduction 
1.1 Hepatitis B Disease 
Hepatitis B is a health problem of major global importance, with an estimated 5010 of 
the world's population infected with the causative agent, Hepatitis B virus (HBV). The 
geographical distribution of HBV is uneven, with very low rates of infection in Europe 
(0.1-0.5%) and high rates (up to 15%) in parts of Africa and Asia. Methods of 
transmission vary correspondingly, in the West most often via injection of blood or 
blood-derived products, or by sexual contact, while in the East perinatal transmission 
is most common. 
Hepatitis B virus is not itself cytolytic and the hepatitis resulting from infection is due 
to the host immune response to that infection, which varies from one individual to 
another, thereby resulting in the many different manifestations of hepatitis B. "Acute" 
hepatitis is the most common response and is characterised by diffuse inflammation 
of the liver. In most cases HBV antigens are difficult to detect in the liver, reflecting 
the active elimination of infected cells by the host immune response and subsequent 
resolution of the infection. However, in more severe acute cases, HBV antigens can 
be detected in a high percentage of hepatocytes. This indicates an inability to eliminate 
HBV-infected cells and in such cases there is a high propensity to progress to 
"chronic" hepatitis. This disease state occurs in 5-10% of infected individuals and is 
diagnosed when inflammation of the liver has persisted without improvement for 6 
months. It can be divided into 2 further classes - "chronic active hepatitis" (CAH) and 
"chronic persistent hepatitis" (CPH). CAR is characterised by significant parenchymal 
damage and a higher number of hepatocytes containing Hepatitis B Core antigen 
(HBcAg) than Hepatitis B Surface antigen (HBsAg), while in CPH inflammatory 
infiltrates are present but there is minimal cell damage and the proportions of HBcAg 
and HBsAg are approximately reversed compared to CAR. 
Various markers of infection can be detected in serum during HBV infection and this 
also reflects the difference in host immune response in the acute and chronic disease 
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states, as shown in Figure 1.1. Detection of such markers in routine blood bank 
screening and general population screening has revealed a large number of chronically 
infected individuals without hepatitis B symptoms or signs of chronic liver disease 
who are thus termed "healthy" or "chronic carriers" and it has been estimated that as 
many as 50% of chronically-infected persons may be such healthy carriers. The host 
response to chronic liver injury results in cirrhosis of the liver which is associated 
with bands of fibrosis throughout the liver, which are, in turn, associated with nodules 
of parenchymal tissue. Necrosis of the hepatocytes stimulates liver regeneration, but 
lack of tight control of cell proliferation means that cell division continues beyond the 
level of replacement and, in the case of HBV infection, large hyperplastic nodules 
form. A combination of fibrosis and nodule formation can lead to both rupture of 
veins in the liver, causing massive haemorrhaging, and reduced access of oxygen and 
nutrients within the liver, resulting in hepatocyte dysfunction and subsequent liver 
failure. Distribution of HBV antigens within cirrhotic livers is heterogeneous, probably 
reflecting the different stages of maturation of individual nodules. 
Finally, a strong association between HBV and primary hepatocellular carcinoma has 
been noted. Approximately 80% of primary hepatocellular carcinomas (pHCCs) in the 
world are associated with chronic HBV infection (W.H.O., 1983), and carriers of HBV 
are at least 100 times more likely to develop pHCC than non-carriers (Beasley et al., 
1981). In addition, pHCC has been demonstrated to develop in woodchucks, ground 
squirrels and ducks infected with the appropriate hepadnavirus, and hepadnavirus DNA 
has been found to be integrated into host DNA in a very large number of individuals 
with pHCC. However, such integration appears to be non-uniform and no region of 
the HBVgenome or the host genome is consistently involved in integration events. 
The recent discoveries that the HBV-encoded proteins HBxAg and a truncated preS/S 
protein can act as transcriptional transactivators (Section 1.3.4) has led to the 
proposition that these proteins may be involved in tumorigenesis if expressed from 
integrated HBV DNA. In particular, it has been demonstrated recently that HBxAg 
acts by a mechanism involving an increase in the levels of protein kinase C in the cell 
(Kekule et al., 1993). It is known that over-production of protein kinase C results in 
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Figure 1.1 
The appearance of HBV antigens, and antibodies to them, in serum during acute and 
chronic infection. The variable nature of the appearance of these markers is indicated 





















0 	4 	8 
time (years) 
disordered growth of mammalian cells and so the predicted oncogenicity of HBxAg 
may be mediated in this manner. A further important factor common to chronically-
infected individuals is damage to the liver, which stimulates regeneration of liver cells. 
Such a rapidly-growing population of liver cells will provide greater opportunities for 
alterations to cells which may lead to tumorigenesis. 
1.2 Virion and Genome Structure 
The initial report of the association of the so-called "Australia" antigen with Hepatitis 
B (Blumberg et al., 1965) was followed by the observation under the electron 
microscope that this antigen was present in serum in the form of 20-25nm virus-like 
particles (Bayer et al., 1968; Gerin et al., 1969). However, it was subsequently 
discovered (Dane et al., 1970) that such particles, while by far the most abundant of 
virus-derived particles present during infection, are not the actual virions. The latter 
are 42nm in diameter and have a "double-shelled" appearance under the electron 
microscope. That this 42nm particle is in fact the infectious agent of Hepatitis B was 
shown by Robinson and Luttwick (1976). 
Hepatitis B virus is now regarded as the prototype member of the hepadnavirus (for 
"hepatic" and "DNA') family which also includes viruses isolated from the Eastern 
Woodchuck (Summers et al., 1978), the Beechey Ground Squirrel (Marion et al., 
1980), the Pekin Duck (Mason et al., 1980) and most recently the Grey Heron 
(Sprengel et al., 1988). These viruses have been named, respectively, Woodchuck 
Hepatitis Virus (WHy), Ground Squirrel Hepatitis Virus (GSHV), Duck Hepatitis B 
Virus (DHBV) and Heron Hepatitis B Virus (HHBV), and are grouped together on the 
basis of their hepatotropism, similar virion morphology and common genome size, 
structure, and replication strategy. Hepadnaviruses also show a very narrow host range 
and the human virus, for example, infects only humans and a few higher primates, of 
which the chimpanzee is the best known example. 
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The structure of the HBV virion is represented in Figure 1.2A. The envelope consists 
of host-derived lipid interspersed with HBsAg molecules. This envelope surrounds the 
virus nucleocapsid, an icosahedral structure of 27nm diameter composed of subunits 
of HBcAg, and inside this are contained the viral polymerase, the viral genome and 
the genome-linked protein. Titres of Dane particles vary between infected individuals 
from iU - 106  particles/ml. However, far in excess of this are the subviral HBsAg 
particles viewed initially by Bayer et al. (1968) and Gerin et al. (1969). These are 
essentially "empty envelopes", consisting only of lipid and HBsAg, but with a HBsAg 
composition different from that of Dane particle envelopes (Section 1.4.1), and are 
found in 2 forms - 22nm diameter spheres and filaments of the same diameter and 
variable length. (Figure 1.2b). The biological function of these non-infectious particles 
is unclear, but they may act as "decoys" by attracting neutralising antibodies. Indeed, 
acutely-infected patients often have arthritis due to to deposition of subviral 
particle/antibody complexes in their joints (Gocke, 1975). 
The circular nature of the genome of HBV was determined by electron microscopic 
examination by Robinson et al. (1974) and Overby et al. (1975) and its characteristic 
and unusual partially double-stranded nature was deduced by Summers et al. (1975) 
and is shown in Figure 1.3. The long strand serves as the template for viral 
transcription and is thus termed the minus strand. In the HBV isolate used in this work 
it is 3190 bases in length (Burrell et al., 1979; Pasek et al., 1979; Pugh et al., 1986). 
The single-stranded gap varies from 20-80% of unit length and the 5' end of the short 
strand is fixed while the 3' end is variable. The long strand is not covalently-c lose d 
and is terminally redundant. The circular nature of the genome is maintained as the 
5' end of the short strand is approximately 300 nucleotides downstream of the 5' end 
of the long strand. Annealing of the long and short strands creates a tail from the 8bp 
overlap to which a protein is covalently attached (Gerlich and Robinson, 1980). The 
5' end of the short strand is also unusual in its covalent attachment to a short capped 
oligoribonucleotide, first demonstrated for DHBV (Lien et al., 1986), and determined 
to be approximately 17 bases in length. 
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Figure 1.2 
Structure of the HBV virion. 
The viral envelope consists of surface antigen (S protein S , M protein 	, and L 
protein 	) embedded in a lipid bilayer. This surrounds the nucleocapsid 
composed of Core antigen, which in turn surrounds the viral genome, polymeraseRM  
and genorne-linked proteins 
Structure of subviral spheres and filaments. These are similar to empty viral 
envelopes, but have a smaller diameter and different surface antigen composition. 
Filaments have the same diameter as spheres, and are of variable length. 
2 2n 
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Figure 1.3 
Structure of the partially double-stranded DNA genome of HBV. 
represents the genome-linked protein attached to the terminus of the redundant portion of 
the (-) strand. 
represents the capped oligoribonucleotide attached to the 5' terminus of the (+) strand. 
DR = Direct Repeat. 

Within the genome are two llbp directly repeated sequences, termed DR1 and DR2 
which are located close to the 3' end of the minus strand and the 5' end of the plus 
strand, respectively. These direct repeats, together with the genome-linked protein and 
the covalently-attached oligoribonucleotide are important for replication of the viral 
genome and will be discussed in section 1.5. 
1.3 Genome Organisation and Viral Transcription 
At 3.2kb the genome of HBV is one of the smallest DNA virus genomes known. 
Indeed, it was initially suggested (Overby et al., 1975) that a helper virus may be 
required to programme the life cycle of the virus. However, the cloning in E. coli, and 
subsequent sequencing, of the genomes of several HBV isolates (Galibert et al., 1979; 
Pasek et al., 1979; Valenzuela et al., 1980; Fujiyama et al., 1983; Ono et al., 1983; 
Kobayashi and Koike, 1984; Okamoto et al., 1986) has revealed a very full use of the 
entire genome, with extensively overlapping coding sequences, thus allowing infection 
to proceed without the aid of a helper virus. 
The HBV genome was found to contain four major open reading frames (ORFs) in the 
minus strand, termed S, C, P and X, utilising all three translational frames. No 
conserved open reading frames of significant length are present in the plus strand. 
However, as there are at least seven viral gene products, the transcriptional strategy 
is complex, with several transcriptional control regions, which are also themselves 
transcribed during active infection, and necessarily within a short distance of each 
other. The organisation of the HBV genome is shown in Figure 1.4, which 
demonstrates the multiple capacity of the majority of nucleotide sequences in the 
genome. In this thesis, the numbering system used for HBV DNA is that of Pasek et 
al. (1979), whereby nucleotide number 1 is the first nucleotide of the coding sequence 
of HBcAg. 
Figure 1.4 
HBV genes and transcripts. 
The genome is represented in a linear manner and nucleotide positions of the 
beginning and end of each open reading frame are shown. 
spl = preSi promoter 
spIT = pres2/s promoter 
enh/Xp = enhancer/X promoter 
Cp = core promoter 
= HBV polyadenylation signal at nucleotide position 16. 
Viral transcripts are represented by dashed lines and the transcription initiation sites 
by vertical lines. 
(From Rossner, 1991) 
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Initial studies of transcription of HBV genes were hampered by the lack of a cell 
culture system for propagation of HBV. Therefore the earlier studies involved 
examination of transcripts from a cell line derived from a human hepatoma 
(Chakraborty et al., 1980; Edman et al., 1980), rodent cells transformed with multiple 
copies of the HBV genome (Pourcel et al., 1982; Gough and Murray, 1982) and the 
livers of chimpanzees infected with HBV (Cattaneo et al., 1983; 1984). More recently, 
however, cell lines derived from human hepatomas that do not have integrated HBV 
DNA, such as HepG2 (Aden et al., 1979) and HuH7 (Nakabayashi et al., 1982) have 
been found, after transfection with HBV DNA, to support HBV replication (Sureau 
et al., 1986; Sells et al., 1987; Yaginuma et al., 1987) and to produce infectious 
virions (Acs et al., 1987; Sureau et al., 1988). Primary duck hepatocytes have also 
been cultured and shown to be permissive for DHBV infection (Tuttleman et al., 
1986b). However, the cells remain in a differentiated state for only a short time, thus 
limiting the experiments that can be performed. 
The HBV genome contains only one polyadenylation signal and therefore all 
messenger RNAs (mRNAs) terminate at the same position. The RNA species produced 
by HBV can be divided into two classes - genomic and sub-genomic transcripts. As 
the genome replicates via reverse transcription of an RNA intermediate (Section 1.5), 
genomic RNAs serve the dual role of template for (i) translation to produce viral 
polypeptides, and (ii) reverse transcription to produce genomic DNA. In contrast, sub-
genomic transcripts act only as templates for translation. 
1.3.1 Genomic Transcriits 
These RNAs are approximately 3.3kb in length and are therefore terminally redundant. 
Their synthesis is under control of the C (or genomic) promoter which directs 
transcription of two subsets of genomic transcripts (Figure 1.4). The larger of these 
initiates upstream of the pre-core start site and therefore encodes the precore/core 
polypeptide precursor of HBeAg. The more abundant transcript initiates at nucleotide 
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position 3001+/-2 (Will et al., 1987), immediately downstream of the precore start 
site, and therefore cannot encode the pre-core region. This mRNA encodes the core 
and polymerase proteins of the virus (Ou et al., 1990). As these genes overlap by 
142bp it was initially suggested that the polymerase may be produced by processing 
of a core/pol fusion protein resulting from ribosomal frameshifting during translation 
of this mRNA, in a manner analagous to retroviruses. However, it has subsequently 
been shown that translation of the polymerase sequences in DHBV begins at the first 
internal AUG in the polymerase gene (Chang et al., 1989b; Schlicht et al., 1989b; 
Kawamoto et al., 1990) and this has also been demonstrated to occur in HBV (Jean-
Jean et al., 1989c; Kawamoto et al., 1990; Roychoudhury and Shih, 1990). In addition 
to its protein coding capacity, this mRNA is also indispensable for viral replication 
since it is the template for reverse transcription to produce the viral DNA genome 
(Will et al., 1987). This will be discussed in further detail in section 1.5. 
1.3.2 Sub-genomic Transcripts 
Immediately upstream of the S gene are two regions termed preSi and preS2 (Figure 
1.4). Translation of these regions results in three surface proteins: S, preS2/S and 
preSl/preS2/S. These are not produced by post-translational processing of the latter, 
but by differential transcription of the preS and S ORFs. There are two classes of 
surface mRNAs - those of approximately 2.4kb in length, and those of approximately 
2.1kb. The former initiate approximately 45bp upstream of the first initiation codon 
of the preSl ORF and therefore include coding capacity for preS1/preS2/S (Laub et 
al., 1983; Rail et al., 1983; Ou and Rutter, 1985). However, this is a minor surface 
mRNA class, comprising only an estimated 2% of total surface mRNAs (Ou and 
Rutter, 1985). 
The more abundant transcripts are approximately 2.1kb in length. These have 
heterogeneous initiation sites within the preS region (Cattaneo etal., 1983; 1984; Laub 
et al., 1983; Yaginuma et al., 1987), clustered around the AUG codon of preS2 (Ou 
P. 
and Rutter, 1985). Transcripts initiating upstream of the preS2 AUG can encode the 
preS2/S protein, while those initiating downstream encode S only. These transcripts 
are produced in approximately equal amounts (Ou and Rutter, 1985; Yaginuma et al., 
1987), but the predominant form of surface antigen produced in infected hepatocytes 
is S, suggesting inefficient translation initiation at the preS2 AUG. This has been 
found to be the case when this mRNA was injected into Xenopus oocytes (Standring 
et al., 1986) or expressed in mammalian cells under control of a heterologous 
promoter (McLachlan et al., 1987; Ou and Rutter, 1987; Molnar-Kimber et al., 1988). 
An additional set of transcripts of approximately 1kb in length has been mapped to 
the X gene of HBV, both in mammalian cells transfected with the complete HBV 
genome (Gough, 1983; Zelent et al., 1987; Koike et al., 1989), or with a fragment of 
the HBV genome containing the surface and X ORFs (Simonsen and Levinson, 1983; 
Saito et al., 1986; Siddiqui et al., 1986; Bulla and Siddiqui, 1988, 1989). The X 
polypeptide is proposed to be produced in vivo by translation of this 1kb mRNA and 
not by initiation of translation at an internal site in any other HBV mRNA. There is 
one report of an X-specific RNA detected in vivo, but the RNA in this case was 
0.65kb and postulated to be the X mRNA lacking its polyA tail (Kaneko and Miller, 
1988). 
All of the above mRNAs are non-spliced and for many years it was thought that this 
was true for all HBV transcripts. Recently, however, there have been several reports 
of a singly-spliced transcript of approximately 2.2kb (Su et al., 1989; Suzuki et al., 
1989; Terre et al., 1991; Wu et al., 1991) and a doubly-spliced transcript of 
approximately 2.6kb (Chen et al., 1989; Suzuki et al., 1990; Terre et al., 1991; Wu 
et al., 1991), which share the 5' and 3' extremities of the genomic transcripts and have 
been detected in HBV DNA-transfected HepG2 cells and in HBV-infected liver. Such 
spliced transcripts are not essential for viral replication but it has been reported (Terre 
et al., 1991) that these transcripts are packaged into viral nucleocapsids and reverse 
transcribed in vivo, contributing to the population of defective viruses often found in 
chronically-infected individuals. However, the importance and biological function of 
these transcripts remains unclear. 
1.3.3 Regulation of Transcription 
Cis-acting elements 
Four promoter elements have been functionally determined to be present within the 
HBV genome. Functional core/genomic promoter elements have been found to be 
contained in the region 2975-3100 and no TATA or CAAT box homology is found 
within this region. (Honigwachs et al., 1989; Yaginuma and Koike, 1989). However, 
approximately 25 nucleotides upstream of the initiation site of preS1/preS2/S mRNA 
is a TATA-like sequence: 876-TATATAA-882 (Rall et al., 1983) which corresponds 
to the position of such an element in most eukaryotic promoters. The minimal 
preS1/preS2/S promoter element was determined to contain this element and to lie 
between positions -90 and +35, relative to the transcription initiation site. (Raney et 
al., 1990). 
As in the case of the core/genomic promoter, sequences upstream of the start sites of 
the preS2/S mRNAs have no TATA or CAAT-like sequences. However, sequences 
upstream of these start sites do have homology to another eukaryotic TATA-less 
promoter - the SV40 late promoter (Brady et al., 1982), at a similar position relative 
to initiation of transcription (Cattaneo et al., 1983). Subsequent reports (Raney et al., 
1989; DeMedina et al., 1988) suggest, however, that this region of homology is not 
essential for promoter activity and that upstream and downstream sequences may also 
be important. The fourth promoter element of the HBV genome lies upstream of the 
X gene and directs transcription of its 1kb mRNA. It has been identified to lie within 
200 nucleotides 5' to the X ORF and can direct transcription of a heterologous 
reporter gene (Siddiqui et al., 1987; Treinin and Laub, 1987; Wollersheim et al., 
1988). This region also contains the viral enhancer, removal of which drastically 
reduces X promoter activity. The viral enhancer can therefore be thought of as an 
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integral part of the X promoter. 
Two enhancer elements have been identified within the HBV genome - the first is that 
described above, within the X promoter region, and is termed Enhancer I (Shaul et al., 
1985). Transcription from all HBV promoters has been shown to be increased in the 
presence of this enhancer element and its deletion from HBV genomic DNA resulted 
in reduced initiation of transcription from all HBV promoters in transiently transfected 
cells (Hu and Siddiqui, 1991). A second region, termed Enhancer II, was described 
by Yee (1989) as encompassing nucleotides 2966-3056. This 88bp fragment, located 
upstream of the C gene, has subsequently been shown to enhance transcription from 
the core, preS and S promoters of HBV (Su and Yee, 1992). 
Negative regulation by cis elements within the HBV genome has also been observed. 
The preSi promoter was shown to be negatively regulated by DNA sequences 
containing the downstream preS2 promoter region (Bulla and Siddiqui, 1989). This 
repression was demonstrated to be at the level of transcription and not to be effected 
by preS2IS or S proteins. This may also contribute to the relative paucity of preSi 
transcripts. 
Finally, all hepadnaviral RNAS terminate at the same position, approximately 20 
nucleotides downstream of the conserved sequence 16-TATAAA-21 (Cattaneo et al., 
1983; 1984; Simonsen and Levinson, 1983), which is very similar to the 
polyadenylation signal AATAAA found in eukaryotes (Proudfoot and Brownlee, 
1976). However, this sequence alone has been shown to be insufficient for efficient 
mRNA processing and that approximately 30 nucleotides of downstream sequence are 
also required (Simonsen and Levinson, 1983). In order to produce the greater-than-
genome-length transcripts required for genome replication and precore/core, HBcAg 
and viral polymerase production; the polyadenylation signal must be ignored on first 
passage, but it must be recognised and used on the second encounter. This is thought 
to be effected by the one nucleotide difference between the HBV polyadenylation 
signal and the consensus signal, and by the participation of multiple upstream 
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elements. As only one of the major upstream elements is present between the initiation 
site of pregenomic RNA and the processing site, this was thought to explain why the 
processing signal is used so inefficiently (Russnak and Ganem, 1990; Russnak, 1991). 
However, a recent report (Cherrington et al., 1992) demonstrates that this element 
alone is sufficient for polyadenylation and that it is rather the short distance from the 
cap site of pregenomic mRNA to the UAUAAA sequence that causes bypass of the 
5' poly(A) site, as this supression can be relieved by increasing the distance to 230- 
400 nucleotides. 
1.3.4 Transcription regulation by viral gene products 
The X gene product of HBV has recently been shown to act as a transcriptional 
transactivator of many viral and cellular promoters. Most importantly for the viral life 
cycle, HBxAg has been shown to regulate transcription from the HBV core 
promoter/enhancers, the HBV preSl promoter/enhancers and the X promoter/enhancer. 
(For a recent comprehensive review see Rossner, 1992). In addition, human hepatoma-
derived cells tranfected with an HBV genome mutant in HBxAg had reduced levels 
of viral transcription (Coigrove et al., 1989; Koike et al., 1989). Therefore the X 
antigen is proposed to be involved in HBV transcriptional regulation in vivo. A second 
class of HBV-derived transcriptional transactivator has recently been identified. 
(Kekule et al., 1990; Caselmann et al., 1990). 3' truncated preS2/S sequences were 
found to stimulate in trans the SV40 promoter attached to the CAT reporter gene. 
Such transactivation was not seen with intact preS2/S sequences. As these sequences 
were initially identified as being the integrated HBV DNA sequences in a human 
hepatoma-derived cell line, it has been proposed that this truncated protein may be 
involved in the development of primary hepatocellular carcinoma. However, as such 
a truncated protein has not been detected during normal HBV infection, it is unlikely 
to have a role in the transcriptional transactivation of HBV promoters in the normal 
life cycle of the virus. 
Finally, negative regulation of a cellular gene (human 3-interferon) by HBV has been 
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reported (Twu and Schloemer, 1989) and it has been proposed that this function is 
performed by the C gene product, HBcAg (Whitten et al., 1991). A regulatory 
function for this protein is also suggested by the presence in the HBcAg sequence of 
a nuclear targetting signal (Ou et al., 1989). However, this observation has been 
limited to the [3-interferon gene and there is no evidence that such negative regulation 
is relevant to the HBV life cycle, although it may affect virus/cell interactions. 
1.3.5 Tissue-specificity 
While hepadnaviruses are largely liver-specific with regard to infection, non-
hepatocytes have been found to support hepadnavirus replication both in cultured cells 
(Korba et al., 1988; Galun et al., 1992), infected individuals (Blum et al., 1983; Korba 
et al., 1989; Ogston et al., 1989) and HBV-transgenic mice (Perfumo et al., 1992). It 
has also been noted that the pattern of extra-hepatic infection in chronically- and 
acutely-infected woodchucks is different (Korba et al., 1989) but it is not known 
whether this is a cause or a symptom of the different pathologies. The mechanism of 
this relative hepatotropism is unclear, but association between viral transcriptional 
control elements and liver-specific factors is thought to be likely and several candidate 
elements and factors have been identified. 
While the preS2/S promoter is not stringently liver-specific and can be utilised in 
mouse L cells (Pourcel et al., 1982), its expression has been found to be higher in the 
liver and kidney of HBV transgenic mice (DeLoia et al., 1989). In contrast, the preSi 
promoter is highly liver-specific, and has been found to express 5-90 times more 
efficiently in differentiated hepatoma-derived liver cell lines than in either de-
differentiated liver cells or non-liver cells (Raney et al., 1990). In addition, it has been 
shown that a liver-specific factor (HNF-1) binds to a HNF-1 binding site within the 
preSi promoter (Chang et al., 1989a) and that this factor is also responsible for the 
differentiation-specific expression from this promoter. The core/genomic promoter is 
also expressed to a greater extent in differentiated hepatoma- derived cells (Raney et 
al., 1990) and this partial tissue-specificity has been shown to become almost 
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complete when the core promoter and enhancer I are present together (Honigwachs 
et al., 1989). A specific factor found in hepatoma-derived cells has been demonstrated 
to interact with an essential element within the core promoter (Yaginuma and Koike, 
1989; Karpen et al., 1988) while such a factor is not present in the non-hepatic HeLa 
or NIH 3T3 cells. However, negative regulation by factors present in non-liver cells 
may also be involved. Guo et al. (1993) found that the transcriptionn factor HNF-4, 
which is enriched in hepatocytes, stimulated transcription of a core promoter 
containing a HNF-4 binding site by approximately 20-fold but that the presence of 
sequences upstream of the HNF-4 binding site in the core promoter prevented 
stimulation of transcription by HNF-4 in HeLa cells, but not in hepatoma-derived 
HuH7 cells. 
The enhancer elements of HBV have been studied extensively with regard to tissue-
specificity and while Vannice and Levinson (1988) found no cell-type specificity of 
enhancer I this has been disputed by several other reports. Although enhancer I is 
functional in non-liver cells, expression is dramatically increased in liver-derived cells 
(Karpen et al., 1988, Antonucci and Rutter, 1989; Honigwachs et al., 1989; Huan et 
al., 1992). Protein-binding sites within this enhancer were identified by Karpen et al. 
(1988) and it has recently been shown that within the enhancer I is a retinoid X 
response element, to which RxR binds (Huan et al., 1992). This factor is highly 
enriched in liver but is still present in other cell types, possibly providing an 
explanation for the "leaky cell type-specificity of this element. In contrast, enhancer 
II is stringently liver-specific and possibly differentiation stage-specific (Yee, 1989; 
Su and Yee, 1992). These specificities have recently been confirmed by Tay et al. 
(1992), who have also identified an apparently liver-specific protein (E213P), which 
can transactivate enhancer II both in liver-derived cell lines, and in non-hepatic cell 
lines when both enhancer II and E2BP are transiently transfected. However, maximal 
stimulation is not seen with E213P alone and two as yet unknown proteins found to 
bind to enhancer II in addition to E2BP may be required for optimal enhancer effect. 
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1.4 Viral Polypeptides 
1.4.1 Surface Antigens 
As described above, the surface antigen of HBV was originally termed the Australia 
antigen and was first found in the context of subviral particles, the overproduction of 
which is a hallmark of HBV infection. It was subsequently also found to be present 
on the surface of HBV virions (Dane et al., 1970) and therefore was termed "surface 
antigen". 
Examination of the S ORF reveals three in-frame translation initiation codons, all of 
which are utilised during natural infection to produce three polypeptides. The largest 
of these is termed the L protein, which initiates at the first AUG and thus consists of 
regions preSi, preS2 and S (Heerman et al., 1984). It exists in both unglycosylated 
(p39) and glycosylated (gp42) forms and is also acylated at its amino terminal glycine 
residue with myristic acid (Persing et al., 1987). It is the least abundant of the three 
forms of surface antigen and preSi-containing proteins represent only 10-20% of the 
surface proteins in HBV virions and subviral filaments, and only 1-2% of the surface 
proteins in the 20nm diameter spherical subviral particles. 
The middle surface antigen, the M protein, initiates at the second AUG and therefore 
consists of the preS2 and S regions. It also exists in two forms. Gp33 is glycosylated 
only at amino acid 4 of the preS2 domain while gp36 is additionally glycosylated 
within the S domain (Stibbe and Gerlich, 1983). The proportion of preS2/S proteins 
is similar in all three particulate forms and is estimated to be approximately 10% 
(Heermann et al., 1984). 
The smallest surface antigen, the S protein, initiates at the third AUG and therefore 
contains no preS sequences. It is the most abundant form of HBsAg in the circulation 
of infected individuals and is present in both un-glycosylated (p24.) and glycosylated 
(gp27) forms. The S protein is estimated to constitute approximately 70% of the 
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HBsAg present in Dane particles and subviral filaments (Ganem, 1991), and an even 
higher proportion in 20nm subviral spheres (Heermann et al., 1984). Indeed, cells 
expressing only the S protein have been found to be capable of producing 20nm 
particles of apparently normal morphology (Liu et al., 1982; Laub et al., 1983), thus 
indicating that all the necessary information for 20nm particle formation lies within 
the S domain. This is not the case for virion formation, however, for which both the 
L protein and the S protein appear to be necessary (Bruss and Ganem, 1991; Ueda et 
al., 1991). The role of the M protein in virion assembly is currently unclear. Ueda et 
al. (1991) detected no Dane particle formation in the absence of the M protein, while 
Bruss and Ganem (1991) found the M protein to be unnecessary for virion formation, 
and, in addition, replacement of the majority of the preS2 domain with foreign 
sequence did not prevent incorporation into the virion envelope. The non-essential 
nature of the M protein is also suggested by reports of the frequent occurrence in 
chronically-infected patients of a dominant virus population whose genomes cannot 
encode preS2-containing proteins (Fernholz et al., 1991; Santantonio et al., 1992). 
The high proportion of cysteine residues within the HBsAg sequence (14 per 226 
amino acid monomer) suggests the possibility of both intra- and inter-molecular 
disulphide bonds. The presence of inter-molecular disulphide bonds was confirmed by 
Mishiro et al. (1980) who demonstrated that the spherical subviral particles contain 
a polypeptide of approximately 49kD. This polypeptide exhibited all antigenic 
determinants of subviral particles, and in the presence of 3-mercaptoethano1 was 
cleaved into two polypeptides of 22kD and 27kD respectively. This would suggest that 
the predominant structural unit of surface antigen consists of a dimer of the S protein, 
one glycosylated and the other unglycosylated, in agreement with the observation that 
the two forms of this protein are present in approximately equal amounts in both 
virions and subviral particles (Heermann et al., 1984). HBsAg has distinct 
hydrophobic and hydrophilic regions which have led to the proposition of a model for 
its structure within the HBV envelope (Figure 1.5 ), which is supported by 
experimental mapping of exposed sites (Peterson et al., 1982). This structure 
accommodates dimer formation and also the preS regions, both of which have been 
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Figure 1.5 
Proposed structure of HBsAg in the outer envelope of the HBV virion. 





shown experimentally to be exposed in Dane particles and spherical particles (Stibbe 
and Gerlich, 1983; Heermann et al., 1984; 1987). 
As HBsAg is the viral antigen residing on the surface of the virus particle, it is the 
protein to which neutralising antibodies would be expected to be directed. This is 
indeed the case and the original HBV vaccine consisted of subviral particles purified 
from plasma of chronic carriers of the virus (Hilleman et al., 1978). The only HBV 
proteins present in this vaccine are the surface proteins and it was found to be safe 
and effective as a vaccine (Szumess et al., 1980). However, its high cost and the 
perceived danger of using material, although highly purified, from an infected 
individual led to the development of an alternative vaccine. This was made possible 
by the ability of yeast (Saccharomyces cerevisiae) after expression of a foreign S gene 
to produce subviral particles of apparently normal morphology, which could be 
produced and purified on a large scale, reliably free from contamination. Such a 
preparation was shown to protect chimpanzees upon subsequent challenge with HBV 
(Murray et al., 1984) and, following clinical trials, is now in general use for 
vaccination of human populations. 
Characterisation of antibodies to HBsAg defined distinct epitopes within HBsAg 
(Hirschman et al., 1969). These were further defined to be (i) the a determinant, 
which is common to all HBV isolates and (ii) two pairs of sub-type determinants - dly 
and nw. One of each pair is normally present, giving rise to four possible determinant 
combinations and hence subtypes - adr, adw, ayr and ayw (Le Bouvier et al., 1973). 
However, the cloned HBV DNA used in the work presented in this thesis is of a 
complex subtype adyw. The serum from which this virus was originally isolated 
displayed this serotype (Burrell et al., 1979) and may have arisen via infection by 
more than one virus subtype. 
While full immunogenicity of HBsAg is apparent in the context of a dimer of the 
molecule (Mishiro et al., 1980), localisation of specific determinants, for example the 
a determinant (Bhatnagar et al., 1982; Prince et al., 1982) and, more generally, sites 
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within the S protein which elicit production of virus-neutralising antibodies (Gerin et 
al., 1983; Purcell and Germ, 1985) have been effected with the use of short peptides. 
Similar peptide studies involving the preS regions (Neurath et al., 1985; 1986b; 1987; 
Iwarson et al., 1985a; Milich and McLachlan, 1987; Emini et al., 1989) taken together 
with studies involving the full-length proteins (Milich et al., 1985; Schlicht et al., 
1987) demonstrate that the preS region, and in particular preS2, is more immunogenic 
than the S region. Indeed antibodies specific to the preS2 sequences are virus-
neutralising (Iwarson et al., 1985; Neurath et al., 1986b; Emini et al., 1989) and can 
also cross-react with HBV subtypes other than that against which they were raised 
(Neurath et al., 1987; Emini et al., 1989). These observations, when taken together 
with the finding that peptides corresponding to both the preSl and preS2 regions can 
prime T cell help for antibody production to epitopes within preSi, preS2 and S, 
thereby potentially circumventing the non-responsiveness to vaccination with the S 
protein only (Milich et al., 1985; Milich and McLachlan, 1987); has led to the 
suggestion that preS sequences be included in any future HBV vaccine. 
1.4.2 Polymerase 
The first indication of a HBV polymerase activity came in 1973 when it was 
discovered that preparations of HBV from the sera of chronically-infected individuals 
contained an endogenous polymerase activity capable of filling-in the incomplete 
strand of the HBV genome (Kaplan et al., 1973). That the P gene is expressed during 
HBV infection has been demonstrated by the detection of polymerase-specific 
antibodies in sera from a convalescent chimpanzee (McGlynn and Murray, 1988). 
When the sequence of HBV became known (Galibert et al., 1979; Pasek et al., 1979) 
a candidate gene for production of this polymerase activity was identified, the P open 
reading frame, on the basis of the molecular weight of the predicted product. In 
addition, this sequence shares homology with the polymerase genes of retroviruses and 
other genetic elements which employ reverse transcription, in domains responsible for 
DNA polymerase/reverse transcriptase and RNaseH activities (Toh et al., 1983; 
Khudyakov and Makhov, 1989; Radziwill et al., 1990), thus proposing this gene 
product as containing the activities required for replication of the HBV genome (See 
section 1.5). However, efforts to examine this protein have been hampered by its low 
abundance in HBV virions and its insoluble nature, and expression in tissue culture 
and heterologous systems had failed to produce protein which was sufficiently 
enzymatically active for detailed biochemical study. While sufficient, and sufficiently 
active, protein has been produced in such systems to indicate that the reverse 
transcriptase and RNaseH activities required for HBV replication reside within this 
protein (McGlynn and Murray, 1988; Bavand et al., 1989; Chang et al., 1990; 
Radziwill et al., 1990), a recent report may allow more detailed biochemical analysis 
in the future. Wang and Seeger (1992) and Howe et al. (1992) report expression of 
the polymerase ORF of the duck hepatitis B virus in a cell-free rabbit reticulocyte 
lysate system, in an enzymatically active form, expressing reverse transcriptase 
activity, while McGlynn et al. (1992) report expression of enzymatically active HBV 
polymerase/reverse transcriptase in the baculovirus system. A more detailed discussion 
of the roles of the HBV P gene product is presented in Section 1.5. 
Initial observations that a protein was tightly attached to the HBV genome (Kaplan 
et al., 1973; Landers et al., 1977) and specifically to the 5' terminus of the long, 
minus strand (Gerlich and Robinson, 1980; Molnar-Kimber et al., 1983) led to much 
speculation as to its nature and role. Evidence has now accumulated, both in the 
DHBV system (Bartenschlager and Schaller, 1988; Radziwill et al., 1988; Bosch et 
al., 1988; Wang and Seeger, 1992) and for HBV (Radziwill et al., 1990) that the 
genome-linked protein is encoded by the P gene. It has further been demonstrated by 
the use of antibodies specific for different segments of the P polypeptide, that an N-
terminal domain of the P gene product, distinct from its other functional domains, is 
responsible for this DNA linkage (Bosch et al., 1988; Bartenschlager and Schaller, 
1988) and indeed, amino acid sequence comparison of this area of the P protein with 
the terminal proteins of picornaviruses found a region of conservation with the VPg 
protein of human rhiriovirus (Khudyakov and Makhov, 1989) leading the authors to 
suggest that the HBV protein acts in a similar manner to VPg; that is, as a protein 
primer for DNA synthesis. This has recently been confirmed experimentally by Wang 
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and Seeger (1992). However, this region alone is not sufficient to prime DNA 
synthesis, and neither, in the in vitro system used by the authors, is the full protein 
sufficient to polymerise more than a few nucleotides. This observation suggests that 
some modification of the protein may be required to alter its function from a primer 
to a polymerase, perhaps by formation of a dimer (Wang and Seeger, 1992) or even 
cleavage at the end of the terminal protein domain, thus releasing the reverse 
transcriptase, polymerase and RNaseH domains (Bartenschlager and Schaller, 1988). 
1.4.3 X Antigen 
Until recently, no biological function had been described for the product of the X 
ORF, hence its name. That it is expressed during HBV infection has been 
demonstrated by the presence of antibodies specific to HBxAg in the sera of HBV-
infected individuals (Kay et al., 1985; Moriarty et al., 1985; Meyers et al., 1986; 
Weber et al., 1988). Detection of X-encoded protein, although with molecular weight 
slightly higher than expected, from liver tissue of HBV-infected individuals with X-
specific antibodies has also been reported (Moriarty et al., 1985), in addition to 
detection in human hepatoma cells with integrated HBV DNA (Moriarty et al., 1985; 
Chisaka et al., 1987) and in cell lines transiently transfected (Chang et al., 1987) or 
transformed (Pugh et al., 1986) with HBV DNA. 
It had been suspected that the X gene encoded the genome-linked protein, but this role 
has now been assigned to the product of the polymerase gene (Section 1.4.2) and it 
has become apparent that HBxAg functions as an effective transcriptional 
transactivator. A huge range of target sequences of wide-ranging origins have been 
shown to be susceptible to this transactivation by HBxAg (for a recent comprehensive 
review see Rossner, 1992) including the HIV LTR, the SV40 early promoter/enhancer, 
cellular f3-interferon promoter and the c-myc promoter. HBxAg has also been shown 
to transactivate HBV DNA sequences, specifically, in conjunction with enhancer I or 
II, the core promoter, the preSi promoter, the preS2 promoter and the X promoter. 
The promiscuous nature of this transactivation suggests a more general method of 
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action than specific binding of HBxAg to a target DNA sequence and it has indeed 
been demonstrated that HBxAg does not bind to its target DNA (Seto et al., 1990). 
In addition, only a subset of promoters capable of transactivation by HBxAg can be 
transactivated in any one cell line (Seto et al., 1989; Rossner, 1992) suggesting that 
HBxAg acts via multiple cell type-specific transcription factors. This more general 
method of action would also concur with the ability of HBxAg to transactivate both 
RNA polymerase II and RNA polymerase III promoters (Aufiero and Schneider, 
1990), and the absence of any obvious sequence motifs within the 154 amino acids 
of HBxAg (Coigrove et al., 1989). Recently, however, three short regions of HBxAg 
(amino acids 46-52, 61-69 and 132-139) have been shown to be essential for its 
transactivation function while amino- and carboxy- term inal amino acids appear to be 
dispensable. Several candidate cellular transcription factors have been identified for 
interaction with HBxAg, the most notable being NF- KB (Twu et al., 1989; Faktor 
and Shaul, 1990; Lucito and Schneider, 1992), AP-2 (Seto et al., 1990) and TFIIIC 
(Aufiero and Schneider, 1990), the latter in the case of RNA polymerase III promoter 
transactivation. The details of the mechanism of this action were recently made more 
clear by a report indicating that HBxAg transactivation proceeds by a complex tumour 
promoter pathway (Kekule et al., 1993). The presence of HBxAg causes elevation of 
the level of diacyl glycerol (by an as yet unknown mechanism), which then activates 
protein kinase C. The latter protein in turn activates a wide variety of transcription 
factors and this would go some way to explaining the wide variety of promoters 
transactivated by HBxAg. 
It has been reported that HBxAg has intrinsic serine/threonine protein kinase activity 
(Wu et al., 1990a). However, the protein shares no homology with, and is much 
smaller than, known protein kinases and demonstration of protein kinase activity 
specific to HBxAg has not been achieved in other laboratories (including Rossner, 
1991). A recent report in which the X gene was expressed in HepG2 cells from a 
recombinant vaccinia virus found a fraction of the HBxAg produced to be 
phosphorylated, suggesting a possible method of regulation of its activity (Schek et 
al., 1991). The authors also reported detection of a higher molecular weight HBxAg 
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species, comprising approximately 10% of the total HBxAg, which may be 
glycosylated, and found that all the HBxAg produced in general had a short half-life. 
If this accurately reflects the situation during natural infection, the unstable nature of 
HBxAg may contribute to the very low level of HBxAg apparently present. 
An enigma of the X gene is its presence, and conservation of sequence (Summers et 
al., 1978; Marion et al., 1980) and function (Coigrove et al., 1989) in mammalian 
hepadnaviruses, but apparent absence in avian hepadnaviruses (Mason et al., 1980; 
Sprengel et al., 1988). It has been suggested (Feitelson and Miller, 1988) that 
sequences related to the X gene are present in the core gene of duck and heron 
hepatitis B viruses, but to date no experimental evidence has emerged to demonstrate 
HBxAg-like functions for these viruses. In addition, while ground squirrels infected 
with mutant GSHV lacking a functional X gene failed to develop normal GSHV 
infection (Ganem and Varmus, 1987), transient transfection of X-minus HBV DNA 
into several liver cell lines resulted in apparently normal levels of viral proteins, 
replicative intermediates and virion export (Blum et al., 1992). Therefore, it may be 
that the importance of the X gene product to the viral life cycle is different in GSHV 
and HBV, or that X is crucially involved in the initial events of infection, which were 
not investigated in the latter study. If the X protein product is not central to the viral 
life cycle, its role may be in the pathogenicity of hepadnavirus infection. 
Finally, due to the properties of HBxAg outlined above, and the observation that X 
sequences are often found to be integrated into the host DNA in liver tumours (Miyaki 
et al., 1986) it has been proposed that the X gene product may contribute to 
hepatocarcinogenesis (Zahn et al., 1988; Koshy and Hofschneider, 1989; Kekule et 
al., 1993). 
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1.4.4 Core antigen 
The core antigen of HBV is encoded by the C ORF which spans nucleotides 1 to 549, 
and the antigen therefore comprises 183 amino acids. Its amino acid sequence is 
highly conserved, both between subtypes of HBV and between mammalian 
hepadnaviruses (Figure 6). The C gene product is a protein of approximately 21kD 
which polymerises to form the viral nucleocapsid, the inner structure of the virus 
which houses the HBV genome and polymerase (Figure 1.2). The nucleocapsid is a 
regular structure with icosahedral symmetry which consists of approximately 180 
subunits, as demonstrated by examination under the electron microscope (Onodera et 
al., 1982). The amino acid sequence of the core protein of DHBV (not shown), while 
broadly similar to HBV and the other mammalian hepadnaviruses, has several regions 
of amino acid insertions, which apparently are manifested as tiny spikes protruding 
from the surface of the nucleocapsid (Mason et al., 1980). Despite this characteristic, 
and the larger size of the nucleocapsids, the structure is sufficiently similar for the 
study of DHBV nucleocapsids to be relevent, in general, to HBV. 
HBcAg has proved most amenable to expression in heterologous systems, including 
tissue culture cell lines (Gough and Murray, 1982; Roossinck et al., 1986; Roossinck 
and Siddiqui, 1987; Ohori and Matsuda, 1989), yeast (Saccharomyces cerevisiae) 
(Kniskern et al., 1986; Miyanohara et al., 1986; Imamura et al., 1988), baculovirus 
(Hilditch et al., 1990), Acetobacter methanolicus (Schroder et al., 1991) and Xenopus 
oocytes (Zhou and Standring, 1991). However, possibly the simplest and most 
commonly-used expression system for HBcAg is E. coli (Burrell et al., 1979; Edman 
et al., 1981; Stahl et al., 1982). This system can be utilised to express large quantities 
of HBcAg which assemble within the bacterium into nucleocapsid-like structures. 
These have physical properties apparently identical to nucleocapsids isolated from 
infected liver, and examination with the electron microscope shows these recombinant 
particles to be morphologically indistinguishable from those produced in vivo (Cohen 
and Richmond, 1982). 
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Figure 1.6 
Amino acid sequence of HBcAg of HBV subtypes, WHV and GSHV, with identity 
sequence shown below. Note the complete conservation of amino acids 1-10, and of 
the four cysteine residues at amino acid positions 48, 61, 107 and 183 (bold). 
HBV adyw Pugh et al. (1986) 
HBV adr Ono et al. (1983) 
HBV adw Ono et al. (1983) 
HBV ayw Galibert et al. (1979) 
HBV ayr Okamoto et al. (1986) 
HBV adw2 Valenzuela et al. (1980) 
HBV adr4 Fujiyama et al. (1983) 
WHV Girones et al. (1989) 
GSHV Seeger et al. (1984). 
1 50 
HBVadyw MDIDPYKEFG ATVELLSFLP SDFFPSVRDL LDTAAALYRD ALESPEHCSP 
HBVadr MDIDPYKEFG ASVELLSFLP SDFFPSIRDL LDTASALYRE ALESPEHCSP 
HBVadw MDIDPYKEFG ATVELLSFLP SDFFPSVRDL LDTASALYRE ALESPEHCSP 
HBVayw MDIDPYKEFG ATVELLSFLP SDFFPSVRDL LDTASALYRE ALESPEHCSP 
HBVayr MDIDPYKEFG ASVELLSFLP SDFFPSIRDL LDTASALYRE ALESPEHCSP 
HBVadw2 MDIDPYKEFG ATVELLSFLP SDFFPSVRDL LDTASALYRE ALESPEHCSP 
HBVadr4 MDIDPYKEFG ASVELLSFLP SDFFPSIRDL LDTASALYRE ALESPEHCSP 
WHV MDIDPYKEFG SSYQLLNFLP LDFFPDLNAL VDTATALYEE ELTGREHCSP 
GSHV MDIDPYKEFG SSYQLLNFLP LDFFPDLNAL VDTAAMYEE ELTGREHCSP 
IDENTITY MDIDPYKEFG . . . .LL.FLP .DFFP .... L .DTA.ALY.E .L ... EHCSP 
51 100 
HBVadyw HHTALRQAIL CWGDLMTLAT WVGTNLEDPA SRDLVVSYVN TNVGLKFRQL 
HBVadr HHTALRQAIL CWGELMNLAT WVGSNLEDPA SRELVVSYVN VNMGLKIRQL 
HBVadw HHTALRQAIL CWGELMTLAT WVGNNLQDPA SRDLVVNYVN TNMGLKIRQL 
HBVayw HHTALRQAIL CWGELMTLAT WVGVNLEDPA SRDLVVSYVN TNMGLKFRQL 
HBVayr HHTALRQAIL CWGELMNLAT WVGSNLEDPA SRELVVSYVN VNMGLKIRQL 
HBVadw2 HHTALRQAIL CWGELMTLAT WVGNNLEDPA SRDLVVNYVN TNVGLKIRQL 
HBVadr4 HHTALRQAIL CWGELMNLAT WVGSNLEDPA SRELVVSYVN VNMGLKIRQL 
WHV HHTAIRQALV CWDELTKLIA WMSSNITSEQ VRTIIVNHVN DTWCLKVRQS 
GSHV HHTAIRQALV CWEELTRLIT WMSEN.TTEE VRRIIVDEVN NTWGLKVRQT 
IDENTITY HHTA.RQA.. CW. .L. .L.. W ... N ..... .....V. .VN .. .GLK.RQ. 
101 150 
HBVadyw LWFHISCLTF GRETVLEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVP. 
HBVadr LWFHISCLTF GRETVLEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVR 
HBVadw LWFHISCLTF GRETVLEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVR 
HBVayw LWFHISCLTF GRETVLEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVR 
HBVayr LWFHISCLTF GRETVLEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVR 
HBVadw2 LWFHISCLTF GRETVLEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVR 
HBVadr4 LWFHISCLTF GRETVLEYLV SFGVWIRTPP AYRPPNAPIL STLPETTVVR 
WHV LWFHLSCLTF GQHTVQEFLV SFGVWIRTPA PYRPPNAPIL STLPEHTVIR 
GSHV LWFHLSCLTF GQHTVQEFLV SFGVWIRTPA PYRPPNAPIL STLPEHTVIR 
IDENTITY LWFH.SCLTF G. .TV.E.LV SFGVWIRTP. .YRPPNAPIL STLPE.TV.R 
151 183 
HBVadyw RR.....GRS PRRRTPSPRR RRSQSPRRRR SQSRESQC 
HBVadr RR.....GRS PRRRTPSPRR RRSQSPRRRR SQSRESQC 
HBVadw R ... RDRGRS PRRRTPSPRR RRSQSPRRRR SQSRESQC 
HBVayw R ..... RCRS PRRRTPSPRR RRSQSPRRRR SQSRESQC 
HBVayr RR.....GRS PRRRTPSPRR RRSQSPRRRR SQSRESQC 
HBVadw2 RR. . DRORS PRRRTPSPRR RRSPSPRRRR SQSRESQC 
HBVadr4 R.....RGRS PRRRTPSPRR RRSQSPRRRR SQSRESQC 
WHV RRGGARASRS PRRRTPSPRR RRSQSPRRRR SQSPSANC 
GSHV RRGGSRAA.RS PRRRTPSPRR RRSQSPRRRR SQSPASNC 
CONSENSUS R.......RS PRRRTPSPRR RRS.SPRRRR SQS .... C 
The ease of expression of HBcAg in heterologous systems, and the ability to purify 
nucleocapsids from infected liver (Barker et al., 1974; Hruska and Robinson, 1977) 
have allowed HBcAg to be studied in detail. The ease of expression in E. coli is partly 
due to the apparent lack of post-translational modification of HBcAg. However, 
HBcAg can exist as a phosphoprotein. Incubation of nucleocapsids, purified from 
infected liver, with 32P resulted in phosphorylation of HBcAg on Serine residues 
(Albin and Robinson, 1980; Gerlich et al., 1982; Feitelson et al., 1982) and 32P 
orthophosphate-labelling of cells transiently transfected with the C gene of HBV 
produced a similar result (Roossinck and Siddiqui, 1987). In the DHBV system, 
Schlicht et al. (1989a) showed the majority of this phosphorylation to be localised to 
the serine-rich carboxy-terminus of DHBcAg and this has subsequently been 
confirmed to be the case for HBcAg also (Machida et al., 1991; Yeh and Ou, 1991). 
In addition, it has been noted that HBcAg produced in E. coli is not phosphorylated 
(Schlicht et al., 1989a). As HBcAg produced in E. coli is not phosphorylated, but still 
forms nucleocapsid-like particles, it would appear that HBcAg phosphorylation is not 
a requirement for core particle formation. The function of this phosphorylation is 
currently unclear. Pugh et al. (1989) demonstrated that intracellular, non-enveloped 
DHBV core particles are heterogeneous with regard to phosphorylation status, and that 
phosphorylation is on the surface of the particles, while nucleocapsids isolated from 
mature DHBV virions are not phosphorylated. This observation led the authors to 
propose that de-phosphorylation of nucleocapsids may act as a signal of maturation 
of their viral genome and target them for packaging and export from the cell as 
mature virus. 
It is well-documented that the protein kinase activity associated with the viral 
nucleocapsid is very tightly linked to the core particles and that they co-purify during 
standard purification (Albin and Robinson, 1980; Gerlich et al., 1982). The identity 
of the protein responsible for this kinase activity is currently unknown. Due to the 
close association of the activity with the nucleocapsid, it is possible that HBcAg itself 
is responsible. However, the amino acid sequence of HBcAg has no homology with 
known serine/threonine kinases, and that DHBcAg produced in E. coli is neither 
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phosphorylated itself nor has kinase activity (Schlicht et al., 1989a) suggests that the 
activity is not intrinsic to HBcAg. A controversial report (Wu et al., 1990a) suggested 
that the source of kinase activity is HBxAg (Section 1.4.3) but other laboratories have 
failed to confirm this (including Rossner, 1991). As no ORF product of HBV bears 
any resemblance to known serine/threonine kinases, it may be that the nucleocapsid-
associated kinase activity is derived from the host cell. This idea is supported by the 
observation that proteins consisting of the COOH-terminus 40 amino acids of HBcAg 
fused to human alpha-globin and human growth hormone were phosphorylated within 
HBcAg sequences as normal (Yeh and Ou, 1991). As this phosphorylation proceeded 
in the absence of other HBV gene products, and it is unlikely that the 40 amino acids 
of HBcAg in the fusion proteins contain the kinase activity, it is probable that the 
phosphorylation was mediated by cellular kinases, and that this may also be the case 
in normal viral infection. 
Another notable feature of the COOH-terminus of HBcAg is its extreme arginine-
richness (Figure 1.6) This protamine-like nature (Pasek et al., 1979) suggests a 
nucleic-acid binding activity for the protein, which has indeed been demonstrated. 
Nucleocapsids isolated from HBV-infected liver have been shown to have DNA-
binding activity (Petit and Pillot, 1985; Machida et al., 1991) while more extensive 
studies with HBcAg produced in E. coli has demonstrated that the protein can bind 
both DNA and RNA (Matsuda et al., 1988; Gallina et al., 1989; Hatton et al., 1992). 
It has also been proposed that this nucleic acid-binding is not completely non-specific. 
Nucleocapsids isolated from infected liver bound HBV DNA more efficiently than the 
unrelated pBR322 DNA (Petit and Pillot, 1985), while examination of RNA contained 
within core particles produced in E. coli showed an enrichment of core protein mRNA 
over other cellular mRNAs (Birnbaum and Nassal, 1990). However, it is not clear 
whether this is due merely to the large amount of HBcAg mRNA present in the cells. 
Mutational analysis of HBcAg has confirmed the proposed location of nucleic acid-
binding activity to the COOH-terminus of the protein. While Gallina et al. (1989) 
detected no nucleic acid within particles formed in E. coli from core proteins lacking 
the carboxy-terminus region, HBeAg (essentially a non-particulate truncated HBcAg. 
25 
See section 1.4.5) isolated from the serum of an infected individual was shown to bind 
DNA to a similar extent to HBcAg produced in E. coli (Matsuda et al., 1988); and 
transient transfection of C gene DNA lacking the arginine-rich region coding 
sequences resulted in production of core particles competent for pregenomic RNA 
packaging. However, an intermediate situation has also been found in which particles 
lacking the COOH-terminus, produced in either E. coli or by transient transfection of 
HuH7 cells, have been shown to contain a small but detectable amount of RNA 
(Birnbaum and Nassal, 1990; Hatton et al., 1992; Nassal, 1992a) suggesting the 
presence of an additional nucleic acid-binding motif between amino acids 1 and 144 
of HBcAg. On the basis of secondary structure predictions of HBcAg, this site has 
been proposed to lie between amino acids 100 and 120 of the protein (Matsuda et al., 
1988) but experimental evidence has not yet emerged to confirm this. 
The discovery of a role for the DNA-binding activity of HBcAg was perhaps 
unexpected as the function of HBcAg had been thought to be limited to binding and 
hence encapsidation of the RNA pre-genome prior to reverse transcription. This DNA-
binding activity may have a role in the negative regulation of the human 13-interferon 
gene by HBcAg observed by Twu and Schloemer (1989), as may the two nuclear 
localisation signals demonstrated to be present within the arginine-rich domain of the 
protein (Yeh et al., 1990; Eckhardt et al., 1991). A recent detailed dissection of the 
nucleic acid-binding capabilities of the COOH-terminus of HBcAg produced in E. coli 
(Hatton et al., 1992) has revealed four repeated sequence motifs. Repeat I (150-
RRRDRGRS-157), the first 8 amino acids of the protamine-like region in the adw 
subtype studied, was shown to be sufficient for RNA packaging, as determined by the 
RNA content of purified core particles electrophoresed on agarose gels. In addition, 
this sequence could be replaced by four arginines with no significant alteration in 
RNA packaging capability resulting. While this sequence (Repeat I) did not bind 
DNA, the three other repeats bound DNA much more efficiently than RNA and the 
authors suggest that this function may be required during the process of reverse 
transcription, in order to make it energetically more favourable. This and other reports 
describing viruses with genomes mutant in the C gene to be deficient in various 
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aspects of genome replication (Schlicht et al., 1989a; Nassal, 1992a) suggest a more 
extensive role for HBcAg in genome replication than was previously thought, and this 
will be discussed in more detail in Section 1.5.2. 
That assembly of recombinant HBcAg into morphologically normal core particles 
proceeds spontaneously in the heterologous expression systems described above 
demonstrates that no other HBV gene products are required to catalyse the process, 
or to form part of the nucleocapsid structure itself. That similar particles are produced 
in systems as diverse as liver-derived cell lines, insect cells and E. coli also suggests 
that no specialised host proteins are involved. This has been confirmed by the 
observation that core particles produced in E. coli, and subsequently purified, can be 
dissociated into monomers which can then be re-formed into particles which are 
normal, by morphological and immunological criteria (M. Dyson, personal 
communication). In addition, the purification procedure used by Stahl and Murray 
(1989) involved the dissociation of particles formed from HBcAg fusion proteins, 
followed by re-association in the absence of contaminating proteins. Therefore, it 
would appear that the ability to form nucleocapsid structures is intrinsic to HBcAg and 
requires neither the viral components contained within it in the mature virus particle, 
nor any cellular proteins. Requirements for assembly-competence within HBcAg itself 
have recently been investigated and will also form part of the work presented in this 
thesis. 
Several reports have indicated that the COOH-terminal region of HBcAg is not 
required for formation of normal core particles, when expressed both in E. coli (Stahl 
and Murray, 1989; Salfeld et al., 1989; Gallina et al., 1989; Birnbaum and Nassal, 
1990) and in liver-derived cells (Nassal, 1992a). Similarly, deletion of 36 amino acids 
at the COOH-terminus of DHBcAg did not prevent formation of nucleocapsid-like 
particles in HepG2 cells (Schlicht et al., 1989a). In addition, the entire arginine-rich 
region can be replaced by foreign sequences of varying length, without disruption of 
the ability to form core particles (Borisova et al., 1989; Stahl and Murray, 1989; 
Schoedel et al., 1992; A. Shiau, personal communication). As these particles are 
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highly immunogenic with respect to both HBcAg and the fused foreign epitopes 
(discussed below) and react with antibodies to the foreign epitope, those sequences 
must be present on the exterior of the particle. However, as the arginine-rich native 
COOH-terminus of HBcAg has been demonstrated to bind nucleic acid and has been 
proposed to have a role in replication of the genome, it would be expected that this 
region would be located on the interior of the capsid. This notion concurs with the 
observation that while the COOH-terminus of HBcAg produced in Xenopus oocytes 
is readily accessible to degradation by proteinase K when in a non-particulate form, 
it is apparently resistant to proteinase K when it is in the context of particles, 
suggesting an interior location (Zhou et al., 1992). In addition, no major antibody 
binding sites of core particles have been localised to the arginine-rich region and 
fusion proteins in which foreign epitopes are inserted at the start of and without 
deletion of, the arginine-rich tail form particles whose foreign epitopes are recognised 
by antibody (Borisova et al., 1989). However, the whereabouts of the COOH-tail 
within this structure are unknown. Therefore it may be that the very unusual and basic 
nature of the native COOH-terminus causes it to be internal to the particle, while more 
normal peptide regions are exposed on the surface. 
Sequences at the NH2-terminus have also been found to be required for the formation 
of HBcAg which is immunologically normal. Stahl et al. (1982) demonstrated that 
HBcAg produced in E. coli which consisted of 8 amino acids of -ga1actosidase 
followed by 3 linker amino acids followed by amino acids 3-183 of HBcAg reacted 
well with polyclonal anti-HBcAg while a protein which differed only in the deletion 
of amino acids 3 and 4 of HBcAg, failed to react significantly with antibody. 
Similarly, Salfeld et al. (1989) found a drastic loss of antigenicity with a protein 
consisting of amino acids 12-183 of HBcAg. However, in neither case was it 
determined whether core particles were formed. Further investigation of the results of 
Stahl et al. (1982) will be presented in chapter 3 of this thesis. 
While HBcAg itself is detected only rarely in the serum of infected individuals 
outwith Dane particles (Chemello et al., 1988), it does occur in the liver early in acute 
infections, and antibodies to HBcAg are the first antibodies to appear following 
infection (Cohen, 1978) and are produced at a high titre (Figure 1.1). Trevisan et al. 
(1982) found that antibody bound to membranes of hepatocytes in liver from 
chronically infected patients is anti-HBcAg, and not anti-HBsAg, and Mondelli et al. 
(1982) demonstrated that T cells directed against hepatocytes of chronically-infected 
indivduals were directed specifically against HBcAg and not HBsAg. Therefore, it is 
apparent that HBcAg is displayed on the surface of infected hepatocytes, and this has 
been confirmed by immune electron microscopy of HBcAg in liver cell plasma 
membranes (Kojima etal., 1987). Therefore an immune response against HBcAg may 
be important in the elimination of cells replicating virus. Also, as noted in section 1.1, 
the distribution of HBcAg is characteristic of the disease state of infected individuals, 
with focal distribution of HBcAg in livers of patients with chronic active hepatitis, and 
more diffuse distribution or absence in the more mild chronic persistent hepatitis state 
and cases of HBV infection with no apparent liver disease (Feitelson, 1989). This is 
concurrent with the suggestion that HBcAg may be recognised by the immune system, 
thereby contributing to HBV disease pathology by eliminating cells expressing 
HBcAg. 
The major epitope on HBcAg recognised by anti-HBcAg antibodies has been located 
by Salfeld et al. (1989). Various segments of HBcAg were produced in E. coli and 
their cross-reaction with polyclonal and monoclonal antibodies examined, such that a 
single conformational determinant was mapped to a region around amino acid 80. As 
HBcAg is a non-secreted, internal component of the virion, it was perhaps surprising 
that antibodies directed against it are produced at such high levels during infection. 
However, this may be explained by the observation of Milich and McLachlan (1986) 
that HBcAg is both a T cell-independent and a T cell-dependent antigen. That is, it 
can stimulate B cells to produce anti-HBcAg antibodies both directly, as demonstrated 
by the induction of anti-HBcAg 1gM and IgG in nude mice, despite the absence of T 
cells within these mice; and via T helper cells. 
The T cell-independent stimulatory activity was observed only with particulate HBcAg 
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and non-particulate HBcAg required a helper T cell function to elicit antibodies. 
Investigations using inbred murine strains showed multiple but distinct T cell sites in 
HBcAg of 16-21 residues in size. The site recognised predominantly was dependent 
on the H-2 haplotype of the mouse examined (Milich and McLachlan, 1986), and 
further work showed that a synthetic peptide representing a T cell site was sufficient 
to prime production of antibody in a manner similar to the native protein (Milich et 
al., 1987b). More surprising, however, was the observation in the same report that 
priming by a T cell site peptide or whole HBcAg followed by challenge with HBV 
elicited antibodies not only to HBcAg, but also to S, preSi and preS2. This antibody 
production was achieved only if HB5Ag and HBcAg were present in the same 
structure (the virion) and not if challenge was with a mixture of separate HBcAg and 
HBsAg particles. A model for the mechanism operating in this situation is dependent 
upon the observation that B cells can act as antigen-presenting cells (Lanzavecchia, 
1985) and is depicted diagramatically in Figure 1.7. This model also explains the 
unexpected results of experiments in which chimpanzees were protected from infection 
by vaccination with HBcAg (Murray et al., 1984; 1987; Iwarson et al., 1985b; Tabor 
and Gerety, 1984). In addition, a mouse non-responsive to the S region of HBsAg 
produced anti-S antibodies after priming with a synthetic HBcAg peptide T cell site 
and challenge with virion, as anti-S antibody production could be mediated via a 
HBcAg-specific T-cell site and not the S T-cell site which was lacking in this mouse 
strain. Combined with the observation that almost 100% of chronically-infected 
patients produce high titres of anti-HBcAg (Hoofnagle et al., 1973), the use of HBcAg 
as a vaccine against HBV is suggested as it appears to be effective in preventing HBV 
infection and could, perhaps, circumvent the non-responsiveness to the current HBsAg-
containing vaccine, seen in 2-5% of vaccinees. The enhanced immunogenicity of 
HBcAg at both the B and T cell level also indicates a role as an effective carrier in 
multi-valent vaccines. To this end, very many fusion proteins have now been produced 
consisting of HBcAg sequences fused to a foreign epitope, either preS and/or S 
sequences of HBV (Stahl and Murray, 1989; Borisova et al., 1989; Schoedel et al., 
1992) or epitopes from other viruses (Clarke et al., 1987; Stahl and Murray, 1989; 




HBcAg is taken up by an antigen-presenting cell (APC) which then displays HBcAg 
T cell epitopes, in conjunction with MHCII molecules, on its surface. These epitopes 
are recognised by a HBcAg-specific T cell which then proliferates to form an 
expanded population. 
ChalIene 
Upon challenge with HBV, HBsAg eposed on the surface of the virus is recognised 
by a HBsAg-specific B cell. As this B cell can also act as an antigen-presenting cell 
(Lanzavecchia, 1985), it presents on its surface, in addition to its HBsAg receptor, 
both HBsAg and HBcAg peptides in conjunction with MHCII molecules. The HBcAg 
T cell epitopes within these peptides are then readily recognised by the expanded 
HBcAg-specific T cell population produced by the initial priming with HBcAg. 
Lymphokines released by such a T cell after recognition then stimulate the B cell, 
which is HBsAg-specific and therefore secretes HBsAg-specific antibodies, which bind 
to and neutralise the virus. 
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1990; Francis et al., 1990; Brown et al., 1991; Urich et al., 1991) 
1.4.5 HBeAg  
HBeAg was discovered in 1972 (Magnius and Espmark) in the serum of HBV-infected 
patients. At that time the authors suggested a link between the presence of HBeAg in 
serum and the "contagiousness" of the patient. This has since been shown to be the 
case and high titres of HBeAg are correlated with high levels of virus replication and 
high titres of Dane particles in the serum, and therefore high infectivity (Okada et al., 
1976; Ganem, 1982). Similarly, seroconversion to anti-HBeAg is indicative of 
clearance of the infection. Indeed, a difference of more than one million-fold was 
observed between sera containing HBeAg and sera containing anti-HBeAg when their 
infectivity was compared by titration in chimpanzees (Shikata et al., 1977). Unlike 
HBcAg, HBeAg is found in the serum mainly as soluble dimers, a non-particulate 
structure, but it has also been demonstrated in association with Dane particles (Ohori 
et al., 1979). 
The source of HBeAg was determined when the conversion of HBcAg reactivity into 
HBeAg reactivity was achieved by treatment of purified nucleocapsids with pronase, 
sodium dodecyl sulphate, chaotropic agents or centrifugation in CsCl (Takahashi et al., 
1979; Budkowska et al., 1979; Ohori et al., 1980). However, an unequivocal 
demonstration that HBeAg could be generated from HBcAg was provided by MacKay 
et al. (1981) who converted HBcAg, produced in E. coli in the absence of other HBV 
gene products, to HBeAg by proteolytic degradation under dissociating conditions, 
thereby proving that no other HBV protein was the source of HBeAg. The nature of 
the conversion of the 21kD HBcAg to the 16kD HBeAg was further defined by 
Takahashi et al. (1983) who, via amino acid sequencing, determined the COOH-
terminus of HBeAg to be 33-35 amino acids upstream of the COOH-terminus of 
HBcAg, suggesting therefore, that cleavage of these amino acids was involved in the 
conversion. 
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It has subsequently been discovered that this is the second of two processing steps, 
and that native HBcAg is not the natural precursor. Upstream of the initiation codon 
of the C gene lies another in-frame AUG which has been shown to be utilised in vivo 
(Section 1.3.1). Translation of this longer mRNA yields a core protein with an 
additional 29 amino acids at the NH.-terminus. This additional amino acid sequence 
is termed the pre-core region which, due to its hydrophobic nature, was proposed to 
be a signal peptide (Sabatini, 1982) and this has proved to be the case. Transient 
transfection of COS cells with the C gene plus or minus pre-core sequences in an 
SV40 vector showed that the presence of the pre-core region resulted in secretion of 
HBeAg, and a strong association of p25, the HBeAg precursor protein, with cell 
membranes, probably the endoplasmic reticulum (Ou et al., 1986). Similarly, partial 
deletion of pre-core sequences in stably-transformed rat cell lines resulted in the 
abolition of secretion of HBeAg (Roossnick et al., 1986). The signal peptide also 
functions in Xenopus oocytes (Standring et al., 1988) and while secretion signalled by 
a eukaryotic signal sequence would not be expected to occur in bacteria, expression 
of pre-C plus C in E. coli results in production of a protein with a strong affinity for 
the cellular membrane (Uy et al., 1986). The observation that intracellular HBeAg is 
approximately 21kD, as opposed to the 24kD coding capacity of pre-C plus C is 
consistent with co-translational cleavage of a signal sequence by a signal peptidase 
(McLachlan et al., 1987; Jean-Jean et al., 1989a). In fact, it is only the first 19 amino 
acids of the 29 amino acid NH2-terminal extension which form the signal sequence 
and are cleaved off, leaving 10 amino acids fused to the HBcAg polypeptide (Bruss 
and Gerlich, 1988; Garcia et al., 1988; Standring et al., 1988). A striking feature of 
the ER translocation of HBeAg is its inefficiency. Precursor proteins with the signal 
sequence still attached were detected consistently in the sera of HBV carriers 
(Takahashi et al., 1991) and the livers of WHV-infected woodchucks (Weimer et al., 
1987), and in vitro assays have demonstrated abortion of translocation of pre-C, 
following signal sequence cleavage, in 70-80% of cases, followed by release of the 
product into the cytoplasm, in the in vitro translation/translocation system employed 
(Garcia et al., 1988). This translation abortion may therefore be responsible for the 
protein populations described by McLachlan et al. (1987) and Jean-Jean et al. (1989) 
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(above). Similarly, in the Xenopus oocyte system a significant fraction of p25 
precursor proteins evade translocation and processing (Yang et al., 1992). Ou et al. 
(1989) report that such proteins can then be transported into the nucleus and this may 
be similar to the nuclear transport observed for HBcAg (Summers et al., 1990). As the 
conformations of HBcAg and the p25 precursor proteins are different, it may be that 
removal of the signal sequence allows the correct configuration for nuclear transport 
to form. However, the role of the results of this inefficiency of HBeAg precursor 
translocation in the viral life cycle is unclear. 
The remaining 10 amino acids attached to the NH2-terminus of HBeAg have also 
recently been shown to be important. HBe proteins expressed from recombinant 
vaccinia virus vectors and secreted under control of the authentic signal sequence were 
compared to proteins fused to the un-related influenza hemagglutinin signal sequence. 
The hemagglutinin sequence produced secreted HBeAg which was a disulphide-linked 
dimer, capable of forming nucleocapsid-like particles with HBe and HBc antigenicity, 
while HBeAg with the authentic signal sequence was a monomer with only HBe 
antigenicity which did not form core particles (Schlicht and Wasenauer, 1991). Further 
examination showed that the 10 amino acids which remain linked to the HBcAg 
sequence are the most important factor in the difference in properties of HBeAg and 
HBcAg. In particular, the presence of the cysteine residue within this sequence 
prevents formation of disulphide-linked dimers (possibly by forming an intra-
molecular disulphide bond) as a protein in which the cysteine is mutated forms such 
dimers, and hence particles, which have both HBe and HBc antigenicity (Wasenauer 
et al, 1992; Schodel et al., 1993). Also, mutation of Trp-Leu-Trp, within the 10 amino 
acid peptide, to less hydrophobic amino acids allowed core particles to assemble, 
independent of the presence of the cysteine (Wasenauer et al., 1992). Proteins 
consisting of the 29 amino acids of the pre-core region fused to HBcAg, when 
expresed in yeast, formed particles of 27nm diameter which were, however, unstable 
and readily dissociated by high salt (Miyanohara et al., 1986). In this case, the 
additional 19 amino acids at the NH2-terminus may be masking the preventive effect 
on particle formation of the 10 amino acids immediately upstream of the HBcAg Met. 
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After translocation to the ER, COOH-terminal cleavage of the protein takes place 
during travel through the secretory pathway (Standring et al., 1988). Specifically, 
conversion of p22 to p16 is prevented by brefeldin A, which inhibits transport from 
the ER to the Golgi apparatus. Also, subcellular fractionation revealed p22 in both ER 
and the Golgi, but p16 was detected only in the Golgi fraction, thereby suggesting that 
the COOH-terminal processing of p22 to p16 takes place in the Golgi apparatus 
(Wang et al., 1991) 
The detection of regions of homology between known aspartyl proteases and the NH.-
terminal region of the HBcAg sequence (Miller, 1987) prompted suggestion that 
HBeAg may be generated from its precursor by proteolytic self-cleavage. However, 
mutation of the proposed enzymatic site did not prevent secretion of appropriately-
processed HBeAg from trans iently- transfected human and mouse cell lines (Jean-Jean 
et al., 1989b; Nassal et al., 1989). It is therefore more likely that the processing 
protease involved may be of cellular origin. Specifically, the observation that pepstatin 
both reduced HBeAg secretion and caused accumulation of the 22kD processing 
intermediate (Jean-Jean et al., 1989b) suggests that the protease may be an aspartyl 
protease. 
While HBeAg and HBcAg have a large degree of amino acid identity, they are 
serologically distinct. Monoclonal antibodies specific to HBeAg or HBcAg have been 
produced and with these it has been shown that while HBeAg, in its non-particulate 
form, has only HBe antigenicity conferred by two main epitopes; particulate HBcAg 
has both a HBcAg determinant and a HBeAg determinant. The HBe determinant 
shared by HBcAg and HBeAg is linear, while the determinants specific to HBcAg and 
HBeAg are conformational (Milich et al., 1988; Salfeld et al., 1989). Surprisingly, the 
linear HBe determinant overlaps with the conformational determinant but they are 
presented simultaneously, suggesting that the subunits of the nucleocapsid may be 
present in slightly differently-folded conformations. Thus it appears that while both 
HBeAg and HBcAg share a linear epitope, the HBc nucleocapsid structure exposes a 
conformational HBc-specific epitope determinant while masking the HBe-specific 
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determinant, and that the opposite situation is true for HBeAg (Salfeld et al., 1989). 
As the T cell epitopes identified by Milich et al. (1987a) consist of sequences 
common to HBcAg and HBeAg, it was expected that these antigens would be 
equivalently immunogenic at the level of T cell activation and this has been 
demonstrated to be the case (Milich et al., 1988). In one strain of mice the T cell 
response to HBcAg was superior to that to HBeAg, suggesting the presence of a T cell 
epitope within the arginine-rich COOH-terminus of HBcAg, but such an epitope has 
yet to be identified (Milich et al., 1988). This cross-reactivity at the T cell level may, 
in part, be responsible for the high levels of anti-HBcAg antibodies produced during 
infection, despite the low levels of HBcAg exposed to the immune system. The large 
amount of HBeAg in circulation in an infected individual may cause expansion of a 
Th  cell population which can drive anti-HBcAg production, in addition to anti-HBeAg. 
However, the levels of anti-HBe detected in serum are generally lower than those of 
anti-HBc and this may be due to both the lower efficiency of HBe in terms of 
stimulation of antibody production (Milich et al., 1988), and the forming of immune 
complexes between HBeAg and anti-HBeAg, thus reducing the amount of "free" anti-
HBeAg available for detection in standard assays. 
The conservation of pre-core and core sequences between mammalian hepadnaviruses 
suggests an important function of HBeAg for the virus, but to date this function has 
not been determined. HBeAg produced from recombinant vaccinia viruses in HepG2 
cells can be either secreted, or incorporated into the outer cell membrane where it is 
recognised by anti-HBe positive serum from HBV-infected patients (Schlicht and 
Schaller, 1989). If this situation is reflected in vivo, antibody-mediated elimination of 
such cells may occur, which would concur with the correspondence of seroconversion 
from HBeAg to anti-HBeAg with virus clearance. However, this would not be 
advantageous to the virus itself. In the DHBV system, mutation of the pre-C region 
had no effect on viral replication, assembly or infectivity (Chang et al., 1987; Schlicht 
et al., 1987; Schneider et al., 1991) and so the reason for retention of the pre-C region 
in HBV, and HBeAg expression during viral infection, remains unknown. 
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1.5 HBV Replication 
1.5.1 Receptor-Binding 
The first stage in HBV infection is the binding of the virus to the hepatocyte. Until 
recently, the molecules involved in this reaction were very difficult to identify due to 
the lack of an in vitro infection system. However, the development of primary duck 
hepatocyte tissue culture (Tuttleman et al., 1986b) and the achievement of infection 
of HepG2 cells with HBV virions obtained from the serum of a chronic carrier (Bchini 
et at., 1990) may make this goal more easily attainable. 
The observation that polymerised human serum albumin (pHSA) binds to HBV virions 
(Imai et al., 1979) suggested that this molecule may act as an intermediate in 
HBV/receptor binding. It has subsequently been shown that pHSA binds to both the 
preS2 region of surface antigen (Machida et al., 1983; 1984, Persing et al., 1985) and 
the pHSA receptor present on hepatocytes. However, while the glutaraldehyde-
polymerised pHSA used in the above assays binds the preS2 region well, this is not 
true for naturally-occurring pHSA, which does not bind significantly. In addition, 
human serum albumin occurs in sera naturally predominantly in a monomeric form 
and so the relevance of this observation to the in vivo situation is far from certain. 
However, several reports have confirmed that it is the preS region which is 
predominantly involved in hepatocyte binding. Assays involving affinity columns of 
cellulose-linked surface antigens through which were passed HepG2 cells or non-
nuclear fractions of HepG2 cells, found that binding was inhibited by antibodies 
specific to the preS region and not the S region (Neurath et at., 1985). Specifically, 
the preSi region appears to have a critical role in hepatocyte-binding as antibodies to 
preSi prevented binding, while the reduction, but not abolition, of binding achieved 
by anti-preS2 antibodies suggests an auxiliary role in binding for preS2 (Neurath et 
at., 1986a). These results were mirrored by Pontisso et at. (1989) who employed both 
solid and liquid phase assays in which liver plasma membranes were exposed to the 
three forms of surface antigen. Only proteins containing the preSi region could bind 
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directly to liver plasma membranes, but in the presence of pHSA, preS2IS proteins 
also bound, and binding of preS1/preS2/S proteins was enhanced. A recent report 
employing anti-idiotype antibodies has further implicated preSi as the HBV 
polypeptide responsible for hepatocyte receptor-binding (Petit et al., 1992). 
While S sequences are highly conserved between hepadnaviruses this is not true for 
the preS regions. Therefore binding mediated by preS may explain the strict species-
specificity of hepadnaviruses. There is also some sequence variability between human 
HBV subtypes but antibodies raised to synthetic peptides from preSl and preS2 of one 
subtype of HBV were found to recognise all HBV subtypes (Neurath et at., 1987). 
Therefore, antibodies raised to preS would prevent HBV binding to hepatocytes and 
thereby prevent infection. This would obviously be a useful response to a vaccine and 
it has been proposed that preS proteins should be included in future HBV vaccines. 
The results of Neurath et al. (1987) described above, demonstrate that the sequence 
variability of preS betwen different human isolates does not represent an impediment 
to the use of preS immunogens for worldwide immunisation. 
Finally, the discovery by Peeples et at., (1987) of a receptor for the S protein on Vero 
cells (derived from African Green Monkey kidney) has led to speculation that a 
similar receptor may exist on extrahepatic cells infected with HBV, but as yet there 
is no experimental evidence to confirm this. 
Following uptake of the virion, the viral nucleocapsid is transported to the nucleus 
(Summers et at., 1990) where viral genome replication begins. 
1.5.2 Genome Reolication 
Examination of HBV DNA isolated from infected liver revealed, in addition to relaxed 
circular DNA, covalently-closed circular DNA and linear single-stranded DNA of 
various lengths, presumed to be nascent DNA (Ruiz-Opazo et at., 1982; Mason et at., 
1982; Weiser et at., 1983). The discovery that this single-stranded DNA was of the 
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(-) type only, and that no (+) single-stranded DNA was detected (Mason et al., 1982) 
was inconsistent with a mechanism by which (-) DNA was produced by 
polymerisation on a (+) DNA template, and was the first indication that hepadnaviral 
replication proceeds by an unusual mechanism. A major step in the elucidation of this 
mechanism was made by Summers and Mason (1982) who demonstrated that the 
polymerase present within HBV nucleocapsids isolated from infected liver, synthesised 
the virus (-) strand DNA from an RNA template and degraded the RNA template as 
it was copied. Thus reverse transcription of an RNA intermediate is central to HBV 
genome replication. The full replication cycle has now been elucidated (reviewed by 
Seeger et al., 1991) and is represented in Figure 1.8. 
The first step in viral genome replication is the formation of covalently-closed circular 
DNA (cccDNA) from the partially double-stranded genome present in mature virions. 
cccDNA can be detected in the liver of DHBV-infected ducks 6-16 hours after 
infection (Mason et al., 1983; Tagawa et al., 1986), before other HBV DNA or RNA 
intermediates. Formation of cccDNA requires not only the filling in of the single-
stranded gap but also the removal of the genome-linked protein, the removal of the 
terminal redundancy on the (-) strand DNA of the genome, followed by ligation of the 
5' and 3' ends of this strand, the removal of the RNA primer present at the 5' end of 
(+) DNA and the ligation of the 5' and newly-formed 3' end of (+) DNA. It is not yet 
clear whether these processes are facilitated by cellular or viral products, and while 
it has been demonstrated that the HBV polymerase can fill in the single-stranded gap 
in the genome (Kaplan et al., 1973), specific inhibition of the viral enzyme by 
foscarnet does not prevent cccDNA formation (Mason et al., 1987), suggesting that 
this function can also be carried out by a cellular polymerase activity. It is therefore 
unclear which enzyme completes (+)-strand DNA synthesis in vivo. 
cccDNA is then amplified within the infected cell, in the absence of further infection 
(Tuttleman et al., 1986a; Petcu et al., 1988; Wu et al., 1990b) before being utilised 
as the template for transcription of pre-genomic RNA (described in section 1.3.1). This 
terminally-redundant RNA contains three copies of an llbp direct repeat (DR) which 
Figure 1.8 
Replication cycle of the HBV genome. 
The partially double-stranded DNA genome (A) is converted to covalently-closed 
circular DNA (B) which is then amplified. Transcription begins upstream of DR1 and 
terminates on recognition, at the second encounter, of the polyadenylation signal 
downstream of DR1; thus forming the pre-genomic RNA (C). Reverse transcription 
of the RNA pre-genome initiates within DR1 and proceeds to the 5' end of the 
template, thus forming (-) DNA with a short terminal redundancy and the genome-
linked, polymerase-derived, protein attached to its 5' terminus (D). The RNA template 
is degraded during this process. Plus-strand DNA synthesis initiates at DR2 and 
continues to the 5' end of the (-) DNA strand (D). DNA synthesis continues after a 







contain signals important for minus- and plus-strand DNA synthesis (see below). 
Reverse transcription to synthesise the viral genome takes place in the nucleocapsid 
of the virus, and so the next stage in genome replication is the packaging of pre-
genomic RNA into the nucleocapsid, proposed to occur by interaction of HBcAg with 
the pre-genomic RNA. Of all the RNAs produced by HBV, only genomic, and not 
sub-genomic, transcripts are packaged (Enders et al., 1985). And of the genomic 
transcripts, only the shortest, which contain the initiation codon for core but not that 
for pre-core, are packaged (Will et al., 1987; Enders et al., 1987; Junker-Niepmann 
et al., 1990). Both sets of transcripts contain the encapsidation signal within the pre-C 
sequence (Bartenschlager et al., 1990; Junker-Niepmann et al., 1990; Chiang et al., 
1992) but recognition of this signal in the context of the longer transcripts is believed 
to be blocked by the presence of ribosomes (Nassal et al., 1990). The COOH-terminus 
of HBcAg, due to its protamine-like nature (Pasek et al., 1979), was expected to be 
the region of the protein responsible for RNA encapsidation, and it has indeed been 
demonstrated that HBcAg lacking this region does not package nucleic acid in 
significant quantity (Gallina et al., 1989). Deletion mutation of these sequences has 
localised this RNA encapsidation function to amino acids upstream of amino acid 164 
(Nassal, 1992a) but the remainder of the COOH-terminus also appears to be required 
for other steps of genome replication, discussed below. In addition, the HBV 
polymerase gene product is required for RNA encapsidation (Bartenschlager et al., 
1990; Hirsch et al., 1990; Chiang et al., 1990; Chen et al., 1992) and in fact binds to 
the encapsidation signal (Bartenschlager and Schaller, 1992), thereby explaining the 
very small amount of polymerase detected in virions. 
The next step is reverse transcription of the RNA pre-genome by the viral polymerase 
gene product to form the (-) sense DNA strand of the genome, which has a terminal 
redundancy. Reverse transcription initiates in DR1 (Seeger and Maragos, 1990) and 
is primed by a protein primer, the reverse transcriptase itself, which remains 
covalently linked to the nascent DNA (Wang and Seeger, 1992). The RNA pre-
genome is degraded during (-) DNA synthesis by the RNaseH activity of the viral 
polymerase (Radziwill et al., 1990). The formation of the complementary (+) strand 
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DNA is also primed by an unusual mechanism. A capped oligoribonucleotide derived 
from the 5' end of pregenomic RNA is found covalently attached to the 5' end of (+) 
DNA (Dudley et al., 1972; Lien et al., 1986) and primes formation of (+) DNA, 
whose 5' end maps to the first nucleotide downstream of DR2 (Lien et al., 1986; 
Seeger et al., 1986). However, as the (-) DNA template terminates just downstream 
of DR2, in order to form a complete (+) DNA strand, nascent (+) strands must switch 
to the 3' portion of (-) DNA. This transfer may be facilitated by the genome-linked 
protein. Polymerisation then continues but not to completion, possibly due to lack of 
sufficient nucleotides within the nucleocapsid, hence the partial double-stranded nature 
of the genome. Core antigen has recently been implicated in (+) DNA synthesis by the 
observation that HBV with core antigen lacking amino acids 165-183 produces (+) 
DNA inefficiently. This may be due to a condensing function of HBcAg which would 
package DNA in a manner akin to histones, thus allowing (+) strand synthesis to 
proceed in the limited space inside the nucleocapsid (Nassal, 1992a). 
1.5.3 Virion Assembi 
As described in section 1.4.4, core particle assembly proceeds spontaneously, and once 
pre-genomic RNA and the attached polymerase is packaged and replication has begun, 
the particle can be considered to be a complete nucleocapsid. In order to become a 
complete virion this nucleocapsid must acquire an outer envelope. This is presumed 
to occur via an interaction between the nucleocapsid and HBsAg embedded in the 
endoplasmic reticulum, the primary position of HBsAg in the cell (Ou and Rutter, 
1987). All three forms of surface protein are found in virions (Heerman et al., 1984) 
and the L and S (and possibly M ) proteins are essential for virion formation (Bruss 
and Ganem, 1991; Ueda et al., 1991). Budding into the ER via this interaction results 
in the formation of Dane particles which are then secreted from the cell by normal 
pathways of vesicular transport and not by lysis of the infected cell. 
It has been proposed that, as only replicated genomes (i.e. not pre-genomic RNA) are 
found in extracellular virions, genome replication causes an alteration in the 
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nucleocapsid, which then acts as a signal to trigger virus export. The discovery that 
HBcAg in mature DHBV virions is not phosphorylated, while intracellular HBcAg is 
phosphorylated (Pugh et al., 1989), suggests that de-phosphorylation of HBcAg occurs 
during genome replication and may be such a signal. 
1.6 Protein Structure and Disulphide Bonds 
There are four levels of structure in proteins: 
Primary structure 	- the sequence of amino acids in the polypeptide chain 
Secondary structure 	- structural motifs such as alpha helices and beta sheets 
Tertiary structure 	- the formation of separate domains within a polypeptide 
chain, which contain elements of secondary structure. 
Quaternary structure 	- the association of separate polypeptide chains to form the 
functional protein. 
HBV nucleocapsids contain all four levels of structure. As the rules for determining 
the structure of a protein are not as straightforward as those for DNA for example, 
protein structure prediction is very difficult and currently relies on computer programs 
which do not give wholly accurate results. Therefore experimental evidence for protein 
conformation is still required. 
While the amino acids of a protein are covalently linked to form a chain, the areas of 
the chain brought together during folding are held together, in the main, by non-
covalent forces (hydrogen bonds) which can be easily disrupted. For example, 
exposure to high temperature will cause the disruption of such hydrogen bonds, and 
the abolition of secondary, tertiary and quaternary structure. However, this will be 
impeded if disulphide bonds are present within the protein. These covalent bonds form 
between cysteine residues only, specifically between the sulphur atoms of these amino 
acids, as shown in Figure 1.9 (for a review of disulphide bond formation see 




A disulphide bond (B) will form between two cysteine residues (A) which are in the 
correct positions, in an oxidative environment. 
This bond can be broken by the action of an excess of reducing agent (R-SH) to create 
once again the two constituent cysteine residues (A). 
The structure of dithiothreitol, the reducing agent used in this work, is shown at the 
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involved should be in the range 0.4-0.9ijm (Creighton, 1984b). These bonds are stable 
once formed, unless exposed to reducing agent which would result in the reversible 
cleavage of the bond (Figure 1.9), or by oxidants which can cleave disulphide bonds 
irreversibly, to the sulphinic (RS02H) and suiphonic (RS03H) acids. Other 
nucleophiles can also break disulphide bonds, reversibly. Therefore the nature of the 
environment in which cysteine residues are present is also important in determining 
whether disulphide bond formation will occur. As intracellular proteins are in a 
reductive environment, they generally do not contain disulphide bonds, but such bonds 
are often found in extracellular proteins. Extracellular proteins which have been 
secreted from cells have passed through the lumen of the endoplasmic reticulum, the 
first compartment of the secretory pathway, and it is thought to be here that disulphide 
bond formation occurs, possibly by the action of the enzyme protein disulphide 
isomerase which is localised to the ER (reviewed by Freedman, 1984). However, HBV 
core particles produced in E. coli form disulphide bonds only after disruption of the 
host bacteria and exposure to an oxidative environment, as they are not naturally 
secreted from the cell. 
HBcAg has four cysteine residues which are completely conserved among mammalian 
hepadnaviruses and therefore all four are candidates for disulphide bond participation. 
As HBcAg molecules associate to form the nucleocapsid, the possibility exists for both 
intra- and inter-molecular disulphide bonds to be formed, and an investigation of 
disulphide bond formation in HBV core particles is presented in Chapter 4. 
1.7 Aims of the Thesis 
At the time when the work presented in this thesis was initiated, very little was known 
about the structure of HBV nucleocapsids. Electron microscopy had demonstrated that 
these nucleocapsids are regular structures of approximately 27 nm diameter, with 
icosahedral symmetry, and are composed of 180 subunits. As HBcAg has proved to 
be resistant to crystallisation, no crystal structure data was available and so molecular 
biological methods were required to investigate the structure further. 
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It had been demonstrated previously that when the C gene of HBV was expressed in 
E. coil, nucleocapsid-like particles were formed with morphology indistinguishable 
from nucleocapsids isolated from HBV-infected individuals, and so E. coli was an 
ideal system in which to produce core particles for further study. While creating 
plasmids from which higher levels of HBcAg could be expressed in E. coli, Stahl et 
al. (1982) found that expression of a plasmid encoding amino acids 3 to 183 of 
HBcAg resulted in an ammonium sulphate-precipitated extract which reacted well with 
anti-HBcAg antibodies, but that this was not true for a plasmid encoding amino acids 
5 to 183 of HBcAg, which failed to react significantly with antibody. The aim of the 
work presented in Chapter 3 of this thesis was to investigate the reason for this lack 
of reactivity. This was to be achieved by creating a series of substitution and deletion 
mutants involving amino acids 3 to 6 of HBcAg and investigating their levels of 
expression in E. coli, and the reaction of the purified proteins with anti-HBc 
antibodies, alongside the original proteins. 
The cloning and sequencing of various HBV subtypes and mammalian hepadnaviruses 
revealed complete conservation of the four cysteine residues of HBcAg. In 
combination with the unpublished observations of our laboratory that core particles 
would enter a denaturing polyacrylamide gel during electrophoresis only after 
incubation with an excess of reducing agent, this suggested that the cysteines of 
HBcAg may be involved in inter-molecular disulphide bonds. The aim of the work 
presented in Chapter 4 of this thesis was to determine, firstly, which if any of the 
cysteines of HBcAg are linked by inter-molecular disulphide bonds; secondly, which 
if any of the cysteines are involved in intra-molecular disulphide bonds, and thirdly 
to determine the importance of the completely conserved cysteine residues to the 
integrity and properties of the core particles. These aims were to be achieved by 
creation and examination of the behaviour during non-reducing SDS-PAGE of a panel 
of mutant proteins in which cysteines were substituted by serines in various 
combinations. Work by Stahl and Murray (1989) demonstrated that the removal of the 
arginine-rich carboxy-terminal region of HBcAg did not affect the ability of the 
protein to form nucleocapsid-like structures when expressed in E. coil. In order to 
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investigate whether removal of the carboxy-terminal region of the protein had any 
effect on disulphide bond formation in the particle, the cysteine mutants were also 
examined in the context of truncated proteins. 
Finally, the aim of the work presented in Chapter 5 was to extend the investigation 
of the effect of the carboxy- terminus of HBcAg on disulphide bond formation in the 
remainder of the protein by examining disulphide bond formation in three HBcAg 
fusion proteinsby the use of non-reducing SDS-PAGE. These proteins, created by 
Stahl and Murray (1989), consist of foreign sequences fused to amino acid 144 of 
HBcAg, and the foreign sequences differ from each other, and from the carboxy-
terminal region of HBcAg, in terms of both length and cysteine content. 
While the specific aim of this work was to determine the role of particular amino 
acids of HBcAg in determining the structure of core particles, it was also anticipated 
that such observations could be a means of drawing further, more general, conclusions 
about the structure of the HBcAg monomer and of the particles it forms, in particular 
by indicating their spatial arrangements. 
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CHAPTER 2: Materials and Methods 
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2A MATERIALS 
2A.1 SUPPLIERS OF LABORATORY REAGENTS 
Restriction endonucleases: 
Boehringer Mannheim plc; Mannheim, Germany 
New England Biolabs Inc; Beverly, Massachusetts, USA 
Pharmacia LKB Biotechnology; Milton Keynes, UK 
E. coli DNA Polymerase I (Kienow fragment): 
Boehringer Mannheim plc 
Northumbria Biologicals Limited, Northumberland, UK 
T4 DNA Ligase: 
Boehringer Mannheim plc 
T4 Polynucleotide Kinase: 
Prepared by S. Bruce (Reference: Midgely and Murray, 1985) 
Deoxyribonuclease I: 
Sigma Chemical Co.; Poole, UK 
Ribonuclease A: 
Sigma Chemical Co. 
M-MLV Reverse Transcriptase: 
Gibco-BRL Life Technologies; Paisley, UK 
Thermus aquaticus (Taq) Polymerase: 
International Biotechnologies Inc. (IBI); New Haven, Connecticut, USA 
Boehringer Mannheim plc 
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Deoxynucleoside triphosphates and dideoxynucleoside triphosphates: 
Boehringer Mannheim plc 
Radioactive nucleoside triphosphates and deoxynucleoside triphosphates: 
Amersham International plc; Aylesbury, UK 
Standard Laboratory Reagents (various grades): 
BDH Chemicals Ltd; Poole, UK 
Fisons Chemicals; Loughborough, UK 
Gibco BRL Life Technologies 
Sigma Chemical Co. 
Bacterial Media Reagents: 
Becton-Dickinson UK Ltd; Oxford, UK 
Difco Laboratories; East Mosely, UK 
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2A.2 MICROBIOLOGICAL MATERIALS 
2A.2.1 BACTERIAL STRAINS 
Escherichia coli K12 strains used in this work are listed below: 
Strain: 	 TG1 
Relevant Genotype: 	hsd5, (lac,pro), supE, thi, [F' traD36, proA+, lacZ 
M1 5, lacI] 
Use: 	 host for bacteriophage M13 vectors 
Reference: 	 Amersham International (in catalogue supplied with 
product RPN2322) 
Strain: 	 BMH71-18 mutL 
Relevant Genotype: 	mutL::TnlO, (lac, pro), supE, thi, [F' proAB, lacZ 
MiS, lacP] 
Use: 	 transformation host for heteroduplexes produced by 
SDM using bacteriophage M13 






F lac with laclq 
Use: 
	
host for tac expression vectors 
Reference: 
	
Stahl and Murray (1989) 
2A.2.2 BACTERIOPHAGE AND PLASMIDS 
E. Coli plasmids and bacteriophage used in this work are listed below. Construction 
of derivative plasmids and bacteriophage is described in chapters 3 and 4. 
Name: 	 M13mp18 
Description: 	E. coli bacteriophage M13-based vector used for generating 
single-stranded DNA for sequence determination and site-
directed mutagenesis. This vector contains a portion of the lacZ 
gene and multiple cloning sites. 
Reference: 	Messing and Vieira (1982); Norrander et al. (1983) 
Name: 	 pRI-11 
Description: 	Amp'. This plasmid contains the coding sequence for amino 
acids 1-8 of 3-galactosidase followed by three linker amino 
acids (GluPheHis) followed by amino acids 3-183 of HBcAg, 
under the control of the lac UV5 promoter, in a pBR322 
background. 
Reference: 	Stahl et al. (1982) 
Name: 	 pRl-4 
Description: 	Ampr. This plasmid contains the coding sequence for amino 
acids 1-8 of -galactosidase folowed by three linker amino 
acids (GluPheHis) followed by amino acids 5-183 of HBcAg, 
under the control of the lacUV5 promoter, in a pBR322 
background. 
Reference: 	Stahl et al. (1982) 
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Name: 	 pTacHpaIIR2 
Description: 	Ampr, Tetr. This plasmid contains the coding sequence for 
amino acids 1-8 of -galactosidase followed by three linker 
amino acids (GluPheHis) followed by amino acids 3-144 of 
HBcAg, under the control of the tac promoter, in a pBR322 
background 
Reference: 	Stahl and Murray (1989) 
Name: 	 pHBcpresl(1-20), pHBcpres 1(1-36), pHBcE46 
Description: 	Amp'. These plasmids are derived from pTacHpaIIR2 and have 
sequences inserted at the appropriate position to encode the 
following fusion proteins: 3-galactosidase (amino acids 1-8) 
/GluPheHis/ HBcAg (amino acids 3-144) followed by, 
respectively: 
HBV preSi (amino acids 1-20) 
HBV preSi (amino acids 1-36) 
HIV env (amino acids 728-751) 
Reference: 	Stahl and Murray (1989) 
2A.2.3 MICROBIOLOGICAL MEDIA 
Luria Broth (L-Broth) 
1% 	(w/v) Difco Bacto Tryptone 
0.5% (w/v) Difco Bacto Yeast Extract 
1% 	(w/v) NaCl 
pH adjusted to 7.2 
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L-Agar 
1% 	(w/v) Difco Bacto Tryptone 
0.5% (w/v) Difco Bacto Yeast Extract 
1% 	(w/v) NaCl 
1.5% (w/v) Difco Agar 
pH adjusted to 7.2 
Top Agar 
1% 	(w/v) Baltimore Biological Laboratories trypticase 
0.5% (w/v) NaCl 
1% 	(w/v) Difco agar 
(0.1mM X-gal and 1mM IPTG if required) 
5x Spizizen Salts 
0.2% (w/v) (NH4)2SO4 
1.4% (w/v) K2HPO4 
0.6010 (w/v) KH2PO4 
0.1% (w/v) tn-sodium citrate 
0.02% (w/v) MgSO4 
Minimal Agar 
1.5% (w/v) Difco Bacto Agar 
0.2% (w/v) glucose 
lx Spizizen Salts 
A 
ampicillin used at 1004ugIml 
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2B GENERAL METHODS 
213.1 NUCLEIC ACID METHODS 
213.1.1 Phenol Extraction of Nucleic Acid 
Phenol was equilibrated with 1M Tris-HC1 pH8.0 prior to use. An equal volume of 
phenol was added to the solution of nucleic acid, vortexed thoroughly and subjected 
to centrifugation at 17000x g for 5 minutes at room temperature. The upper aqueous 
phase containing nucleic acid was removed and retained. 
2B.1.2 Phenol/Chloroform/Isoamyl Alcohol (PCI), Chloroform or Butanol Extraction 
of Nucleic Acid 
PCI 	50% phenol 
48% chloroform 
2% isoamyl alcohol 
These methods are the same as that for phenol extraction of nucleic acid but with PCI, 
chloroform or butanol substituted for phenol. 
2B.1.3 Ethanol Precipitation of Nucleic Acid 
TE 	25mM Tris 
10mM EDTA 
pH adjusted to 8.0 
To a solution of nucleic acid was added 0.1 volume of 3M sodium acetate pH5.2 and 
2.5 volumes of cold (-20°C) absolute ethanol. This was mixed thoroughly and 
incubated at -20°C for a minimum of 30 minutes. Nucleic acid was sedimented by 
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centrifugation at 17000x g in a microfuge for 15-30 minutes, or at 12000x g in a 
Sorvall centrifuge for 30-45 minutes at 4°C. The pellet was dried under vacuum and 
redissolved in TE. 
2B.1.4 Isopropanol Precipitation of Nucleic Acid 
The method is that for ethanol precipitation of nucleic acid but substituting 0.4 volume 
5M ammonium acetate for sodium acetate, and 2 volumes of cold (-20°C) isopropanol 
for ethanol. 
2B.1.5 Quantification of DNA 
The optical density (OD) of nucleic acid solutions at 260 im  was measured using a 
Unicam Ultraviolet and Visible Spectrophotometer (SP500 Series 2). An OD,60 value 
of 1.0 represents a concentration of 501ug/ml for double-stranded DNA and 38uglml 
for single-stranded DNA. 
2B.2 ENZYMATIC MANIPULATION OF DNA 
2B.2.1 DNA ligation 
lOx Ligation Buffer 	500mM Tris pH 7.8 
100mM MgCl2 
200mM DTI' 
WITI 01 TO WMH 
5001ug/ml BSA 
Ligation of cohesive ends was carried out with an insert:vector ratio of approximately 
3:1. Ligation of blunt ends was carried out with an insert:vector ration of 
approximately 5:1. The DNA was incubated for 15-19 hours at 14°C in lx Ligation 
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Buffer in the presence of 1 unit of T4 DNA ligase per 4ug of DNA. 
2B.2.2 Restriction enzyme digestion 
DNA was digested at 37°C, unless stated otherwise, in lx restriction buffer (supplied 
by the manufacturer) by 5-10 units of enzyme per 4ug DNA. Reactions were terminated 
by either incubation at 70°C for 15 minutes or, when BamHI was used, by phenol 
extraction followed by ethanol precipitaion. 
2B.3 PURIFICATION OF DNA 
2B.3.1 Electrophoresis of Nucleic Acid 
10xTBE 	 108gTris 
9.3g EDTA 
55g Boric acid 
made to 1 litre with H20 
pH 8.3 
5 x DNA Sample Buffer 	15% (w/v) ficoll, molecular weight 400000 
50mM EDTA 
0.125% (w/v) bromophenol blue 
0.125% (w/v) xylene cyanol FF 
DNA was fractionated on the basis of fragment size by electrophoresis in submerged, 
horizontal, agarose slab gels. Agarose gels consisted of 1% (w/v) agarose, which was 
melted in 1 x TBE buffer in a microwave oven. Gels were cast containing 0.5ug/ml 
ethidium bromide. Prior to loading, 0.2 volume of 5 x DNA Sample Buffer was added 
to each sample. Electrophoresis was carried out in 1 x TBE buffer, at 5-20 volts/cm. 
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1kb Ladder (Bethesda Research Laboratories) was used for DNA size markers and 
consists of DNA fragments of sizes (bp): 
12,216 	8,144 	4,072 1,018 	298 	142 
11,198 	7,126 	3,054 516/506 	220 	75 
10,180 	6,108 	2,036 394 	200 
9,162 	5,090 	1,635 344 	154 
2B.3.2 Warm Phenol method for elution of DNA from a low-melting point agarose 
gi 
DNA was electrophoresed through a 1% low melting point agarose gel in the presence 
of 14uglml ethidium bromide. After viewing under an ultra-violet lamp, the piece of 
gel containing the appropriate fragment of DNA was excised with a clean scalpel. To 
this was added an equal volume of TE followed by incubation at 65°C until the 
agarose melted. This was then extracted twice with phenol (equilibrated to 37°C), once 
with PCI (room temperature) and once with butanol (room temperature). The DNA 
was recovered by ethanol precipitaion, dried under vacuum and resuspended in an 
appropriate volume of TE. 
3.3 "Geneclean II" (Bio 101 Inc) method for elution of DNA from an aarose 
DNA was electrophoresed through a low melting-point agarose gel in lx TBE. The 
appropriate piece of the gel was removed and to it was added 0.5 volume "TBE 
Modifier" (a mixture of concentrated salts) and 4.5 volumes 6M Nal followed by 
incubation at 50°C for 5 minutes. "Glassmilk" (a suspension of silica matrix in H10) 
was then added (5ul for 5g or less of DNA and an additional 11u1 for every further 
0.51ug of DNA) and incubated on ice for 5 minutes (or 15 minutes if the total volume 
was greater than 1.5ml), with occasional mixing. The "Glass milk"/DNA complex was 
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then pelleted by centrifugation at 17000x g at room temperature for 5 seconds and all 
supernatant removed. The pellet was washed 3 times with "New Wash" (50% ethanol, 
NaCl, Tris-HC1, Tris-base, EDTA pH 7.0-8.5), followed by addition to the pellet of 
an equal volume of TE. This was incubated at 50°C for 3 minutes and then subjected 
to centrifugation at 17000x g for 30 seconds at room temperature. The supernatant was 
removed and retained. 
2B.3.4 Small-Scale Preparation of Plasmid DNA from E. coli 
Lysis Buffer 	25mM Tris-HCI pH8.0 
10mM EDTA 
50mM glucose 
Lysis Solution 	0.2M NaOH 
1% (w/v) SDS 
(freshly prepared) 
1.5ml of a stationary phase E. coli culture, grown in the presence of ampicillin, was 
centrifuged at 17000x g for 2 minutes at room temperature. The supernatant was 
discarded and the cell pellet resuspended in 100l of Lysis Buffer. 2004ul of Lysis 
Solution was then added, mixed by inversion and incubated on ice for 5 minutes. After 
addition of 15014 of 3M sodium acetate pH 5.2 and incubation on ice for 20 minutes, 
the heavy precipitate of denatured protein and chromosomal DNA was pelleted by 
centrifugation at 17000x g for 10 minutes at room temperature. This centrifugation 
step was repeated to remove residual debris. The plasmid DNA was recovered from 
the supernatant by ethanol precipitaion and the resulting DNA pellet was washed with 
70% (v/v) ethanol, dried under vacuum and resuspended in 50ul of H20- 
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2B.3.5 Small-Scale Preoaration of M13 Reølicative Form DNA from E. coli 
imi of L-Broth was innoculated with 154u1 of a stationary phase culture of TG1 cells, 
and with a single fresh M13 plaque. After shaking for 6 hours at 37°C, the procedure 
followed was that for the small-scale preparation of plasmid DNA from E. coli 
(above). 
2B.3.6 Large-Scale Preparation of Plasmids from E. coli 
50m1 of a stationary phase E. coli culture, grown in the presence of ampicillin, was 
centrifuged at 10000x g for 10 minutes at 4°C and the cell pellet resuspended in 3.5m1 
of Lysis Buffer. To this was added 8mg of lysozyme dissolved in 0.5m1 Lysis Buffer 
and the mixture incubated on ice for 1 hour. 8 ml of Lysis Solution was added and 
thoroughly mixed, followed by incubation on ice for 1 hour. Addition of 5ml of 3M 
sodium acetate pH5.2 and vigorous mixing followed by incubation on ice for 1 hour 
produced a heavy precipitate which was peileted by centrifugation at 11000x g for 45 
minutes at 4°C. The supernatant was extracted with PCI and the DNA in the aqueous 
layer was recovered by precipitation with isopropanol and centrifugation at 11000x g 
for 15 minutes at 4°C. The DNA pellet was dried under vacuum and resuspended in 
0.5m1 of H10. Ribonuclease A was added, to a final concentration of 0.2mg/mi, 
followed by incubation at 37°C for 20 minutes. This was extracted with PCI until the 
interface between the aqueous and organic phases was clear and the DNA was then 
recovered from the aqueous phase by ethanol precipitation. The pellet was resuspended 
in TE to a final concentration of 11ug/1ul. 
2B.4.1 DEPC-HO Preparation 
To lOOmI of H20 was added 2001ul of DEPC. This was shaken vigorously and allowed 
to stand at room temperature for 20 minutes before being sterilised in an autoclave. 
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AU solutions used in RNA work were made using DEPC-H20. 
2B.4.2 Small-Scale Preparation of RNA from E. coli 
The method used was essentially that of Barry et al. (1992). 
50ul of a stationary phase culture of the appropriate plasmid-carrying cells, grown in 
selecting medium, were added to 5m1 L-Broth containing ampicillin and shaken at 
37°C until 0D650 = 1.0. IPTG was then added to a final concentration of 0.5mM and 
the culture shaken at 37°C for approximately 14 hours. 1.5m1 of this culture was then 
centrifuged at 17000x g for 2 minutes, the supernatant discarded and the cell pellet 
resuspended in 204u1 of DEPC-H20 to which was added 34ul of 0.5% DEPC. 2004ul ice-
cold acetone was then added and mixed by hand before centrifugation at 17000x g for 
2 minutes. The supernatant was removed and the pellet resuspended in 30ul of DEPC-
H20. 11ul of 1004ug/mI Proteinase K was added, the mixture incubated on ice for 10 
minutes and 3.51ul DEPC (0.5%), 2004ul phenol (pre-heated to 70°C) and 1501u1 
chloroform added and mixed by hand. After centrifugation at 17000x g for 5 minutes 
the aqueous phase was removed and added to lml of ethanol and the RNA allowed 
to precipitate at -20°C for 1 hour before recovery by centrifugation at 12000x g for 
15 minutes and resuspension of the RNA pellet in 1001u1 DEPC-H20. RNA was stored 
at -700C. 
2B.4.3 Removal of DNA from RNA Preparations 
501ul of RNA from the above preparation was precipitated with ethanol and 
resuspended in 501ul of 10mM Tris! 1mM EDTA. To this was added 504u1 of DNase 
Cocktail and the mixture incubated at 37°C for 15 minutes. This reaction was stopped 
by the addition of 251 4 of DNase Stop Mix followed by one PCI extraction, one 
chloroform extraction and ethanol precipitation and the resulting pellet resuspended 
in 50,ul of DEPC-1120. 
2B.4.4 RNase Treatment of Control RNA Samples 
To 25l of DNase-treated RNA was added 21u1 of 10mg/mi RNase A which was then 
incubated at 37°C for 30 minutes. This was then extracted once with PCI and once 
with chloroform and then added to 2.5 volumes ethanol. After incubation at -20°C for 
1 hour the solution was centrifuged at 12000x g for 15 minutes and 251u1 of DEPC-
H20 added to the Eppendorf tube. 
213.4.5 Reverse Transcription of RNA 




0.5mM each of dGTP, dATP, dTTP, dCTP 
10ug/m1 oligonucleotide* 
* oligonucleotide = pd(T)15 or pd(N)6 
101 4 of each RNA sample was incubated in the above conditions, in a total volume 
of 201u1, at 65°C for 3 minutes. 200 units of M-MLV Reverse Transcriptase were then 
added to each sample and the mixture incubated at 37°C for 1 hour. These two steps 
were repeated once more and followed by incubation at 70°C for 5 minutes. 21u1 of 
each reaction mixture was then used directly in the Polymerase Chain Reaction as 
described below. 
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2B.5 POLYMERASE CHAIN REACTION 
5x PCR Buffer 100mM Tris-HCl pH8.3 
500mM KC1 
15mM MgCl2 
0.1% (w/v) gelatine 
0.1% (v/v) Tween 20 
0.1% (v/v) NP40 
All reactions were carried out using either a Techne Programmable Dri-Block PHC1-1 
or a Biometra Thermo-Trioblock. 
To 100pg-lg of DNA were added: 21ul of 10mM dNTPs, 101u1 PCR Buffer, 
approximately lOOpmol of each oligonucleotide and 0.5u1 of Taq Polymerase. H20 
was added to give a total volume of 50ul, and 501u1 of mineral oil was layered on top 
of this to prevent evaporation of the reaction constituents. Annealing temperature and 
extension times were dependent on the nature of the DNA being amplified. Annealing 
temperature was determined by the following calculation: 
annealing temperature (°C) = 	4x (total G+C in oligonucleotide) + 
2x (total A+T in oligonucleotide) - 5°C 
Only those nucleotides which were complementary to the original DNA sequences 
were included in the above calculation and other nucleotides, for example those 
included in the oligonucleotide to create a restriction enzyme recognition site, were 
excluded. 
Extension times used were : 	1 minute for 1 to 400 bases 
1-5 minutes for 400-1000bases. 
MOO 
Thus for each reaction: 	 denaturation: 93°C, 1 minute 
annealing: 	specific temperature, 1 minute 
extension: 	72°C, specific time 
All reactions proceeded for 30 cycles. 
In the case of samples derived from reverse transcription of RNA (2B.4.5), an 
additional 3 cycles were employed at the start. These were: 95°C for 5 minutes, 
specific temperature for 2 minutes and 72°C for 1 minute. 
Positive controls utilised plasmid DNA to which primers were known to hybridise. 
Negative controls were identical to test samples but lacked DNA. 
To remove oligonucleotides and dNTPs from the reaction products, reaction mixtures 
were electrophoresed through a 1% low melting point agarose gel and the DNA of the 
appropriate size cut out of the gel and eluted using either the hot phenol method or 
Geneclean II (Bio 101 Inc.). 
213.6 E. coli TRANSFORMATION 
2B.6.1 Transformation of E. coli with plasmid DNA 
TSB 	10% (w/v) PEG 3000 (molecular weight approximately 3000) 
5% DMSO (v/v) 
10mM MgCl2 
10mM MgSO4 
Made to final volume with L-Broth 
50 ml of L-Broth was innoculated with 0.5 ml of a stationary-phase culture of 
W31101q, TG1 or mutL cells and shaken at 37°C until 0D650=0.3. Cells were 
centrifuged at 4000x g for 5 minutes at room temperature and the cell pellet 
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resuspended in 0.1 volume of TSB, followed by incubation in glass tubes on ice for 
at least 30 minutes. DNA was added to lOOdUl of the cell suspension and this was 
incubated on ice for 30 minutes. 2004u1 TSB and 201u1 20% (w/v) glucose were added, 
and the mixture shaken at 37°C for 1 hour and then spread onto L-Amp agar plates. 
Plates were incubated for approximately 16 hours at 37°C. 
213.6.2 Transformation of E. coli with M13 ReDlicative Form or Single-Stranded DNA 
The procedure followed was that for transformation of plasmid DNA up to and 
including the incubation of cells and DNA on ice. After this, lml of TSB and 204ul 
20% (w/v) glucose were added and the mixture shaken at 37°C for 1 hour. 2.5ml 
molten (45°C) Top agar containing X-gal and IPTG was then added together with 
2004u1 of E. coli cells in L-Broth of 0D650=0.3 and the mixture was poured onto 
minimal agar plates and allowed to solidify before incubation at 37°C for 
approximately 16 hours. 
2B.7 DNA SEQUENCING 
2B.7.1 Small-Scale M13 Temolate Preoaration 
M13 TE 	10mM Tris 
0.1mM EDTA 
A culture of TGI cells in L-Broth of 0D650=0.2 was innoculated with a fresh M13 
plaque and shaken for 4-5 hours at 37°C. The culture was centrifuged at 17000x g for 
2 minutes at room temperature and the cell pellet discarded. To the supernatant was 
added 2004u1 of 2017o (w/v) PEG 6000 in 2.5M NaCl, followed by incubation at room 
temperature for 30 minutes. This was then centrifuged at 17000x g for 5 minutes at 
room temperature, the supernatant discarded and the centrifugation repeated. All 
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remaining supernatant was removed using a drawn-out capillary tube, and 1001 4 M13 
TE was added, together with 50I phenol. This was vortexed vigorously for 10 
seconds, incubated at room temperature for 10 minutes, vortexed for 10 seconds and 
centrifuged at 17000x g for 5 minutes at room temperature. The organic layer was 
discarded and the single-stranded DNA was recovered from the aqueous phase by 
ethanol precipitation. The DNA pellet was resuspended in 50ul of M13 TE. 
213 .7.2 Dideoxynucleotide DNA Sequencing 
TM 	100mM Tris pH 8.5 
50mM MgCl2 




dNTP Termination Mixes (volumes in 1td) 
I 
0.5mM dGTP 6.25 125 125 125 
0.5mM dTTP 125 125 6.25 125 
0.5mM dCTP 125 125 125 6.25 
10mMddGTP 4 
10mM ddATP 0.25 
10mM ddTTP 12.5 
10mM ddCTP 2 
M13 TE 250 125 250 250 
Formamide Dye 	0.1%(w/v) xylene cyanol 
0.1%(w/v) bromophenol blue 
10mM EDTA 
in formamide 
Primer Mix 	84u1 DNA template (approximately 11ug) 
1ul oligonucleotide primer (approximately 0.3 pmole for 17-
mer) 
1ul TM 
Primer Mix for Single Nucleotide Tracking 
3dul DNA template (approximately 0.41ug) 




Kienow Mix (per template 
81ul 10mM Tris pH8.0 
0.8ul 100mM DIT 
4uCi [a-35SdATP (81uCi/1u1; Amersham) 
1.7 units E.coli DNA Polymerase I Kienow Fragment (5U/1u1) 
Oligonucleotide Primers 
705C: 5'-TCA GGA GAC TCT AAG GC-3' 
complementary to nucleotides 121-136 of the sense strand of the C gene of 
HBV. 
159E: 5'-GGC CCA CAT TAG TGT TG-3' 
complementary to nucleotides 267-283 of the sense strand of the C gene of 
HBV. 
193C: 5'-ACG COG CGA TTG AGA TC-3' 
complementary to nucleotides 500-516 of the sense strand of the C gene of 
HBV. 
542E: 5'-AU AGG AAA AGA GGG CG-3' 
complementary to nucleotides 633-649 of HBV130 (Pasek et al., 1989), S'to 
the stop codon of the C gene and within the P ORF. 
The method used was essentially that of Sanger et al. (1977). Template, normally 
made by the small-scale template method, was hybridised to an oligonucleotide 
complementary to a site within either the cloned insert or the lacZ gene of M13mp18, 
by incubation of the template/primer mix at 80°C for 5 minutes followed by cooling 
to room temperature over approximately 15 minutes. Sequencing reactions were then 
performed in microtitre plates as follows. To each well was added: 24ul of G, A, T or 
C mix, 2ul of template/primer mix and 21ul of Klenow mix. These were mixed at the 
bottom of each well and incubated at room temperature for 25 minutes. 21u1 of Chase 
mix was then added to each well, mixed, and incubated at room temperature for 20 
minutes. Reactions were stopped by addition of Formamide Dye (24ul) followed by 
incubation at 80°C for 15 minutes, then cooling on ice before loading onto a 
polyacrylamide gel. 
213.7.3 Single Nucleotide Trackin 
This was used for rapid screening of DNA produced by site-directed mutagenesis and 
the method is essentially that for normal sequencing after the initial hybridisation, but 
only one nucleotide termination mix was used. 
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2B.7.4 Urea-Polyacrylamide Gel Electrophoresis of Sequencing Reaction Products 
Urea-Polyacrylamide Gel Mix (for 6% gel) 
17g urea 
6m1 38%(w/v) Acrylamide, 2%(w/v) B is-acrylamide 
4m1 lOx TBE 
0.24m1 10%(w/v) ammonium persulphate 
0.035m1 TEMED (N,N,N,N'-tetraethylenediamine) 
H20 to final volume of 40 ml. 
Gel mix was poured between 2 glass plates (40cm x 20cm) separated by spacers 
(0.5mm) and allowed to polymerise with the well comb in place. 
Approximately 21u1 of each sample was loaded onto the gel, in the order GATC, and 
the sequencing reaction products separated by electrophoresis in 1xTBE running buffer 
at a constant power of 25 watts. Electrophoresis was continued until the required 
separation was achieved (bromophenol blue migrates with DNA fragments of 
approximately 25 nucleotides in length, xylene cyanol migrates with DNA fragments 
of approximately 75 nucleotides in length). After electrophoresis, the gel was 
transferred to blotting paper and dried on a vacuum gel dryer. X-ray film was exposed 
to the gel for at least 16 hours in a light-excluding cassette, at -70°C to prevent the 
gel from sticking to the film. 
2B.8 SITE-DIRECTED MUTAGENESIS 
213.8.1 Large-Scale Single-Stranded M13 Template Preparation 
2004ul of TG1 cells, grown overnight at 37°C in L-Broth, were added to 20 ml fresh 
L-Broth and shaken at 37°C for 3 hours. 1004 4 of this culture was then added to lml 
L-Broth, which was also innoculated with a fresh M13 plaque, and this was shaken 
at 37°C for 4 hours. After centrifugation at 17000x g for 5 minutes at room 
temperature, the supernatant was removed and added to a lOOmI L-Broth culture of 
TG1 cells (0D550 of 0.3). This was shaken at 37°C for 4 hours and then centrifuged 
at 5000x g for 30 minutes at 4°C. To the supernatant, 0.2 volume of 201yo (w/v) PEG 
6000 in 2.5M NaC1 was added, mixed thoroughly and incubated for 1 hour at 4°C. 
The phage precipitate was pelleted by centrifugation at 15000x g for 20 minutes at 
room temperature and the supernatant removed. Re-centrifugation (15000x g for 5 
minutes) was followed by removal of all remaining PEG/NaCl. The phage pellet was 
resuspended in 5001u1 M13 TE and centrifuged for 5 minutes at 17000x g at room 
temperature to remove any remaining cells. 2001u1 of 20% PEG (w/v) in 2.5M NaC1 
was mixed with the supernatant and incubated at room temperature for 15 minutes. All 
supernatant was removed after centrifugation at 17000x g for 5 minutes at room 
temperature and re-centrifugation at 17000x g at room temperature for 2 minutes. The 
viral pellet was then resuspended in 2001u1 phenol, vortexed for 15 seconds, incubated 
at room temperature for 15 minutes, vortexed for 15 seconds and centrifuged for 3 
minutes at 17000x g. The aqueous layer was removed and subjected to phenol 
extraction as before. 5001ul diethyl ether was then mixed thoroughly with the 
supernatant and the top layer discarded. This was repeated 3 times. The aqueous phase 
was then mixed with 5001u1 chloroform and the organic layer discarded. This was 
repeated once. The single-stranded M13 DNA was then precipitated with ethanol, 
dried and suspended in M13 TE to a final concentration of 1ug/4u1. 
2B.8.2 Phosphorylation of 5' ends of olionucleotides with T4 polynucleotide kinase 
lox LK Buffer 






5' phosphate groups were added to unphosphorylated oligonucleotides by 
polynucleotide kinase. 1 unit of T4 polynucleotide kinase was incubated with 
approximately lOOpmole of oligonucleotide in lx LK Buffer for 90 minutes at 37°C. 
The reaction was stopped by incubation at 70°C for 10 minutes. After PCI extraction, 
the oligonucleotide was precipitated with ethanol and resuspended in 124ul of H20. 
2B.8.3 Mutaenesis 
To 121u1 of phosphorylated oligonucleotide were added 31ug of template and 
approximately lOOpmoIe of M13 universal primer (-20) (New England Biolabs). This 
was incubated in a final concentration of 1xTM at 80°C for 5 minutes and then cooled 
to room temperature, allowing the oligonucleotides to anneal to the template. To this 
mixture was then added 1.5 units of DNA Polymerase I (Kienow fragment) and 5 
units of T4 DNA ligase. This was incubated in the presence of 1004uM dNTPs, 1mM 
ATP, 0.5mM Tris pH8.0 and 5uM EDTA, for 90 minutes at room temperature 
followed by one extraction with phenol and one extraction with butanol. The DNA 
was then precipitated with ethanol, resuspended in 321u1 of H20 and digested with 
EcoRI and BamHL The digestion products were run in a 1% pure low melting-point 
agarose gel and the appropriate band of DNA cut out and eluted by the warm phenol 
method. 
250g of this eluted fragment was ligated to 80g of M13mp18 DNA which had 
previously been digested with EcoRI and BamHI, precipitated with isopropanol to 
remove the small fragment generated by the digestion, and resuspended in an 
appropriate volume of H20. Products of this ligation were transformed into mutL cells 
and plated onto minimal agar plates containing X-gal and IPTG. White plaques were 
picked, small-scale template preparations made and the appropriate nucleotide 
screening performed, followed by complete sequencing of positive templates. 
2B.9 PROTEIN METHODS 
2B.9.1 Preparation of Proteins from E. coli 
Lysis Buffer 	50mM Tris-HC1 pH 8.0 
1% (w/v) Triton X-100 
5ml of a stationary-phase culture of the appropriate plasmid-carrying cells, grown in 
selecting medium, were added to 500m1 of L-Broth containing ampicillin (pre-warmed 
to 37°C) and shaken at 37°C until 0D650 = 1.0. IPTG was then added to a final 
concentration of 0.5mM and shaking at 37°C continued for a further 16 hours. Cells 
were harvested by centrifugation at 10000x g for 10 minutes at 4°C and the cell pellet 
resuspended in 5m1 of Lysis Buffer. This suspension was split between eppendorf 
tubes and each tube subjected to sonication (3 x 15 seconds). Cell debris was removed 
by centrifugation at 11000x g for 10 minutes at 4°C and the supernatant (the crude 
extract) retained. 
2B.9.2 Further Purification of Crude Extract 
Column Buffer 	0.1M NaHCO3 pH 7.0 
0.1mM Phenylmethylsuiphonamide (PMSF) 
0.1mM Benzamidine 
Crude extract underwent 35% ammonium sulphate precipitation by addition of 2g of 
ammonium sulphate per lOmi of extract, gradually over 30 minutes on ice with 
constant stirring, followed by a further 30 minutes of stirring on ice. The precipitate 
was recovered by centrifugation at 13000x g for 10 minutes at 4°C. The pellet was 
then resuspended in 50mM Tris pH 8.0 and dialysed against 50mM Tris pH 8.0 for 
16 hours at 4°C. 
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This was then applied to a 3cm x 10cm, or a 3cm x 40cm Sepharose 4B column 
equilibrated with Column Buffer. Sml fractions were collected and 204ul or 50,ul of 
each fraction electrophoresed through a 15% polyacrylamide gel. Those fractions 
containing the most, and the most pure, desired proteins were then pooled and 
subjected to centrifugation at 100000x g for 1 hour at 4°C and the pellet resuspended 
in 50mM Tris pH 8.0. 
2B.9.3 Electrophoresis of Proteins in Polyacrylamide Gels 
Resolving gel Solution (sufficient for 4 gels) 
8.8ml 30% (w/v) acrylamide, 0.2% (w/v) bis-acrylamide 
0.35ml 10% (w/v) SDS 
7.OmI 1.875M Tris-HC1 pH 8.8 
10.09ml H20 
0.05m1 10% (w/v) ammonium persuiphate (fresh) 
0.02m1 TEMED 
Stacking Gel Solution 
1.67ml 30% (w/v) acrylamide, 0.2% (w/v) bis-acrylamide 
1.0ml 0.6M Tris-HC1 pH 6.8 
0.1ml 10% (w/v) SIDS 
7.l8ml H20 
0.05ml 10% (w/v) ammonium persulphate (fresh) 
0.01ml TEMED 
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Sample Loading Buffer 




0.01g Bromophenol Blue 
10 x Electrophoresis Buffer 
25mM Tris-HC1 
192mM Glycine 
0.1% (w/v) SIDS 
Stain 
0% (v/v) methanol 
10% (v/v) glacial acetic acid 
0.2% (w/v) Coomassie Blue 
De-Stain 
40% (v/v) methanol 
10% (v/v) glacial acetic acid 
All electrophoresis was carried out using the Biorad MiniProtean II Gel Apparatus and 
the method used was the discontinuous buffer system of Laemmli (1970). 
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Resolving gel solution was poured between 2 glass plates (10cm x 7cm) separated by 
0.75mm spacers and left to polymerise at room temperature for at least 1 hour after 
being overlaid with H20. The H20 was then removed and Stacking Gel Solution 
added. The gel comb was inserted and the gel left to polymerise at room temperature 
for at least 20 minutes. 
Samples were loaded and electrophoresis carried out in 1 X Electrophoresis Buffer at 
50 volts until the dye had entered the resolving gel, and then at 200 volts until the dye 
reached the bottom of the gel. The gel was then removed from the apparatus and 
either transferred to nitrocellulose (see below) or stained as follows. The gel was 
immersed in Stain and rotated gently for at least 20 minutes. The stain was removed, 
De-Stain added and rotation continued until the areas of the gel not containing protein 
were colourless. 
Molecular weight markers used were: 
Low Molecular Weight Markers (Pharmacia) 
94kD phosphorylase b 
67kD bovine serum albumin 
43kD ovalbumin 
30kD carbonic anhydrase 
20.1kD trypsin inhibitor 
14.41cD a-lactalbumin 
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Rainbow Molecular Weight Markers (Amersham) 
46kD ovalbumin 
30kD carbonic anhydrase 
21.5kD trypsin inhibitor 
14.3kD lysozyme 
6.5kD aprotinin 
3.41cD insulin (b) chain 
2.35kD insulin (a) chain 
2B.9.4 Preparation of Protein Samples for Electrophoresis 
Reducing Electrophoresis 
An equal volume of Sample Loading Buffer was added to each sample, together with 
DY!' to a final concentration of approximately 0.1M. This was then incubated at 
100°C for 5 minutes (except where stated otherwise) and loaded immediately onto the 
gel. 
Non-Reducing Electrophoresis 
As for Reducing Electrophoresis samples, with the omission of DTI. 
2B.9.5 Lowry Protein Assay 
Solution 1 	2% (w/v) Na2CO3  
0.1M NaOH 
0.01% (w/v) CuSO4.5H20 
0.02% (w/v) sodium citrate 
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Solution 2 	50% Folin-Cocteau Reagent 
50% H20 
0.4 ml of sample was added to 2m1 of Solution 1, mixed and incubated at room 
temperature for 10 minutes. 0.2m1 of Solution 2 was then added, mixed thoroughly 
and incubated at room temperature for 30 minutes. Optical density at 550im was then 
measured. The assay was calibrated using BSA standards of 1-200,ug/ml. 
2B.9.6 Electrophoretic Transfer of Proteins Separated in Polyacrylamide Gels to 
Nitrocellulose Membranes (Western Blotting) 
Transfer Buffer 	 25mM Tris-HC1 pH8.3 
192mM Glycine 
20% (v/v) Methanol 
Amido Black Stain 	0.1% (w/v) amido black NB (Sigma) 
40% (v/v) Methanol 
10% (v/v) Glacial Acetic Acid 
Amido Black de-Stain 	40% (v/v) Methanol 
10% (v/v) Glacial Acteic Acid 
The method used was essentially that described by Towbin et al. (1979). Samples 
were subjected to SDS-PAGE in a 15% polyacrylamide gel which was then laid onto 
a piece of nitrocellulose of equal size. These were then placed between 6 pieces of 
blotting paper cut to the size of the gel, and 2 Scotchbrite pads, all of which had been 
soaked in Transfer Buffer. This sandwich was then inserted into a "Trans-blot" 
apparatus (Biorad) filled with Transfer Buffer. Proteins were transferred to the 
nitrocellulose at 60 V for 1 hour. The temperature was kept low throughout by the 
presence of a water-filled cooling coil. 
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After transfer, nitrocellulose. containing the marker lanes was cut off and stained 
irreversibly with amido black for 30 seconds and then washed in several changes of 
Amido Black de-stain. This step was not required when pre-stained markers (Rainbow 
Molecular Weight Markers) were used. 
2B.9.7 Isolation of anti-HBcAg IgG from Rabbit Serum (for use in Western Blotting) 
PBS 	 4mM NaH2PO4 
6mM Na2HPO4 
150mM NaCl 
pH adjusted to 7.0 
Serum from the third bleed withdrawn 9 days after the third innoculation of rabbit 87, 
with HBcAg produced in E. coli (Biogen Inc.), was diluted with an equal volume of 
PBS, followed by addition of ammonium sulphate, gradually over 30 minutes, to 40% 
saturation followed by stirring on ice for a further 30 minutes. This was centrifuged 
at 13000x g for 10 minutes at 4°C and the pellet resuspended in PBS. The 40% 
ammonium sulphate precipitation was then repeated and the pellet again resuspended 
in PBS and dialysed for at least 16 hours against PBS at 4°C. 
2B.9.8 Immunological Detection of Proteins Immobilised on Nitrocellulose Filters 
TS 	 10mM Tris-HC1 pH 8.1 
150mM NaCl 
Block Buffer 	 5% BSA in TS 
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Developing Solution 	100mM Tris-HC1 pH 9.5 
100mM NaCl 
50mM MgCl2 
0.33mg/mi nitro-blue-tetrazolium (NBT) 
0.25mg/mi 5-bromo-4-chloro-3-indolyl-phosphate 
(BCIP) 
(NBT and BCIP added immediately prior to use) 
The nitrocellulose membrane onto which protein had been electroblotted was incubated 
for at least 1 hour at room temperature, with shaking, in Block Buffer in order to 
prevent non-specific binding of antibody to the membrane. Block Buffer was removed 
and the membrane incubated with the primary antibody (anti-HBcAg IgG at 
approximately 5ugfm1 in Block Buffer) for 4-16 hours at room temperature with gentle 
shaking. The primary antibody solution was removed and the nitrocellulose washed 
in 5 changes of TS over 30 minutes. Anti-rabbit alkaline phosphatase conjugate 
(5g/ml in Block Buffer) was then added and incubated for 2 hours, gently shaking 
at room temperature. The nitrocellulose was then washed in TS as before and 
developed with Developing Solution for 2-15 minutes at room temperature. The 
reaction was stopped by washing the membrane in several changes of H20. 
2B.10 RADIOIMMUNE ASSAYS 
2B.10.1 Isolation of anti-HBcAg/anti-HBeAQ from Human Serum 
This was performed by the Department of Medical Microbiology of the University of 
Edinburgh. 
Solution A: 0.02M NaH2PO4 
Solution B: 0.02M Na2HPO4 
0.01M Phosphate Buffer pH 7.5 = 190m1 Solution A + 1000ml Solution B 
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2.5m1 of high titre human anti-HBcAg/anti-HBeAg serum was UV-treated for 30 
minutes and then inactivated at 56°C for 30 minutes. This was then centrifuged at 
3000 rpm for 5 minutes and the supernatant placed in dialysis tubing and dialysed for 
approximately 16 hours at 4°C against 0.01M Phosphate Buffer. 12.5g of DEAE 
cellulose (Whatman DE52) was equilibrated with Phosphate Buffer and to it was 
added the inactivated serum which was then mixed gently for 10 minutes with a metal 
applicator, followed by incubation at 4°C for 30 minutes with occasional stirring. 50m1 
of Phosphate Buffer was added to the cellulose/serum mixture and filtered through a 
sintered glass funnel, a further 50m1 Phosphate Buffer added and all filtrate retained. 
lOmi 1.5M NaCl was added to lOOmi of filtrate and concentrated to the original 
volume of serum by using dialysis tubing under vacuum. 
2B.10.2 'I-Labelling of anti-HBcAg/anti-HBeAg Isolated from Human Serum 
This was performed by Peter McCulloch of the Department of Medical Microbiology 
of the University of Edinburgh. 
The method used was essentially that of Hunter and Greenwood (1962). 101ug of anti-
HBcAg/HbeAg (213.10.1) was labelled with 5001uCi 1251 and diluted in RIP Buffer 
(2B.10.3) to give a final concentration of 50000 cpm per 1504ul. 
213.10.3 Microtitre Plate-Based Radioimmune Assay 
Coating Solution 
1201ug!ml anti-HBeAg IgG 
60,ug/ml anti-HBcAg IgG 
RIP Buffer 	0.5% BSA in PBS 
1004u1 of Coating Solution was added to a microtitre plate well and incubated at room 
temperature for 15-30 minutes. The Coating Solution was then removed and the plate 
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washed 3 times with H20 and allowed to dry at room temperature. 754u1 of sample 
(diluted in RIP Buffer) was added to each well and incubation at room temperature 
continued for 16 hours. The sample was then removed and the plate washed 10 times 
with H20 and air-dried at room temperature. 'I -labelled anti-HBcAg IgG (1000cps) 
was added to each well and incubated for 1 hour at 45°C. This was then removed, the 
wells washed 10 times with H20 and the 'I-IgG remaining bound counted with a 
gamma counter (LKB 1275 MiniGamma). 
10.4 Bead-Based Radioimmune Assa 
Beads (diameter 6.4mm) were incubated in 2004u1 Coating Solution per bead for 15-30 
minutes at room temperature, then Coating Solution was removed and the beads air-
dried at room temperature. 1501u1 of sample (diluted in RIP Buffer) was added to each 
bead and incubation proceeded for 16 hours at room temperature. Sample was 
removed and the beads washed 10 times with H20, after which 'I-labelled polyclonal 
anti-HBcAg/anti-HBeAg IgG (1000cps) was added to each bead and incubated for one 
hour at 45°C. After removal of 'I-IgG, beads were washed 10 times with H 2O and 
the 1251-IgG remaining bound was counted with a gamma counter (LKB 1275 
MiniGamma) for 10 minutes. 
213.10.5 Correction Factor 
As each sample was counted for 10 minutes, between the counting of the first and last 
samples, significant 1251 decay occurred. In order that all samples could be compared 
directly, a correction factor was employed to remove the effect of 1251  decay, and was 
calculated as follows: 
'I half-life = 60 days = 86400 minutes 
i.e. after 86400 minutes 'I activity decays by a factor of 0.5, so in time t, the decay 
factor is 0.5t/86400. 
Therefore the amount of decay (in cpm) of the original activity, x (in cpm) 
= x x (0.5t/86400), which in turn = x - y, where y is the actual reading in cpm 
recorded by the gamma counter. i.e. x x (0.5t/86400) = x - y 
which can be re-arranged to give: 1/x = lly - t/172800y. 
As the values for t and y are known, the value for x (the activity before decay) can 
be calculated. 
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CHAPTER 3: The Amino-Terminal Region of HBcAg is Important for Core 
Particle Structure Determination 
ri 
3.1 Introduction 
The amino-terminal region of HBcAg is highly conserved among mammalian 
hepadnaviruses. Indeed, amino acids 1 to 10 are completely conserved (Figure 3.1A) 
and 26 of the corresponding nucleotides (1 to 30) are identical (Figure 3.113). This 
would suggest an important role for these residues. Indeed, Salfeld et aL (1989) found 
that a protein synthesised in vitro which consisted of amino acids 12-183 of HBcAg 
had drastically reduced activity in a radioimmune assay with anti-HBcAg antibodies, 
compared to wild-type HBcAg. 
Further evidence for the importance of the amino-terminal region came from Stahl et 
al. (1982). With the aim of producing a plasmid from which HBcAg could be 
expressed in E. coli with enhanced efficiency, several plasmid constructs were created 
(Figure 3.2A). Ammonium sulphate precipitated extracts of cultures of E. coli 
containing these plasmids were investigated in a radioimmune assay with polyclonal 
anti-HBcAg antibodies (as in section 2B.10.3) (Figure 3.2B). A striking difference was 
apparent between the activity of the pRI-11 and pRI-4 products. The proteins produced 
from these plasmids differ in only two amino acids. Both plasmids encode amino acids 
1 to 8 of f3-galactosidase followed by three linker amino acids, but pRI-11 then 
encodes amino acids 3 to 183 of HBcAg while pRI-4 lacks HBcAg amino acid codons 
3 and 4 and encodes amino acids 5 to 183. The product of pRI-11 was shown to form 
particles morphologically and immunologically indistinguishable from HBV 
nucleocapsids isolated from infected individuals, and has been subsequently used 
extensively in studies of HBcAg. 
The product of pRI-4 has been investigated further in this work, in order to determine 
whether its lack of activity in the radioimmune assay was due to the level of 
expression of the protein in E. coli, which was not previously investigated, or to a 
difference in the structure of the core particles it forms, if indeed it forms core 
particles, thus reducing its affinity for anti-HBcAg antibodies. Similar investigations 
were also undertaken of a panel of substitution and deletion mutants involving amino 
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Legend 3.1 
Conservation of amino acids 1 to 10 between HBV subtypes and the other 
mammalian hepadnaviruses. 















HBVadyw ATGGACATTG ACCCTTATAA AGAATTTGGA 
HBVadr ATGGACATTG ACCCGTATAA AGAATTTGGA 
HBVadw ATGGACATTG ACCCTTATAA AGAATTTGGA 
HBVayw ATGGACATCG ACCCTTATAA AGAATTTGGA 
HBVayr ATGGACATTG ACCCGTATAA AGAATTTGGA 
HBVadw2 ATGGACATTG ACCCTTATAA AGAATTTGGA 
HBVadr4 ATGGACATTG ACCCGTATAA AGAATTTGGA 
WHV ATGGACATAG ATCCTTATAA AGAATTTGGT 
GSHV ATGGACATAG ATCCCTATAA AGAATTTGGT 
IDENTITY ATGGACATG A CC TATAA AGAATTTGG 
Figure 3.2 
(from Stahl et at., 1982) 
Sequences of plasmid constructions produced by Stahl et at. (1982). The region 
shown extends from the start point of translation of the 3-galactosidase gene 
to amino acid 6 of the HBcAg gene. The deletions extend from nucleotide 2 
of the Pro codon following the EcoRI linker, to the points indicated by the 
arrow heads. Note particularly deletions 4 and 11. 
* = stop codon. 
Results of radioimmune assay of ammonium sulphate-precipitated extracts of 
E. coli cultures expressing the plasmids described in A (above), with 
polyclonal anti-HBc/HBe antibodies (Stahl et at., 1982). Note particularly the 









D ilution of extract  
acids 3 to 6, which were created in this work by site-directed mutagenesis. 
3.2 Results 
3.2.1 Plasmid Constructions 
Plasmids pRI-11 and pRI-4 contain HBcAg sequences under control of the lacUV5 
promoter (section 2A.2.2). The tac promoter had been shown to be more efficient for 
HBcAg expression in E. coli (Stahl and Murray, 1989), and so the coding regions of 
pRI-11 and pRI-4 were transferred to a vector in which they could be expressed under 
control of the tac promoter in order to maximise their expression. 
Plasmid pTacpCore contains sequences encoding amino acids 1-8 of 3-galactosidase 
fused to 3 linker amino acids (Glu Phe His) which are in turn fused to amino acids 
3-183 of HBcAg. These sequences are expressed under control of the tac promoter, 
expression from which is induced by the presence of IPTG. This plasmid was created 
by the digestion of pRI-11 (section 2A.2.2) with EcoRI and BamHI to liberate a 
1005bp fragment containing the coding sequences described above, minus the l-
galactosidase amino acid codons; which was then ligated to the larger (4373bp) 
EcoRI/BamHI digestion product of pTacHpallR2 (section 2A.2.2), which contains the 
tac promoter and the coding sequences for amino acids 1 to 8 of -galactosidase. The 
resulting plasmid was used to express large amounts of HBcAg in E. coli, referred to 
in the remainder of this thesis as wtHBcAg or as CWT. 
Plasmid pTacpRl-4 was created in the same manner as pTacpCore but with pRI-4 
(section 2A.2.2) substituted for pRI-11, thereby creating a final product which encodes 
amino acids 1-8 of 3-ga1actosidase fused to three linker amino acids (Glu Phe His) 
which are in turn fused to amino acids 5-183 of HBcAg. 




Wild-type and deletion mutants of the coding sequences for the amino-terminal region 
of HBcAg 
All sequences shown are the non-coding strand and read, from left to right, GATC and 
from top to bottom, 3' to 5'. All show the EcoRI site (GAATTC) at the top of each 
photograph. 
The deleted codons are indicated by A. 
CWT is pTacpCore 
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3.2.2 Site-Directed Mutagenesis 
The template for mutagenesis was created by insertion of the lOOSbp fragment 
produced by EcoRI/BamHI digestion of pRI-11, between the EcoRI and BamHJ sites 
of M13mp18, such that single-stranded template contained the "sense" strand. A large 
scale template preparation (2B.8.1) of this was prepared and used in site-directed 
mutagenes is. 
Deletion Mutants 
Three single deletion mutants were created using the following oligonucleotides: 
A11e3  
oligonucleotide: 367E 5' - CTI' TAT AAG GGT CGT GGA ATF CGT AA - 3' 
As p4 
oligonucleotide: 366E 5' - AU CU TAT AAG GAA TGT GGA AU CG - 3' 
APro5  
oligonucleotide: 365E 5' - CCA AAT TCT UA TAG TCA ATG TGG AAT T - 3' 
These mutants were sequenced along the length of the coding region and are shown 
in Figure 3.3. 
Five substitution mutations were also created, using the following oligonucleotides. 
The partners of the nucleotides to be mutated are underlined: 
lie3 - Asp 
oligonucleotide: 561C 5' - TTA TAA GG TCA TCG TGG AAT TCG T - 3' 
Asp4 - Asn 
oligoncleotide: 562C 5' - TTA TAA GGG TTA ATG TGG A - 3' 
Asp4 - Val 
oligonucleotide: 563C 5' - TCT TTA TAA GGCA ATG TGG AAT T - 3' 
Pro5 -b Gly 
oligonucleotide: 564C 5' - AAA TTC TITF ATA ACC GTC AAT GTC GAA - 3' 
Tyr6 - Phe 
oligonucleotide: 565C 5' - CCA AAT TCI' TTA MA GGG TCA ATG T - 3' 
The sequences of these mutants were verified by DNA sequencing along the length 
of the coding region and are shown in Figure 3.4. 
3.2.3 Expression and Purification 
All plasmids were introduced into E. coli strain W31101q and expression of the 
desired proteins induced by exposure to 0.5mM IPTG. Crude extracts were made 
which were then subjected to ammonium sulphate precipitation at 35% ammonium 
sulphate saturation. Passage of dialysed ammonium sulphate precipitated extracts 
through a Sepharose 4B column resulted in all HBcAg-derived proteins present being 
eluted from the column before fraction 11. This corresponds to a species of very high 
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Figure 3.4 
Wild-type and substitution mutants of the coding sequences for the amino-terminal 
region of HBcA 
All sequences shown are the non-coding strand and read, from left to right, GATC 
and, from top to bottom, 3' to 5'. All show the EcoRI site (GAATTC) at the top of 
each photograph. 
* indicates the nucleotides that have been mutated. 
CWT is pTacpCore 
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molecular weight, such as a core particle composed of 180 molecules of full-length 
protein, which has a predicted molecular weight of approximately 3.7 x 106D. The 
behaviour of all the mutant proteins during purification was therefore consistent with 
their existence in the form of high molecular weight particles. 
A measurement of the levels of expression of the proteins was achieved by 
comparison of the final yield of each protein after purification. That the differences 
shown below were due to the amount of protein produced and not due to differential 
loss of protein during purification was verified by examination by eye of the amount 
of the desired protein present in reducing SDS-polyacrylamide gels of the crude 
extract, before purification (not shown). 
Average yield from two 500ml cultures: 
pTacRI-4 (AJle3Asp4) 	 501ug 
AJle3 	 75ug 
Asp4 - Asn 	 10O4ug 
Asp4 - Val 	 804ug 
Pro5 - Gly 	 7501ug 
Tyr6 - Phe 	 850,ug 
pTacpCore 	 8754ug 
AAsp41  iPro5 and 11e3 - Asp proteins could not be detected, either on Coomassie 
stained gels or on Western Blots. This was true when expression was attempted both 
in W31101q cells and in TG1 cells (not shown). 
85 
3.2.4 Detection of Messenger RNA 
In order to determine whether the genes encoding the above proteins were being 
expressed, the presence or absence of C gene-specific mRNA within these cells was 
determined. This was achieved by making use of the polymerase chain reaction. Total 
RNA preparations were made from E. coli cultures containing the appropriate plasid, 
expression from which had been induced by IPTG (strains W31101q and TG1) as 
described in Section 2B.4.4. Half of this preparation was stored at -70°C while the 
remainder was treated with DNase (Section 213.4.3) to remove any contaminating 
DNA. Finally, half of this DNase-treated RNA was further treated with RNase 
(Section 2B.4.4). All three RNA preparations were then subjected to two rounds of 
reverse transcription, using either the oligo dT primer or the random hexamer primer, 
and a proportion of each completed reaction mixture employed as template for the 
polymerase chain reaction. The following C gene-specific oligonucleotide primers 
were used in the amplification reaction: 
140R: 5'-GGA AlT CCA CAT TGA CCC TJ'A-3' 
which hybridises to the non-coding strand, beginning at the first nucleotide of the 
EcoRI site. 
542E: 5'-AU AGG AAA AGA GGG CG-3' 
which hybridises to the coding strand 80 nucleotides downstream of the C gene stop 
codon. 
and the annealing temperature used was 45°C. 
All sequences between and including these oligonucleotide primers would be included 
in mRNA expressed from the tac promoter in these plasmids and the polymerase chain 
reaction would be expected to produce a DNA fragment of 630 bp, identified by 
electrophoresis of 54u1 or 201u1 of the PCR reaction mixture through a 1% agarose gel. 
The results of this procedure are summarised in Figure 3.5. As the PCR product (and 
Figure 3.5 
Indirect detection of C gene-specific mRNA by use of the polymerase chain reaction 
RNA was isolated from E. coli in which expression of the appropriate plasmids had 
been induced. These samples were either un-treated, treated with DNase only or 
treated with DNase and RNase before being subjected to reverse transcription. An 
equal volume of the products of reverse transcription of each sample was then used 
as template for the polymerase chain reaction (PCR) using HBV C gene-specific 
primers. PCR reaction products were then electrophoresed through a 1% agarose gel 
and the presence or absence of a 630bp fragment detected by ethidium bromide 
staining. The results are summarised in this table. 
.1 indicates the presence of the 630bp product 
x indicates the absence of the 630bp product 
The results produced were independent of the E. coli strain (W31101q or TG1) or 
reverse transcriptase primer (oligo dT or random hexamer) used and so each / or x 
is representative of four separate results (with the exception of W31101q only and 
TG1 only, which are representative of two separate results). 
Normal positive and negative PCR controls were used. 
SAMPLE RNA RNA (DNase- 
TREATED) 
RNA (DNase + 
RNase- 
TREATED) 
RI-4 (Mle3Asp4) / / x 
M1e3  / / x 
LASJJ4 / / x 
Pro5  / / x 
I1e3-Asp / / x 
Asp4-Asn / / x 
Asp4-*Val / / x 
Pro5-G1y / / x 
Tyr6-Phe / / x 
TacpCore / / x 
W311 01q only x x x 
TGlonly x x x 
hence the reverse transcription product) was obtained when any contaminating DNA 
had been removed but not when RNA was removed, the PCR product was amplified 
from reverse-transcribed RNA, and as only a single band of the expected size was 
produced, the RNA was C gene-specific. Therefore, the lack of protein detected was 
not due to lack of mRNA expression or stability. 
3.2.5 Electron Microscopy 
Examination of the product of pTacpRl-4 (i.e. iXIle3Asp4) with the electron microscope 
demonstrated that the particles it forms are morphologically indistinguishable form 
those formed from wild-type HBcAg (Figure 3.6). AIle3Asp4 has the largest mutation 
of the series examined (deletion of two amino acids) and reacts most abberantly with 
antibodies (see below), and so it may be predicted that the particles formed by the 
other mutant proteins also have morphology similar to that of wild-type particles. 
Therefore, the mutations made do not affect the ability of the proteins to form 
nucleocaps ids-like structures. 
3.2.6 Non-Reducing SDS-Polvacrvlamjde Gel Electroijhoresis 
Following incubation at 100°C for 5 minutes in the absence of reducing agent, fresh 
preparations of all proteins failed to enter a 15% SDS-polyacrylamide gel, or a small 
proportion of the sample ran as a faint smear (Figure 3.7), in the same manner as 
fresh preparations of CWT (see Chapter 4). In order for the protein to be prevented 
from entering the gel, it must have a molecular weight of greater than approximately 
200kD. This would correspond to all protein molecules being present in the form of 
disulphide bond-linked multimers consisting of at least 10 monomers. This would 
require at least 80% of the potential disulphide bonds (see Chapter 4) which form the 
completely disuiphide-linked network in the wild-type protein to be present. 
Figure 3.6 
Electron Microscopy of TacpRI-4 (AI1e 
The purified protein product of pTacpRl-4 was examined with the electron microscope 
by S. Bury. 
Both M1e3Asp4  and CWT are shown at a magnification of 400 000x. 
The nature of the fibrous material in the AIIe3Asp4 electron micrograph is unknown. 
iIIe 3 Asp4  
CWT 
- 
1 - - - 	. 
-4 
Figure 3.7 
Non-reducing SIDS-polvacrylamide gel electrophoresis of amino-terminus mutants 
All proteins which were expressed were purified and subjected to SDS-PAGE after 
incubation at 100°C for 5 minutes in the absence (-) or presence (+) of an excess of 
DTI'. Gels were stained with Coomassie Blue. 
54ug of protein was loaded in each well. 
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3.2.7 Radioimmune Assays 
The interaction of all purified proteins with antibodies was investigated in a bead-
based radioimmune assay. Beads coated with polyclonal anti-HBc/anti-HBe antibodies 
from human serum were incubated with the following dilutions of purified protein: 
5ug of protein was diluted i/iO, 115x103, i/iU, 1/5 x104, 1/105 and 1/106  in BSA 
solution (RIP Buffer, section 2B.10.3). These beads were then incubated with 1251. 
labelled polyclonal anti-HBc/anti-HBe IgG and the activity of the bound 1251-IgG 
measured with a gamma counter. Samples were counted for 10 minutes and a 
correction factor employed (section 2B.10.5) so that samples measured at different 
times after the final wash could be directly compared. All samples were assayed in 
duplicate and the average of the two figures (in counts per minute) for each sample 
calculated. This value was divided by the average of 6 values obtained from beads 
which had been processed in an identical manner to the other beads with the exception 
that no purified protein was added. Therefore, these beads allowed measurement of 
the background binding activity. This figure was termed the"negative" value, and the 
number obtained by dividing the sample value (positive, P) by the negative value (N) 
gave a P/N value which was then plotted on a graph (Figure 3.8). 
This graph shows that the activity of pTacpRl-4 (AIle3Asp4) and that of A11e3 are 
significantly lower than that of wild-type HBcAg, while the other mutants have 
activities similar to that of wild-type HBcAg. 
3.3 Discussion 
From this work, it is apparent that the reasons for the low activity of pRI-4 
(AIle3Asp4) in the original work by Stahl et al. (1982) are two-fold. Firstly, AIle3Asp4 
is present in E. coli expressing the appropriate plasmid at a lower level than wild-type 
HBcAg. Even when the total amount of protein was increased by making use of the 
tac promoter, the relative proportions of wild-type HBcAg and TacpRI-4 (ATle3Asp4) 
remained the same and yields of TacpRI-4 (AIIe3Asp4) were consistently less than 10% 
Figure 3.8 
Radioimmune assay of amino-terminus mutants 
5ug of purified protein was diluted by the factors shown on the x-axis of the graph 
and the radioimmune assay carried Out as described in section 2B.10.4, with 
polyclonal anti-HBc/anti-HBe antibodies. 
P/N = positive (sample) cpm / negative control cpm after employment of the 





















of the yield of wild-type HBcAg (from pTacpCore). Similarly, while substitution 
mutations involving amino acids 5 or 6 (Pro5 - Gly and Tyr6 - Phe) were expressed 
at levels approximating to wild-type, two substitution mutations involving amino acid 
4 were expressed at only approximately 10% of wild-type levels, and expression of 
the substitution mutation involving amino acid 3 (Ile3 - Asp) could not be detected 
at all. In contrast, the deletion mutant A11e3 was expressed, but at very low levels 
(approximately 10% of wild-type), while the expression of iAsp4 and APro5 could not 
be detected. 
The expression of HBcAg in E. coli is apparently highly sensitive to perturbations of 
sequence. Truncated C genes whose coding sequence terminates at the codon for 
amino acid 148 are expressed at higher levels than wild-type full-length HBcAg 
(Figure 4.7), and Nassal et al. (1992a), while various deletion mutants of the C gene, 
involving several different regions of HBcAg, produced no detectable protein (H. 
Davidson, personal communication), and sequence insertions at the amino terminus 
of HBcAg often result in a drastic reduction in expression levels (A. Shiau, personal 
communication), or an inability to express the protein (Clarke et al., 1987) in E. coli. 
This sensitivity may be either at the RNA level, resulting in reduced production of the 
mRNA or reduced translation of the mRNA; or at the protein level, whereby the 
mutant proteins are in fact produced but are more sensitive to protein-degrading 
elements within the cell and are degraded. In the case of the deletion mutants created 
by H. Davidson (above), this is thought not to be the case as samples of cells taken 
immediately after induction of expression with IPTG, and at many time points 
thereafter, contained no detectable HBcAg (H. Davidson, personal communication). 
As HBcAg-specific mRNA was detected indirectly in both TG1 and W31101q cells 
containing each mutant plasmid, it is apparent that lack of production of core-specific 
mRNAor lower stability of this mRNA is not the cause of low detection of the protein 
products. As the assay employed in this work is not quantitative there may be some 
variability in the levels of mRNA present, but it is clear that in the cases where no 
protein can be detected mRNA can be detected. This was also true for the deletion 
mutants created by H. Davidson (above) which produced mRNA but no detectable 
protein (H. Davidson, personal communication). 
The arginine-rich carboxy-terminal region of HBcAg produced in E. coli is known to 
bind both DNA and RNA (Matsuda et al., 1988; Gallina et al., 1989; Hatton et al., 
1992) and so may not be desirable for the cell. In addition, it may bind HBcAg-
specific mRNA, of which there will be large quantities in a cell containing an over-
expressing plasmid with HBcAg-encoding sequences. If this arginine-rich region is not 
present, as in the truncated proteins, no such binding would occur and this may 
explain the higher level of truncated protein relative to full-length protein found upon 
expression of the two proteins from the same promoter in the same E. coli strains. 
Alternatively, a limiting factor may be the availability of sufficient transfer RNAs for 
the large number of arginine residues present at the carboxy-terminal region of the 
protein. If this is indeed the case, it may be remedied by co-transformation with a 
plasmid containing the gene (dnaY) which encodes arginine tRNAs, thus resulting in 
the production of an excess of arginine tRNAs. However, the mutations that result in 
lower levels of protein being produced in this work are so varied in terms of both the 
nature of the mutations and the positions of the mutations within the protein that a 
similar explanation is less likely. 
The results of the radioimmune assay indicate that the low activity of AIle3Asp4 in the 
original radioimmune assay (Stahl et al., 1982) may not have been due entirely to a 
low level of expression of the protein in E. coli. The radioimmune assay used by Stahl 
et al. utilised only ammonium sulphate-precipitated extracts. While each sample was 
used at the same overall concentration, the concentrations of the HBcAg-derived 
proteins within the extracts may not have been the same. Indeed, this work 
demonstrates that the amount ofpTacRl-4 product (AIle3Asp4) present was less than 
10% of that of TacpRI-11. The radioimmune assay in this work, in contrast, makes 
use of purified proteins. As the same amount of each sample was used and each 
sample was of a very similar level of purity, all the samples can be compared directly. 
While the activity of TacpRI-4 (Ldle3Asp4) is not as low, relative to the protein 
consisting of amino acids 3-183 of HBcAg, in the radioimmune assay in this work as 
in the original radioimmune assay, for reasons probably relating to expression levels 
described above, it is still significantly lower than that of the latter protein. Similarly, 
the mutant in which only Ile3 is deleted shows activity significantly lower than wild-
type HBcAg. In contrast, all substitution mutations examined interacted with antibody 
to a similar extent to wild-type HBcAg. As deletion of Ile3 has a similar effect to 
deletion of Ile3  and Asp4 together, and substitution of Asp4 with either Asn or Val has 
no effect, it may be that Ile3 is the more important amino acid in this context. As 
AIle3Asp4 has a slightly lower activity than A11e3 it may be that deletion of Asp4 also 
contributes to the decrease in antibody interaction. However, this radioimmune assay 
may not be sufficiently accurate for such a conclusion to be made. It would therefore 
be useful to achieve expression of AAsP4 and include it in a radioimmune assay. In 
addition, a radioimmune assay involving monoclonal antibodies may be informative 
as this may further elucidate the changes in structure caused by mutations at the amino 
terminus of the protein. 
While in the context of the proteins used in this work amino acids 1 and 2 are not 
important for formation of normal core particles, it would be useful to create 
constructs in which the first amino acid of the expressed protein is amino acid 1 of 
HBcAg, with no fusion sequences present. This would determine whether the effect 
of the deletions described above is peculiar to this protein context or whether it is also 
true of the protein in its normal context and can therefore be extrapolated to the in 
vivo situation. 
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CHAPTER 4: Disulphide Bond Formation in Core Particles 
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4.1 Introduction 
HBcAg contains 4 cysteine residues which are completely conserved among 
mammalian hepadnaviruses (Figure 1.6) and occur at amino acid positions 48, 61, 107 
and 183. In contrast, the nucleotide codons for these residues show no preference for 
T or C in the third position (Figure 4.1). Therefore the conservation appears to be of 
amino acids rather than of nucleotides and suggests an important function for these 
cysteines, the most obvious of which would be their participation in disulphide bonds. 
Disulphide bonds can form between two cysteines only when the amino acids are in 
the correct orientation and the a-carbon atoms are 0.4-0.9 im  apart. The presence of 
an electron acceptor is also essential and so the redox potential of the environment is 
also important. Disulphide bonds can form between cysteines of the same (intra-
molecular) or separate (inter-molecular) polypeptide chains, if all the above criteria 
are met. As 180 subunits of HBcAg interact to form the nucleocapsid of HBV, it was 
possible that the cysteine residues of HBcAg could be involved in both intra-molecular 
(within the same molecule) and inter-molecular (betwen separate molecules) disulphide 
bonds. It has been noted that, in the absence of reducing agent, core particles produced 
in E. coli will not enter a denaturing polyacrylamide gel, while in the presence of an 
excess of reducing agent the protein will run in the gel as a 21kD monomer (our 
laboratory, unpublished observations; Gallina et al., 1989; Jeng et al., 1991). This 
suggests that intermolecular disulphide bonds are indeed formed. 
A straightforward means of determining the nature and importance of these bonds was 
to mutate the coding sequence of the C gene such that cysteine codons were replaced 
by codons for another amino acid. The effects of these mutations on the disulphide 
bond complement of the core particle were then assessed by investigating the 
mobilities of the mutant proteins in a SDS-polyacrylamide gel as disulphide bonds are 
covalent and therefore are not broken by the action of denaturing agents. Cysteine 
codons were replaced by serine codons as the corresponding amino acids are similar 
in size but serine has an oxygen atom in place of the sulphur atom of cysteine. This 
precludes serine residues from any involvement in disulphide bonds, but does not 
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Figure 4.1 
Cysteine codons of HBV Core gene 
CYS48 CYS61 CYS107 CYS183 
HBVadyw TGT TGC TGT TGT 
HBVadr TGT TGT TGC TOT 
HBVadr4 TGT TGT TGT TOT 
HBVadw TGC TGC TGC TOT 
HBVadw2 TGC TGC TGC TGT 
HBVayw TGT TGC TGT TGT 
HBVayr TOT TGT TGC TGT 
WHy TGC TGC TOT TGC 
GSHV TGT TGT TGT TGC 
Overall nucleotide sequence identity of the 549 nucleotides of the Core gene: 
HBV subtypes, WHV and GSHV - 	58.3% 
HBV subtypes only 	 - 	84.5% 
make a gross alteration to the amino acid structure, and potentially therefore, to the 
overall protein structure. Cysteine residues were mutated to serines singly, in pairs and 
in trios, and in the context of both the full-length HBcAg and a COOH-terminally-
truncated (HBeAg-like) protein in order to gauge any effect the arginine-rich carboxy-
terminus may have on the folding of the protein, which may be reflected in the 
disulphide bond pattern of the two proteins as the structural requirements for 
disulphide bond formation are so strict. 
4.2 Results 
4.2.1 Plasmid Constructions 
Plasmid pTacpCore contains sequences encoding amino acids 1-8 of -galactosidase 
fused to 3 linker amino acids (Glu Phe His) which are in turn fused to amino acids 
3-183 of HBcAg. These sequences are expressed under control of the tac promoter, 
which is induced by the presence of IPTG. This plasmid was created by digestion of 
pRI-11 (section 2A.2.2) with EcoRI and BamHI, to liberate a 1005 bp fragment 
containing the coding sequences described above, which was then ligated to the larger 
(4373 bp) EcoRI/BamHI digestion product of pTacHpaIIR2 (section 2A.2.2).] The 
resulting plasmid was used to express large amounts of wild-type HBcAg in E. coli. 
Plasmid pRI-11E contains the coding sequence for amino acids 1-8 of f3-galactosidase 
fused to 3 linker amino acids (Glu Phe His) which are in turn fused to amino acids 
3-148 of HBcAg, which are expressed under control of the tac promoter. This plasmid 
was created as shown in Figure 4.2 by using the polymerase chain reaction to amplify 
the above coding sequences from plasmid pTacpCore, which had been digested with 
EcoRI and BamHI and the resulting 1005 bp fragment ligated between the EcoRI and 
BamHI sites of M13mp18. The oligonucleotide primers used were 
(i) 568C: 5' - ATA ACA AliT TCA CAC AGG AAA CAG C - 3' 
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Figure 4.2 
Construction of plasmids encoding truncated proteins 
DNA encoding the full-length HBcAg was inserted between the EcoRI and 
BanHI sites of mplS. The polymerase chain reaction was then performed 
using primers 568C (section 4.2.1) which hybridises upstream of the EcoRI site 
within mp18; and 400F (section 4.2.1) which hybridises to sequences upstream 
of the codon for amino acid 144 of HBcAg and includes an in-frame stop 
codon and a BamHI site. 
The PCR product was then digested with EcoRI and BamHI 
and inserted between the EcoRI and BamHI sites of pTacHpaIIR2 which had 
been digested with EcoRI and BainIIJ, and the 4373bp vector fragment 
retained. This created a plasmid capable of expression, under control of the tac 
promoter, of amino acids 1-8 of (3-galactosidase followed by three linker 
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EFH 
which hybridises to sequences in the non-coding strand upstream of the EcoRI site of 
M13mp18; and 
(ii) 400F: 5' - GGG ATC CTC AAA CAG TAG TCT CCG GAA GTG - 3' 
which hybridises to sequences within the coding strand up to and including the Val 
148 codon, and also contains an in-frame stop codon immediately downstream of this. 
When both are double-stranded, oligonucleotide 568C contains an EcoRI restriction 
site and oligonucleotide 400F contains a BamHI restriction site, so that digestion of 
the PCR product with EcoRI and BamHI produced a fragment which was then ligated 
to the 4373 bp fragment which resulted from EcoRI/BamHI digestion of pTacHpaIIR2 
(section 2A.2.2). The resulting plasmid was used to produce large amounts of wild-
type truncated HBcAg in E. coli. The sequences of plasmids pTacpCore and pRI-11E 
were confirmed by DNA sequencing (Figures 4.3 and 4.4, respectively) 
4.2.2 Site-Directed Mutaenesis 
The procedure employed is shown in Figure 4.5. 
The template for mutagenesis was created by insertion of the 1005 bp fragment 
produced by EcoRI/BamHI digestion of pTacpCore, between the EcoRI and BamHI 
sites of M13mp18 such that single-stranded template contained the coding strand. A 
Large-Scale Template Preparation (Materials and Methods) of this was made and used 
in site-directed mutagenesis. 
Initially, the following 5 mutants were made and identified by DNA sequencing across 
the mutated region. The mutants are named C (for full-length Core protein) followed 
by the number of the codon(s) mutated to Serine (S). The partner of the nucleotide to 
be mutated is underlined. 
Cys48 - Ser (C48) 
oligonucleotide : 879D 5' - GAG GTG AAG AAT GCT CAG G - 3' 
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Figure 4.3 
Nucleotide Sequence of Full-Length Mutants - amino acid codons 48. 61, 107 and 
183. 
The nucleotide sequence shown is that of the non-coding strand, and reads from 
bottom to top, 5' to 3'. All sequences read, from left to right, GATC 
In all cases, mutation of cysteine codons to serine codons required substitution of a 
C in the second nucleotide position with a G, and this is indicated by the presence of 
CWT - - (48S COS 
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Nucleotide Sequence of Truncated Mutants - amino acid codons 48, 61 and 107. 
The nucleotide sequence shown is that of the non-coding strand, and reads from 
bottom to top, 5' to 3'. All sequences read, from left to right, GATC 
In all cases, mutation of cysteine codons to serine codons required substitution of a 
C in the second nucleotide position with a G, and this is indicated by the presence of 
• - - 	1. 
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The full-length wild-type C gene coding sequence was removed from 
pTacpCore by digestion with EcoRI and BamHI. 
This was inserted between the EcoRI and BamHI sites of M13mp18 such that 
single-stranded template contained the coding strand. This template was then 
subjected to oligonucleotide site-directed mutagenesis, as described in section 
213.8, and initially four single mutants and 
one double mutant (C48,61S) were created. This double mutant was then used 
as template for the creation of 
two triple mutants, C48,61,107S and C48,61,183S, by the same procedure. 
The nucleotides which have been changed are indicated by * 
	
EcoRl 	 BamHI 
, 	48 	61 	107 	18 	 - 




Eco R I/B a rnHI 
_B_ 	 EcoRI 	
B3mHI 
C C C C 
__________L mplS 	
48 	61 	107 	183 
TGT TGC TOT TOT 
TCT 	TCC 	TCT 	TCT 	snIe mutants * * * * 
S 	S 	S 	S 
C 	 EcoRI 	 EaruHi 
- I S S C C 
AND 	- ! 	48 	61 	107 	183 	- - - 
C48.61S - - 	TCT TCC TOT TGT * * 
D 
S S S C 
C48,61,1075 	48 61 107 183, H-- -- 
TCr TCC TCT TOT * * * 
S S C S 
43 61 107 1S3 ..C48,61,183S 
TCT TCC TGT TCT * * 	* 
Cys6l - Ser (C61S) 
oligonucleotide : 880D 5' - CTC CCC AGQ AAA GAA TI'G C - 3' 
Cys107 - Ser (C107S) 
oligonucleotide : 881D 5' - CCA AAA GTG AGA GAA GAA ATG TG - 3' 
Cys183 - Ser (C183S) 
oligonucleotide : 543E 5' - AGG GAT ACT AAG ATI' GAG ATF CC - 3' 
Cys48,61 - Ser (C48,61S) 
oligonucleotides : 879D and 880D (above). 
A large scale template preparation of the double mutant C48,61S template was then 
utilised as template for site-directed mutagenesis to create the mutants: 
Cys48,61,107S - Ser (C48,61,107S) 
Cys48,61, 183S - Ser (C48,61,183S) 
An additional double mutant, Cys61,107 - Ser (C61,107S) was created as shown in 
Figure 4.6, using the polymerase chain reaction. Template C48,61,107S was amplified 
using primers 568C (see pRI-11E production, above) and the M13 (-20) (New England 
Biolabs) primer which hybridises to sequences downstream of the BamHI site in 
M13mp18, in the non-coding strand, thereby producing a DNA fragment of 1025bp 
which contains the entire HBcAg coding region (Product 1). Sequences from template 
C61S were amplified using primers 568C (above) and 
159E: 5' - GGC CCA CAT TAG TGT TG -3' 
which hybridises to the coding strand approximately 30 nucleotides upstream of the 
Cys 107 codon, thereby producing an amplified DNA product of 325bp (Product 2) 
KO 
Figure 4.6 
Construction of plasmid C61,107S 
Mutant C61S template in mp18 was amplified using primers 568C (section 
4.2.1) which hybridises within mp18 upstream of the EcoRI site, and 159E 
(section 4.2.2) which hybridises upstream of the Cys107 codon. 
Mutant C48,61,107S template in mp18 was amplified with 568C (above) and 
the M13(-20) primer which hybridises to mp18 downstream of the BamHI site. 
PCR products were both digested with HincII which cleaves the DNA at the 
5' end of the 159E primer region and the digestion product of Product 1, 
containing Cys48 and Ser6l codons was ligated to the digestion product of 
Product 2, containing Ser107 and Cys183 codons. 
This ligated DNA was then digested with EcoRI and BamHI 
and inserted into the vector fragment of pTacHpaIIR2 which had been digested 
with EcoRI and BamHI. This plasmid has the capacity to encode cysteines at 
amino acid positions 48 and 183 and serines at positions 61 and 107. 
C61,107S construction 
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which encodes from the amino-terminus up to amino acid 94 of HBcAg. Both PCR 
products were then digested with Hind!, which recognises a single site within these 
PCR products and restricts the DNA bluntly one nucleotide from the 5' end of the 
159E primer region. The 269 bp fragment from digestion of Product 2 therefore 
contains sequences encoding a cysteine at position 48 but a serine at position 61 and 
was then ligated to the 700 bp fragment of Product 1, which contains sequences 
encoding a cysteine at position 183 but a serine at position 107. The ligated DNA 
product therefore encodes cysteines at amino acid positions 48 and 183 but serines at 
amino acid positions 61 and 107. 
All mutants were sequenced along the length of the coding region and are shown in 
Figure 4.3. 
Sequences encoding truncated mutant proteins were produced from the mutants 
described above by utilising the M13mp18 templates containing the mutated coding 
sequences as templates for the polymerase chain reaction (Figure 4.2). The procedure 
and the oligonucleotide primers used were those employed to produce plasmid pRI-
liE (above), thereby encoding proteins whose carboxy-terminal amino acid is Va1148. 
Thus the truncated mutant proteins encoded were: 
E48S 	 E48,61S 	 E48,61,107S 
E61S 	 E61,107S 
E1O7S 
where "E" indicates "HBe-like" or truncated proteins and the remainder of the 
nomenclature is the same as that for the full-length proteins. 
All PCR products were cloned into M13mp18 via the EcoRI and BamHI sites, and 
sequenced. The sequence was correct in all cases and therefore no mistakes had been 
made by the Taq polymerase in copying the coding region and flanking restriction 
sites (Figure 4.4). 
Replicative Form preparations were made of the full length mutants, with the 
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exception of C61,107S; and these and the PCR product form of the other mutants 
were digested with EcoRI and BamHI. The products of this digestion were then ligated 
to the 4373bp vector fragment released by EcoRI/BamHI digestion of pTacpCore or 
pTacHpaIIR2 to form the complete expression plasmids. 
4.2.3 Expression and Purification 
These plasmids were introduced into E. coli strain W31101q and expression of the 
desired proteins induced by addition of IPTG to a final concentration of 50mM. 
Examination of crude extracts of these cultures showed that all mutants were 
expressed at a similar level to their wild-type equivalent, but that truncated proteins 
were expressed at a consistently higher level than the full-length proteins (Figure 4.7). 
Crude extracts were then subjected to ammonium sulphate precipitation and all 
HBcAg-derived proteins were precipitated at 35% ammonium sulphate saturation. 
Passage of dialysed ammonium sulphate precipitated extracts through a Sepharose 4B 
column resulted in all HBcAg-derived proteins being eluted before fraction 11. This 
corresponds to a species of very high molecular weight, such as a core particle 
composed of 180 molecules of full-length protein, which has a predicted molecular 
weight of (180 x 21kD) = 3.78 x 106D; or a core particle composed of 180 molecules 
of truncated protein, which has a predicted molecular weight of (180 x16kD) = 3.06 
X 106D. The behaviour of all mutant proteins during purification was therefore 
consistent with their existence in the form of high molecular weight particles. 
4.2.4 Electron Microscopy 
When examined with the electron microscope, truncated proteins were shown to exist 
as particles with morphology indistinguishable from those formed by wild-type full-
length proteins. In addition, all mutant proteins, both full-length and truncated, have 
morphology indistinguishable from wild-type as shown in Figures 4.8 (full-length) and 
4.9 (truncated). In addition, all mutants were examined at the same time by D. 
Notman and were seen to have apparently identical morphology (not shown). 
Figure 4.7 
Crude and Ammonium Sulphate-Precipitated Extracts of Full-Length and Truncated 
Proteins 
Full-length protein = 	C61S 
Truncated protein = 	EWT 
Samples were incubated at 100°C for 5 minutes in the presence of an excess of DTI' 
and immediately electrophoresed through a 15% SDS-Polyacrylamide gel. 
crude = 	 supernatant after lysis and centrifugation of cells 
(section 2B.9.1) 
(NH4)1SO4 	 sample after precipitation with ammonium sulphate at 
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Figure 4.8 
Electron Micrographs of Full-length Proteins 
Proteins CWT, C48S, C61S, C107S, C183S and C48,61S: 
Magnification = 124 000x 
Microscopy by P. Highton 
Proteins C48,61,107S and C48,61,183S: 
Magnification = 75 000x 
Microscopy by D. Notman 
Proteins CWT and C61,107S: 
Magnification = 500 000x 
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Figure 4.9 
Electron Micrographs of Truncated Proteins 
Proteins EWT, E48S, E61S, E107S, E48,61S and E48,61,107S: 
Magnification = 75 000x 
Microscopy by D. Notman 
Protein CWT: 
Magnification = 315 000x 
Microscopy by S. Bury 
Protein E61,107S: 
Magnification = 250 000x 
Microscopy by S. Bury 





From these photographs it is apparent that both full-length and truncated proteins 
produced in this expression system can form apparently normal particles and that 
replacement of cysteines with serines does not alter the structure of the protein in such 
a way as to prevent full-length or truncated proteins from forming particles of normal 
morphology. It can therefore be concluded that "normal" core particles can be formed 
even from full-length HBcAg containing only one cysteine, and from a truncated 
protein which contains no cysteines, demonstrating that cysteine residues and any 
disulphide bonds they may form are not essential for core particle formation. 
4.2.5 Radioimmune Assays 
The interaction of all purified proteins with antibodies was investigated in a bead-
based radioimmune assay. Beads coated with polyclonal anti-HBc/anti-HBe antibodies 
were incubated with the following dilutions of purified protein: 5ug of protein was 
diluted 1/103, 1/5x103, 1/104, 1/5x104, i/iO, 1/106  in BSA solution (RIP Buffer, 
section 2B.10.3). These beads were then incubated with 125j  labelled polyclonal anti- 
HBc/anti-HBe IgG (section 2B.10.2) and the activity of the bound 125 	measured 
with a gamma counter. Samples were counted for 10 minutes and a correction factor 
employed (section 2B.10.5) so that samples measured at different times after the final 
wash could be directly compared. All samples were assayed in duplicate and the 
average of the two figures (in counts per minute) for each sample calculated. This 
value was then divided by the average of 6 values obtained from beads which had 
been processed in an identical manner to the other beads with the exception that no 
purified protein was added. Therefore these beads allowed measurement of the 
background binding activity only. This figure was termed the "negative" value, and 
the number obtained by dividing the sample value (positive, P) by the negative value 
(N) gave a P/N value which was then plotted on graphs (Figures 4.10A and 4.11A). 
Three samples, C48,61S; C48,61,107S and E48,61,107S were not included in the 
initial assay. These samples were assayed at a later date, in conjunction with the same 
positive and negative controls used in the initial assay, and these results are presented 
in Figures 4.10B and 4.11B. 
Figure 4.10 
Results of Radioimmune Assays of Full-Length Proteins 
P/N = sample activity (positive, P) divided by negative control (N) activity (dilution 
buffer only), after the correction factor for decay during counting of samples had been 
applied (section 2B.10.5) 
Dilution Values refer to the dilution of 51ug of purified protein by the value shown on 
the x-axis of the graphs (i.e. 1/103, 1/5x103, i/iO, 1/5x104, 1/105 and 1/106) 
All points on the graph are the average of duplicate samples and all samples shown 
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Figure 4.11 
Results of Radioimmune Assays of Truncated Proteins 
P/N = sample activity (positive, P) divided by negative control (N) activity (dilution 
buffer only), after the correction factor for decay during counting of samples had been 
applied (section 2B.10.5) 
Dilution Values refer to the dilution of 5ug of purified protein by the value shown on 
the x-axis of the graphs (i.e. 1/103, 1/5x103, 1/104, 1/5x104, 1/105 and 1/106) 
All points on the graph are the average of duplicate samples and all samples shown 
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These graphs show that the reaction of all mutant proteins with the polyclonal anti-
HBc/anti-HBe antibodies is broadly similar to the reaction of these antibodies with 
wild-type full-length or wild-type truncated HBcAg, and that the reactivity of the 
truncated proteins and full-length proteins is comparable. Thus the presence of serines 
in place of cysteines, and the varying numbers of disulphide bonds within these 
particles (see below) has not altered their structure in such a way that a large 
difference in affinity for anti-HBc/anti-HBe antibodies has resulted. 
4.2.6 Non-Reducing Gel Electrophoresis of Full-Length Proteins 
Each full-length protein was electrophoresed through a 15% polyacrylamide gel after 
incubation in either the presence or absence of an excess of reducing agent (DTT), at 
the following temperatures for 10 minutes: 0, 20, 40, 60, 80 and 100°C. As shown in 
Figure 4.12, the gels were dried between two sheets of cellulose membrane backing 
(Biorad) and scanned with a densitometer. In order to compensate for any differences 
in loading or staining between tracks or between gels, the densities of bands measured 
by the densitometer are expressed as % monomer and % dimer. In the absence of 
DTT, the same results were achieved at all temperatures and representative 
Coomassie-stained gels are shown in Figure 4.13A. The results of densitometric 
scanning are shown in Figure 4.13B. 
As the triple mutant C48,61,183S (which contains only Cys107) runs as 100% 
monomer, it can be concluded that Cys107 does not form a bond with a Cys 107 on 
another molecule. However, as C48,61,107S (which contains only Cys183) exists as 




Densitometry of Coomassie-stained protein gels 
A Coomassie-stained, non-reducing, denaturing gel (in this case of E61,107S 
after incubation with 504uM Cu2 ) was dried between two sheets of cellophane 
membrane backing (Biorad). 
Scanning by a densitometer of the absorbance at 550m along the gel track in 
A (above) resulted in the production of a graph with two peaks, each 
corresponding to a band on the gel, which in turn corresponds to either the 
monomer (m) or dimer (d) form of the protein. The units on the y axis are 
arbitrary. 
The area under each graph peak was measured by the densitometer, in arbitrary 
units (u), and these were then expressed as a percentage of the total area under 
all peaks measured. 
Thus the amount of each protein species can be expressed as a percentage of 
the total protein present in each lane of the gel. 
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SIDS-Polyacrylamide Gel Electrophoresis of Full-Length Proteins Under Non-Reducing 
Conditions 
Approximately 51ug of each sample was incubated at 20°C for 10 minutes followed by 
addition of an equal volume of Sample Buffer (section 2B.9.3) and electrophoresis 
through a 15% SDS-Polyacrylamide gel. 










Gels were dried between two sheets of cellophane membrane and analysed with a 
densitometer. The absorbance at 550m was measured along each gel track and the 
areas under the peaks of the resulting graphs measured by the densitometer. These 
figures were then converted to % monomer and % dimer (Figure 4.12) 













CWT does 	not 	enter gel 
C48.61.183S 100% monomer 
C48.61107S 100% 	dimer 
C4861S 86% dimer. 14% monomer 
C183S 100% monomer 
C107S does not enter gel 
C6IS multimers 
C48S does not 	enter gel 
C61.107S multirners 
i.e. 
7 	1107 	1107 	1107 
3 	1183 	1183 	1183 
These conclusions are confirmed by the observation that C48,61S (which contains both 
Cysl07 and Cys183) also exists as 100% dimer. 
A comparison of C48S and C107S shows that neither enter the gel and that they have 
two cysteines in common - Cys6l and Cys183. It is therefore possible that a bond 
exists between pairs of cysteine 61s on two monomers, but not between the pairs 
which are involved in a Cys183-Cys183 bond, thereby creating a disulphide -linked 
network which cannot enter the gel. 




The participation of Cys48 in disulphide bond formation can be deduced by 
examination of C61S and C61,107S, both of which run in the gel as a ladder of 
multimers. This suggests that the dimers formed by Cys183 are linked by a Cys48-
Cys48 bond (as Cys48 is the only other cysteine present in C61,107S, and Cys107 is 
thought not to participate in disulphide bonds) but that this bond is not present in 
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100% of cases. The Cys48-Cys48 bond is also necessarily present between the same 
pairs of monomers as Cys61-Cys61 and not Cys183-Cys183. 
i.e. 	I 	 I 
1 
07 107 107 107 
83 183 183 183 
Thus the model at this stage is 
1 1 1 1 
07 107 107 107 
83 183 183 183 
Several points should be made here. Firstly, while the above model is not the only one 
that would explain the results obtained with individual proteins, it is the only simple 
model that can accomodate all the results when taken together (except C183S - see 
below). Secondly, this assay investigates only the presence of inter-molecular 
disulphide bonds and so the presence of intra-molecular disulphide bonds cannot be 
predicted. This question will be addressed in section 4.2.9. Thirdly, the behaviour of 
the mutant C183S is curious as despite containing cysteines 48, 61 and 107, it exists 
only as monomers and not the dimers which the above model predicts. As there is no 
model that can accomodate this result along with the results obtained for all other 
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mutants, it was possible that disulphide bond formation was not complete at this point 
and this was investigated as described below. 
4.2.7 Oxidation of Full-Length Proteins 
1. Air Oxidation 
Approximately 9 months after the samples were prepared, during which time they had 
been stored at -20°C, the gel assay described above was repeated. The mutant C183S, 
which had previously run in the gel as 100% monomer (Figure 4.14A), now ran in the 
gel as 93% dimer and 7% monomer (Figure 4.14C). The behaviour of all other 
proteins was unchanged (results not shown). 
('1124,  innQ  
The formation of disulphide bonds requires not only that the two cysteines involved 
must be positioned correctly, but also that an electron acceptor must be present. The 
role of electron acceptor is usually taken by 02  but the reaction is slow and unreliable 
and is not well characterised. It is apparently dependent upon metal ions, such as Cu2, 
which bind transiently to the thiol (SH) group. As these metal ions act catalytically 
at low concentrations it was possible that incubation of the proteins in the presence 
of low concentrations of CU21  would promote disulphide bond formation. Samples 
were therefore incubated in the presence of 50,uM Cu2(SO4)2 at room temperature for 
20 minutes, before addition of an excess of EDTA and electrophoresis through a 15% 
SDS-polyacrylamide gel as before. 
The original C183S sample, now 93% disulphide-linked dimer after 9 months air 
oxidation (Figure 4.14C), became 100% dimer after incubation with 50 'UMCu2  
(Figure 4.14D). Similarly, a fresh sample of C183S was 100% monomer in the 
absence of Cu" (Figure 4.14A), but 100% dimer after incubation with 50 'UMCu2  




All samples were electrophoresed through 15% SDS-polyacrylamide gels under non-
reducing conditions. The gels were then dried between two sheets of cellophane 
membrane and analysed with a densitometer. The absorbance at 550 was measured 
along each gel track and the areas under the peaks of the resulting graphs calculated 
by the densitometer. These were then converted to % monomer and % dimer and are 
shown alongside the appropriate band in the gel. 
m = monomer 
d = dimer 
Fresh sample 
Fresh sample immediately following 20 minute incubation with 50,uM Cu2 
Sample 9 months after preparation 
Sample 9 months after preparation and immediately following 20 minute 











d 	93% 	 100% 	d 
rn 	7% 
c 
504uM Cu2 (results not shown). 
Thus a more oxidising environment allowed further disulphide bond formation to 
occur in C183S, such that either or both of the Cys48-Cys48 and Cys61-Cys61 
disulphide bonds predicted by the above model could have been formed. 
4.2.8 Non-Reducing Polyacrylamide Gel Electrophoresis of Truncated Proteins 
The procedure followed was that for the full-length proteins. In addition, proteins were 
tested approximately 6 months after preparation, and also after incubation in the 
presence of 501uM Cu2 (both fresh and 6 month samples). The results of this are 
presented in Figure 4.15 and summarised in Figure 4.16. 
The double mutant E48,61S which contains only cysteine 107 exists only as monomer 
and so a Cysl07-Cys107 bond is not present. As in the full-length protein, cysteine 
61 is capable of forming a Cys61-Cys61 bond and does so between up to 1001yo of 
monomers (E48S). In contrast, the double mutant E61,107S, which contains only 
cysteine 48 exists as approximately 50% monomer and 50% disulphide-linked dimer. 
This is attributed to a Cys48-Cys48 bond which, even after exposure to oxidising 
conditions, forms between only 50% of monomers. As the proteins in which both Cys 
48 and Cys 61 are present (EWT, E107S) exist as disulphide-1 inked dimers and not 
higher multimer forms, it is apparent that the Cys48-Cys48 and Cys61-Cys61 bonds 
are between the same monomer. So the model for the truncated proteins is 
8 48 48 48 
1 1 1 61 
107 107 107 107 
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Figure 4.15 
SIDS-Polyacrylamide Gel Electrophoresis of Truncated Proteins Under Non-Reducing 
Conditions 
Approximately 5ug of each sample (except in lane 2 where 14ug was used) was 
incubated at 100°C for 10 minutes followed by addition of an equal volume of Sample 
Buffer (section 2B.9.3) and electrophoresis through a 15% SIDS-Polyacrylamide gel. 







Samples were electrophoresed as described for A. 
samples 6 months after preparation. 
samples 6 months after preparation, immediately following 20 minute 
incubation with 501uM Cu2 . 
C. 	freshly-prepared samples following 20 minute incubation with 50,uM Cu". 
iii 	-ut.1ROOM 
d 	= dimer 
N.B. E61,107S. The behaviour of only freshly-prepared samples of this mutant were 
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Figure 4.16 
Densitometric Analysis of Gels (Figure 4.15) of Truncated Proteins 
The gels were dried between two sheets of cellophane membrane and analysed with 
a densitometer. The absorbance of each gel track at 550im was measured and the 
areas under the peaks of the resulting graphs calculated. These were then converted 
to % monomer and % dimer. 
Cysteines Fresh + Air + 
Protein Present Original Air Cu Cu 
EAT 48,61,107 15% d 79% d 93% d 100% d 
E48S 61,107 59% d 100% d 96% d 100% d 
E61S 48,107 25% d 41% d 48% d 57% d 
E107S 48,61 55% d 77% d 100% d 100% d 
E48,61S 107 100% m 100% m 100% m 100% m 
E61,107S 48 11% d ND 48% d ND 
E48,61,107S 100% m 100% m 100% m 100% m 
Original 	= fresh preparations, no Cu2 (Figure 4.15A) 
Air 	 = following extended air oxidation (Figure 4.15B) 
Fresh + Cu2 	= fresh preparations incubated with 50,uM Cu2 (Figure 4.15Bc) 
Air + Cu2 	= air oxidised preparations incubated with 504uM Cu 2+  (Figure 
4.l5Bb) 
ND 	 = no data, as E61,107S prepared only recently 
M 	 = monomer 
d 	 = dimer 
the same as that deduced for these three cysteines in the context of the full-length 
proteins. However, while the behaviour of the full-length proteins indicated only that 
the Cys48-Cys48 bond was formed between less than 100% of molecules, the 
behaviour of the truncated E61,107S and E61S proteins demonstrate that the bond is 
formed between approximately 50% of molecules. 
4.2.9 Is there an intra-molecular disulphide bond in HBcAg? 
During investigation of the effect of Cu" ions on disulphide bond formation, several 
concentrations of CU21  were employed. Those proteins that did not enter the gel even 
in the absence of Cu2 were not examined as further disulphide bond formation would 
not be detected by this gel electrophoresis assay. At the lowest concentration utilised 
(50,uM) the results were as described above and were consistent with the results of 
prolonged air oxidation of the proteins. However, at higher Cu" concentrations (the 
highest utilised was 50mM) larger multimers were formed. This was true both of fresh 
preparations (Figure 4.17) and of proteins prepared at least 12 months previously 
(Figure 4.18), and the results are summarised in Figure 4.19. 
It is unlikely, however, that any of the additional disulphide bonds formed in the 
presence of 50mM Cu2 are relevent to the disulphide bond pattern found in vivo, as 
the proteins may be at least partially denatured under these high [Cu2 ] conditions. The 
evidence for this is three-fold. 
Firstly, the older samples that had been frozen and thawed more often showed a 
higher degree of additional disulphide bond formation than the fresh samples. 
Secondly, examination with the electron microscope of the older samples after 
incubation with 50mM Cu2 , proved difficult as very few complete particles were 
present, and in several samples no particles were detected (D. Notman, personal 
communication). Similarly, fresh preparations of full-length mutant proteins after 
incubation with 50mM Cu 2+  were particulate but many were incomplete or appeared 
"broken", and the truncated particles had dissociated and could not be seen. In all 
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Figure 4.17 
SDS-Polyacrylamide Gel Electrophoresis of Freshly-Prepared Proteins following 
Incubation with Cu 2+  




and immediately electrophoresed through a 15% SDS-Polyacrylamide gel. 
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SIDS-Polyacrylamide Gel Electrophoresis of Older (Air-Oxidised) Proteins following 
Incubation with Cu2 
Approximately 54ug of all proteins were incubated for 20 minutes with either 
a: 	50uM Cu2 
or 
50mM Cu2 
and immediately electrophoresed through a 15% SDS-Polyacrylamide gel. 
C61,107S and E61,107S were not investigated as only fresh preparations of these 
proteins were available. 
H•sisJStJUIl 
d = dimer 
C6IS 	 C183S 	 C48,61S 
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Summary of Species Present in Gels through which proteins incubated with 50iM and 
50mM CU21  were electrophoresed (Figures 4.17 and 4.18) 
ND = no data, as only fresh preparations were available. 
Protein 50aM Cu"  50mM Cu"  
fresh older 
C61S minor multimers larger multimers does not enter gel 
C183S 100% dimer dimer + larger does not enter gel 
C48,61S 100% dimer dimer + larger dimer + larger 
C61,107S minor multimers fewer multimers ND 
C48,611107S 100% dimer 100% dimer 100% dimer 
C48161,183S 100% monomer monomer + dimer 10017o dimer 
EWT 100% dimer dimer + larger dimer + larger 
E48S 100% dimer dimer + larger dimer + larger 
E61S monomer + dimer monomer + dimer monomer + dimer 
+ larger + larger 
E107S 100% dimer dimer (+ larger) dimer (+ larger) 
E481 61S 100% monomer monomer + dimer 100% dimer 
E61,107S monomer + dimer increased dimer ND 
E48161,107S 100% monomer 100% monomer 100% monomer 
proteins examined, the majority of the protein ran in the gel. If, due to denaturation 
or some other reason, these multimers did not associate to form particles they would 
not be visible under the electron microscope but their mobility in the gel would not 
be affected. 
Finally, as shown in Figure 4.20, the extra bonds formed under these conditions are 
most likely between two Cys107 amino acids, and the proteins in which only Cys48 
would be available for additional disulphide bond formation form very few additional 
disulphide bonds. If it is therefore assumed that the majority of additional disulphide 
bonds are between two Cys107 residues, then Cysl07-CyslO7 bonds are formed 
between different HBcAg subunits in different mutants. It is unlikely that in its native 
conformation amino acid 107 would be in a position where it would be available to 
fulfil the stringent requirements for disulphide bond formation with either of two 
Cys 107 residues on two alternative subunits. However, if HBcAg is a flexible protein, 
it may, very rarely, be in a conformation favourable for such disulphide bond 
formation; and the highly oxidising nature of the environment (50mM Cu2 ) may then 
cause the protein to be 'locked" into this structure. However, it seems unlikely that 
a structural protein such as HBcAg which forms particles of consistent structure would 
be sufficiently flexible for this to occur. 
The information obtained about the additional disulphide bonds formed under these 
conditions is useful, however, in terms of determination of the probability of the 
presence or absence of an internal disulphide bond. By the model deduced previously 
1 1 1 1 
07 107 107 107 
83 183 183 183 
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Figure 4.20 
Position of Additional Disulphide Bonds Formed Following Incubation with 50mM 
Cu2 
Samples C61,107S and E61,107S were freshly-prepared samples (Figure 4.17), 
indicated by * 
All other samples were older (air-oxidised) (Figure 4.18). 
A 	 B 	C 
48 48 48 
61 61 61- 
107 107 107 
183 183 183 
Protein 	 + 50mM Cu" Additional Bonds Between 
Cysteines 	Molecules 
C61S does not enter gel 107-107 A and B 
C183S does not enter gel 107-107 B and C 
C48,61S d + larger 107-107 A and B 
C61,107S* d + larger 48-48 A and B 
C48,61,107S 100% d no additional bonds 
C48,61,183S 100% d 107-107 either pair 
EWT d + larger 107-107 B and C 
E48S d + larger 107-107 B and C 
E61S m + d + larger 107-107 B and C 
E107S d + larger 48-48 B and C 
E48,61S 100% d 107-107 either pair 
E61,107S* d + larger 48-48 either pair 
the only cysteines available to participate in an internal disulphide bond are Cys48 and 
Cys 107, and Cys48 is available in only 50% of molecules, as in the remaining 50% 
of molecules it is involved in a Cys48-Cys48 bond. Therefore an internal disulphide 
bond could be present in only a maximum of 50% of molecules and could be between 
only Cys48 and Cys107. To determine whether this is in fact the case it is useful to 
predict the additional disulphide bond-forming potential of those proteins containing 
cysteines 48 and 107, if an internal Cys48-Cys107 bond was indeed present and then 
to compare this to the actual behaviour of the proteins after exposure to 50mM Cu2 
(Figure 4.18). Older protein preparations were examined as these formed a larger 
number of disulphide bonds after incubation with 50mM CU21  than the fresh 
preparations. 
C6 1S 





and 50% of Cys48 are present as 
107 
then the probability of 
arising is 50% x 50% = 25%. 
As no further bonds can be formed involving this dimer, it would be expected that 
25% of the total protein on the gel would be dimer. This is not the case, however, as 
the protein does not enter the gel after incubation with 50mM Cu2 (Figure 4.18), 
indicating the presence of larger multimers only, so that at least 80% of dimers are 
linked together by a bond invloving Cys48 and/or Cys 107 and no dimers are present. 
C183S 
If 50% of Cys48 are present as 




then the probability of 	 48 	 8 
1 	 1 
107 	107 
being formed is 50% x 50% = 25%. 
No further multimers can be formed by this dimer as there are no free cysteines and 
so 25% of the protein would be expected to run in the gel as dimers. As with C61S 
this is not the case and all the protein, after incubation with 50mM Cu2 , exists as 
larger multimers which do not enter the gel and there are no dimers (Figure 4.18). 
EWT 





and 50% of Cys48 are present as 
109 
then the probability of 
being formed is 50% x 50% = 25%. As this dimer can form no further disulphide 
bonds, having no free cysteines, it would be expected that 25% of the total protein 
would be dimer. However, examination of the EWT gel of older preparations (Figure 
4.18) with a densitometer (Figure 4.12) demonstrates that only 7% of the total protein 
exists as dimer. That is, the density of the dimer band in the gel at 50mM CU21  is only 
7% of the density of the total protein in the gel when no CU21  is present. 
E6 1S 








then as the latter has no free cysteines it can form no multimers, and so 50% of the 
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total protein would be expected to be in monomer form. However, densitometric 
scanning (Figure 4.12) of the E61S gel (Figure 4.18) shows that only a maximum of 
5% of the total protein is monomer. As only protein that has entered the gel is 
measured, those multimers too large to enter the gel cannot be included in the 
calculation and so the figure obtained for monomer as a proportion of total protein is 
the maximum possible. 
Therefore, in particles formed from all four proteins more multimers are formed than 
would be expected if an internal Cys48-CyslO7 disulphide bond was present in 50% 
of cases. These results do not, however, rule out the possibility that an intra-molecular 
disulphide bond can be formed, but in the truncated proteins only, and in significantly 
less than 50% of cases (a maximum of 7% in the case of EWT). 
4.3 Discussion 
The nucleocapsid of HBV fulfils several roles in vivo. Formation of complete, 
replication-competent nucleocapsids requires the initial interaction of HBcAg with 
both the packaging signal on the RNA pre-genome (Junker-Niepmann et al., 1990) and 
the viral polymerase (Bartenschlager et al., 1990; Hirsch et al., 1990). As it has been 
demonstrated that HBcAg alone can form nucleocapsid-like structures, both in E. coli 
(Stahl et al., 1982; Cohen and Richmond, 1982) and other heterologous hosts 
(Kniskern et al., 1986; Roosinck et al., 1986; Nassal, 1992a)), the interactions 
described above are not required for capsid assembly. Once the complete nucleocapsid 
is formed, it is thought to play an active role in viral replication. Specifically, the 
COOH-terminus of HBcAg is essential for viral genome replication and may be 
involved in binding, at least temporarily, to the nascent viral DNA (Nassal, 1992b). 
In addition, envelopment of the nucleocapsid requires its interaction with membrane-
embedded HBsAg and so the nucleocapsid must be in the correct configuration to 
facilitate this. 
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Therefore, the nucleocapsid must maintain its structure, both internally and externally 
and throughout the viral life cycle, for all these roles to be fulfilled successfully. One 
means by which this structure could be maintained is by the stabilising effect of 
disulphide bonds. HBcAg has four cysteines which are completely conserved among 
mammalian hepadnaviruses and all four are therefore likely candidates for involvement 
in disulphide bonds. In this work the role of each was assessed by the effect of its 
elimination, singly and in combination with others, on particle structure and particle 
stability. 
Firstly, the effect on particle structure of substituting cysteine residues with serine 
residues was determined. High molecular weight particles were shown to be formed 
from all 14 mutant proteins by their behaviour during purification. That these particles 
have HBc/HBe antigenicity comparable to that of wild-type particles was determined 
by radioimmune assay, and that these particles were of normal morphology was 
further confirmed by electron microscopic examination. This confirms the observations 
of others (Gallina et al., 1989; Stahl and Murray, 1989; Salfeld et al., 1989; Birnbaum 
and Nassal, 1990; Nassal, 1992b) that HBcAg-derived proteins lacking the arginine-
rich carboxy-terminus form particles of morphology indistinguishable from those 
formed by wild-type full-length proteins. The slightly increased size of particles 
formed from truncated proteins which has been reported (Gallina et al., 1989) was not 
observed with either the wild-type truncated or mutant truncated protein particles 
produced in this work, in agreement with the observations of Zheng et al. (1992). 
Thus, the main structural domain of HBcAg does not include, or does not depend 
upon, the arginine-rich C-terminus which is not involved in essential interactions with 
other HBcAg molecules to form particles. The C-terminus is thought to be (at least 
largely) internal to the particle (Zhou et al., 1992), and may be thought of as a 
separate domain of the protein, possibly protruding into the interior of the capsid. The 
nucleocapsid of Tomato Bushy Stunt Virus also consists of 180 subunits and has 
icosahedral symmetry. In a similar manner to Hepatitis B Virus core particles, these 
capsids are composed of only one monomer type, which also has an internal domain, 
in this case the amino terminal region of the protein. X-ray crystallography has 
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demonstrated that the internal domains of these monomers interdigitate to form an 
internal shell (Harrison, 1985). It is tempting to speculate that this may also be true 
for HBV nucleocapsids and that this internal shell is stabilised by Cys183-Cys183 
disulphide bonds. 
These results also demonstrate that substitution of cysteines with serines causes no 
gross alteration to particle structure as neither the ability to form particles nor the 
reaction of these particles with polyclonal anti-HBc/anti-HBe antibodies is affected. 
The radioimmune assays performed do not exclude the possibility that subtle structural 
changes have taken place, perhaps exposing HBe epitopes rather than HBc epitopes, 
or vice versa, but these have had no effect on the ability of the proteins to form 
particles. However, it has been demonstrated that proteins also produced in E. coil and 
almost identical to those produced in this work, (with the exception that 5 additional 
amino acids (MITNS) are present before amino acid 1 of HBcAg, the truncated 
proteins terminate at amino acid 144, and cysteines are mutated to serines or alanines) 
react to the same extent as wild-type full-length HBcAg with a panel of antisera raised 
against synthetic peptides corresponding to overlapping regions of HBcAg (Zheng et 
al., 1992). In addition, another panel of mutant proteins produced in E. coii which are 
very similar to those studied in this work (with the exception that no non-HBcAg 
sequences are present and truncated proteins terminate at amino acid 149) react with 
a monoclonal antibody which "preferentially recognises particulate core protein" 
(Nassal et al., 1992). This strongly suggests that such alterations to structure have not 
in fact occurred. 
Therefore the cysteines of HBcAg are not required for its correct folding. In addition 
they are not required for particle formation as all mutant proteins form "normal" 
particles even if only one cysteine is present (in the context of the full-length protein) 
or if no cysteines at all are present (in the context of the truncated protein). However, 
as may be expected, the mutant proteins formed particles with stability proportional 
to the number of cysteines present, with the exception of cysteine 107 (unpublished 
observations). This was true in terms of denaturation due to both repeated 
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freeze/thawing of preparations and denaturation due to more artificial (50mM Cu") 
conditions. 
In summary, conclusions derived from the mutant proteins should be able to be 
extrapolated to the native protein as the protein structure does not appear to be altered 
by mutation of cysteines to serines. 
This should also be true for proteins treated with 50,uM Cu2 , the concentration at 
which all "native" disulphide bonds have formed. While there is no direct evidence 
presented here that this is the case, there are three supporting lines of evidence. 
Firstly, as the disulphide bonds formed after exposure to 501uM CU21  were essentially 
the same as those formed after extended air oxidation, it is reasonable to conclude that 
both are in the same physical state. Secondly, the protein preparations used in the 
radioimmune assay and the particles examined under the electron microscope were at 
least 6 months old at the time and were shown to have the same proportion of 
disulphide bonds as both fresh, and equivalently aged, preparations that had been 
exposed to 504uM Cu2 . The structure of these samples was normal and, if these 
samples are indeed in the same state as the Cu2 -exposed particles then they are 
unaltered by 50,uM Cu2 . Thirdly, this is supported by the observation of Nassal et al. 
(1992) that proteins almost identical to those studied here (but containing only 
HBcAg-derived amino acids and terminating at amino acid 149 in the case of 
truncated proteins), after incubation with up to 1004uM Cu2 , were stable particles, as 
determined by sucrose gradient analysis and ELISA assay using a monoclonal 
antibody that preferentially recognised particulate HBcAg. This contrasts sharply with 
the behaviour of these particles after incubation with 2mM Cu" which caused 
truncated particles, except those lacking Cys48, curiously, to dissociate (Nassal et al., 
1992). Similarly, examination under the electron microscope of samples (this work) 
that had been incubated with 50mM Cu2 demonstrated that particles formed from full-
length proteins were now particulate but rarely intact and often "broken" in 
appearance, and that truncated particles had dissociated to an extent whereby they 
could no longer be detected. It seems likely, therefore, that while high (mM) 
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concentrations of Cu" cause deleterious structural effects the low concentration of 
501uM causes no significant such effects. 
Inter-molecular Disulphide Bonds 
The results produced by polyacrylamide gel electrophoresis of the panel of mutant 
proteins under non-reducing conditions clearly define the inter-molecular disulphide 
bonds present within core particles. As the maximum size of disulphide-linked species 
produced by the wild-type truncated protein is dimer this allowed more confident 
allocation of disulphide bond participants than with the full-length proteins, as in the 
former case all the protein entered the gel and could therefore be quantified readily. 
In contrast, of the full-length protein that did not enter the gel, it could not be said 
that it was a 100% disulphide-linked lattice, but only that it existed as disulphide-
linked multimers of at least approximately 10 subunits (approximately 220kD) which 
would require a minimum of only 80% of potential disulphide bonds to have formed. 
Another conclusion that could be immediately drawn from the dimeric nature of wild-
type truncated protein is that any disulphide bonds involving Cys48, 61 or 107 are 
between the same subunits. 
Full-length and truncated proteins that contain only Cys107 contain no disulphide 
bonds in their particles, and the presence of Cys107 does not affect the disulphide 
bond pattern of any of the mutant protein particles. Thus, Cys107 was excluded from 
involvement in inter-molecular disulphide bonds. Also, in all cases the behaviour of 
the full-length proteins mirrored that of their truncated counterparts and confirmed the 
existence of a Cys183-Cys183 bond in 100% of cases as those truncated mutants that 
were monomeric became dimers upon addition of Cys183 and those that had been 
dimers no longer entered the gel. Cys6l is also involved in a disulphide bond with 
Cys6l on an adjacent molecule in 100% of cases, but between monomer pairs not 
linked by Cys183-Cys183 bonds. Curiously, Cys48 exists as a disulphide bond 
participant in only 50% of cases, but always with Cys48 on the same molecule as that 
to which the Cys6l is bonded. Therefore the proposed model for inter-molecular 
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disulphide bond arrangement is 
07 	1107 	1107 	1107 
Intra-molecular Disulphide Bond 
Nassal et al. (1992) reported that their mutant protein equivalent to the E61S protein 
of the work described here existed initially as monomer only, 50% of which was 
converted to dimer upon exposure to 501uM Cu", in agreement with this work. 
However, the monomer ran in a non-reducing polyacrylamide gel as two close bands, 
which could be converted to only the slower-migrating species upon addition of an 
excess of DTI'. It was therefore concluded by the authors that an internal disulphide 
bond was present in approximately 30% of the monomers, causing it to migrate faster 
in the gel. This explanation was further supported by the observation that only the 
slower-migrating form was converted into dimer upon exposure to Cu2 . However, this 
was not observed in any other mutants by Nassal et al. and has not been observed 
with any of the proteins, including E61S, in the work presented in this thesis. It is 
noteworthy, however, that some proteins examined in this work do appear occasionally 
as a doublet in the gel, both when non-reduced (including C183S, Figure 4.14 A and 
D; E61S, Figure 4.1513; C61,107S, Figure 4.17; EWT, Figure 4.17; C183S, Figure 
4.18; E61S, Figure 4.18) and reduced (not shown). However, this was not observed 
consistently and does not correlate with the presence or absence of Cys48 or Cys107 
and a doublet is also observed for dimers where the presence of an internal disulphide 
bond would have precluded dimer formation (including E61S, Figures 4.1513 and 
4.18). A similar phenomenon was also observed by Zheng et al. (1992) with their 
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mutant proteins equivalent to C61S, C48,61S and C61,107S. It is possible that limited 
proteolysis has occurred in both cases, despite the presence of protease inhibitors, but 
as this was not observed consistently with specific mutants in this work it is unlikely 
to be due to any structural differences between different mutants. 
The question of the presence of an internal disulphide bond was answered indirectly 
in this work. As has been discussed above, exposure to 50mM Cu2 resulted in 
disruption or dissocation of particles, but this provided further information concerning 
the availability of cysteines known not to be involved in inter-molecular disulphide 
bonds, as only those cysteines not already involved in disulphide bonds would be 
available to form the new disulphide bonds forced by 50mM Cu". It is unlikely that 
50mM Cu2 causes breakage of existing disulphide bonds as this would require the 
presence of an excess of reducing agent and not an oxidising agent such as Cu2 and 
so the novel protein forms seen are unlikely to have arisen via disulphide bond 
rearrangement. In addition, if disulphide bond breakage was taking place, the same 
disulphide bond pattern may be expected for all mutant proteins after exposure to 
50mM Cu2 , which is not in fact the case. As EDTA was added after incubation with 
Cu2 	and before electrophoresis, it is unlikely that the Cu 2,  ions are an integral part 
of the disulphide bonds formed after exposure to 50mM Cu2 and are more likely 
merely catalysts for the reaction. 
In the proteins in which Cys48 and Cys107 (necessarily the only cysteines between 
which an intra-molecular disulphide bond could form) are both present, their behaviour 
was inconsistent with the presence of an intra-molecular Cys48-Cys 107 bond. Proteins 
in which 25% would be expected to exist as dimer, or 50% as monomer, did exist as 
monomer and dimer, respectively, in the case of the truncated proteins only, but in a 
much lower percentage than predicted. This may indicate the presence of an internal 
disulphide bond in a small number of cases but this is unlikely. Such a model would 
require Cys48 to exist in at least 3 forms - as SH, as inter-molecular disulphide bond 
and as intra-molecular disulphide bond, which would in turn require three different 
forms of HBcAg monomer to exist. 
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There is precedent for the presence of three quasi-equivalent forms of monomer in the 
nucleocapsids of Tomato Bushy Stunt Virus and Turnip Crinkle Virus which are also 
composed of 180 subunits, with icosahedral symmetry (Harrison, 1985). This 
symmetry is known as T=3 symmetry which means that the 60 subunits of the basic 
structure each consist of 3 further subunits, hence T=3. Crystallographic studies of 
these nucleocapsids indicate that the 3 sub-subunits exist in 3 quasi-equivalent forms 
in order to accommodate 180 total subunits into the overall structure, but this means 
that 33% of monomers are in each form and that very small proportions of subunits 
(e.g. the 7% for EWT) would not fit with this model precisely. It is more likely that 
denaturation is not complete and that the full disulphide bonding capacity of the 
denatured protein has not been attained, and that the monomers and dimers present 
contain free sulphhydryl groups. This could be investigated by denaturing the protein 
completely, perhaps by heating, prior to incubation with Cu". It is therefore unlikely 
that Cys48 and Cys107 are involved in an intra-molecular disulphide bond in the 
native particle. This was also the conclusion of Zheng et al. (1992) who determined, 
by means of reaction of their panel of mutant proteins with Eliman's Reagent, the 
number of free SH groups per HBcAg molecule to be 0.5 when Cys48 was present 
and Cys 107 was absent; 1.0 when Cys 107 was present and Cys48 was absent; and 1.5 
when both Cys48 and Cys107 were present. Their work also indicated that Cys107 
was buried within the particle as it reacted with Ellmann reagent only after exposure 
of the particles to 0.1% SDS. This denaturation may be equivalent to the denaturation 
of the protein caused by 50mM Cu" in this work which allowed the free Cys 107 to 
become available for disulphide bond formation. 









This model is in complete agreement with that proposed by Zheng et al. (1992) and 
Nassal et al. (1992). In addition, it is agreed that neither cysteines nor disulphide 
bonds are required for formation of normal core particles in E. coli. This has now 
been taken one stage further by Nassal (1992) who transiently transfected human 
hepatoma-derived HuH7 cells with HBV genomic DNA in which all 4 cysteine codons 
of the full-length C gene had been mutated to serine codons. Comparison of the 
complete virions produced after transfection with this mutant, with those produced 
after transfection with wild-type DNA, showed that complete virions were indeed 
produced. Therefore, lack of cysteines does not critically impair any stages in the viral 
life cycle subsequent to virus infection. However, minor differences between wild-type 
and mutant virus particles were noted. 'Substantially fewer" enveloped cores were 
observed with the mutant than with wild-type but this may reflect the reduced stability 
of mutant virions rather than reduced efficiency of envelopment. The former is thought 
likely as those mutant virions formed were intact and, in contrast to wild-type, 
isopycnic centrifugation during purification of these virions resulted in viral nucleic 
acid being present along with HBcAg in a position characteristic of naked cores. This 
would suggest that a proportion of the virions had lost their envelopes during 
centrifugation, in contrast to the wild-type virions which showed no nucleic acid at 
this position. Data for this observation was not shown and no indication was given of 
the relative quantity of naked, nucleic acid-containing cores present relative to intact 
virions. Therefore, cysteines may be involved not only in the stability of nucleocapsids 
but also in the stability of virions themselves by enhancing the stability of 
nucleocapsid/envelope interactions. As Cys183 is thought to be in the interior of the 
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core particle and Cys107 is not accessible in the absence of denaturing agent, Cys48 
and Cys6l are more likely to be available for involvement in direct Core/Surface 
interactions. Cys6l is involved in disulphide bonds between HBcAg molecules, but 
50% of Cys48 is free. Zheng et al. (1992) have shown that Cys48 readily reacts with 
sulphhydryl reagents even in the absence of denaturing agents and so is exposed in 
the native particle. Antibodies produced against synthetic peptides derived from the 
Cys48 region of the protein also bind native full-length and truncated particles, giving 
further credence to the proposition that Cys48 may be on or near the surface of the 
nucleocapsid (Zheng et al., 1992). As the surface protein HBsAg has 14 cysteines it 
can be envisaged that the 50% of Cys48 not involved in an inter-molecular disulphide 
bond with another HBcAg molecule may be involved in an inter-molecular disulphide 
bond with a cysteine in a HBsAg molecule. As nucleocapsids lacking Cys48 are still 
enveloped, the role of a Cys48-HBsAg disulphide bond may be similar to the role of 
the disulphide bonds of the nucleocapsid in stabilising rather than determining inter-
molecular interactions. 
Another difference in the behaviour of wild-type and mutant nucleocapsids within 
complete virions noted by Nassal (1992b) was a consistently lower proportion (15% 
as opposed to 35%) of relaxed circular (RC) DNA to linear DNA in the mutant. 
Therefore, formation of RC DNA from linear DNA, which involves the primer transfer 
reaction, may be less efficient in the absence of the cysteines of HBcAg. In particular, 
Cys183 may be important for this as it is thought to lie within the capsid and at the 
COOH-terminus of the region of HBcAg proposed to bind the nascent HBV DNA 
formed by reverse transcription. It would therefore be interesting to investigate the 
behaviour of proteins lacking only Cysteine 183 in this regard. 
The role of the cysteines within HBcAg remains unclear. Their strict conservation 
suggests a significant role, but their elimination has no apparent effect on core particle 
formation, at least in vitro. Their observed role in conferring stability to core particles 
and to virions may be important but equally may not be required under conditions of 
normal infection where exposure to environments and treatments as harsh as those 
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imposed in vitro may not occur. As woodchuck hepatitis virus core antigen displayed 
properties identical to HBcAg with regard to cysteines (Zheng et al., 1992) the 
woodchuck model would be an appropriate one in which to test the behaviour of 
mutants lacking cysteines during the normal course of infection. This would also allow 
investigation of the role of the cysteines in initial infection of cells, which cannot be 
tested by transfection of tissue culture cells with DNA only. Alternatively, this could 
be achieved with HBV in the HepG2 system described by Bchini et al., 1990. 
A further possibility is that the cysteines are required for the normal function of 
HBeAg. The mature HBeAg contains cysteines 48, 61 and 107 and an additional 
cysteine within the N-terminal 10 amino acids of the pre-core region which remain 
attached to amino acid 1 of HBcAg after removal of the signal sequence. This 
additional cysteine is thought to be important in determining the disulphide bond 
content and structure of HBeAg as when it is present monomers only and no particles 
are observed, while when it is substituted particles formed from disuiphide-linked 
dimers are produced (Schlicht and Wasnauer, 1991). It has been proposed that this 
additional cysteine may form an intra-molecular disulphide bond, possibly with 
Cys107, thereby altering the overall structure of the dimers and preventing particle 
formation. However, until the precise role of HBeAg during HBV infection is known, 
the effect of removal of cysteine residues cannot be determined. 
Finally, the conservation of the cysteine residues in HBcAg may be telling us that 
although mutation to serine does not affect the ability of the polypeptides to assemble 
into particles that can function apparently normally, the slight change in total free 
energy of these particles in relation to that of particles formed from the wild-type 
protein may be disastrous in the competitive world of evolutionary selection. 
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Chapter 5: The Role of the Carboxy-Terminal Region of HBcAg in 
Determining Disulphide Bond Formation 
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5.1 Introduction 
The unexpected behaviour of the full-length mutant C183S in terms of the lack of 
Cys48-Cys48 and/or Cys61-Cys61 disulphide bond formation in the absence of 
extended air oxidation or Cu"-catalysed oxidation, unlike the other proteins which 
formed the majority of these bonds shortly after liberation of the protein from the 
bacterium, suggested that the nature of the carboxy-terminus may influence 
determination of disulphide bond formation in the remainder of the protein. This was 
investigated by the examination of the behaviour of both full-length and truncated core 
proteins, and fusion proteins constructed previously in our laboratory (Stahl and 
Murray, 1989) which differ in the nature of their carboxy terminal regions. Their 
behaviour was monitored in terms of the ability of the proteins to form particles and 
the mobility of the proteins in non-reducing polyacrylamide gels. 
5.2 Results 
As shown previously, freshly-prepared C183S ran in the gel as 100% monomer and 
no disulphide bonds were present (Figure 4.13). 
In contrast, freshly-prepared CWT, which is the same length as C183S but has a 
cysteine at its carboxy terminus in place of the serine of C183S did not enter the gel 
(Figure 4.13) indicating that, by the model 
1 
07 	1107 	1107 
at least 80% of the possible Cys48-Cys48 and/or Cys61-Cys61 bonds were present, 
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thus causing the formation of multimers too large to enter the gel. Such bonds were 
completely absent in freshly-prepared C183S. 
Similarly, the freshly-prepared truncated protein EWT which contains the same 
cysteines as C183S but lacks amino acids 149-183, runs in the gel as dimer (15%) and 
monomer (85%) (Figure 4.15). In order to form a dimer, by the model deduced 
previously (above) a Cys61-Cys61 and/or Cys48-Cys48 bond must be present between 
15% of molecules. Such bonds were completely absent in freshly-prepared C183S. 
Therefore, either the presence of cysteine 183 or the absence of the arginine-rich 
region of the protein allow immediate formation of bonds that were formed in C183S 
only after prolonged air oxidation, or after oxidation catalysed by Cu2 ions. 
Further investigation of this phenomenon was achieved by utilisation of core fusion 
proteins produced previously in our laboratory (Stahl and Murray, 1989) which are 
described below: 
HBcpreS1(1-20) 
1L j3-gal 8  EFH 31 HBcAg 1144  ISSRELGYS J preSi  120  LDRCP 
Total amino acids = 187 
Total cysteines = 4 
This protein contains cysteines 48, 61 and 107 of HBcAg and a cysteine as the 
penultimate amino acid of the protein (Figure 5.1A). 
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HBcpreSl(1-36) 
j 3-ga1 18  EFH 31 HBcAg 44 ISSRELGYS 'j preSl 136 
Total amino acids = 198 
Total cysteines = 3 
This protein contains only cysteines 48, 61 and 107 of HBcAg. It is a similar length 
to the wild-type HBcAg produced in this work (192 amino acids) but the arginine-rich 
carboxy-terminus of the full-length HBcAg has been replaced by a sequence 
unremarkable in terms of amino acid content (for these purposes) or charge (Figure 
5.1B). 
ffs OR I lot 
3-ga1 EFH 3FHBCAg144IS 72 HIV env 751 
Total amino acids = 179 
Total cysteines = 3 
This protein contains only cysteines 48, 61 and 107 of HBcAg. It is shorter than the 
full-length wild-type HBcAg produced in this work, but longer than the truncated 
proteins (157 amino acids) (Figure 5.1C). 
HBcpreSl(1-20) had previously been shown, by electron microscopy, to form particles 
of normal morphology (Stahl and Murray, 1989). Electron microscopic examination 
of HBcpreSl(1-36) and HBcE46 in this work reveals that they also form such particles 
(Figure 5.2). Immunological assays also demonstrated that the additional amino acids 
in all three fusion proteins are displayed on the surface of the particles. (Stahl and 
Murray, 1989). All fusion proteins used in this work had been prepared (by S. Bruce) 
at least 12 months before being assayed and so can be considered to have undergone 
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Figure 5.1 
Amino Acid Sequences of Fusion Proteins 
All three fusion proteins consist of amino acids: 
n-Gal 	GluPheHis 3] 	HBcAg 	1144 
followed by: 
HBcpreS1(1-20) 
Ile Ser Ser Arg Glu Leu Gly Tyr Ser 'Met Gly Gin Asn Leu Ser Thr Ser Asn Pro Leu 
Gly Phe Phe Pro Asp His Gin Leu Asp2° Leu Asp Arg Cys Pro 
HBcpreSl(1-36) 
Ile Ser Ser Arg Glu Leu Gly Tyr Ser 'Met Gly Gin Asn Leu Ser Thr Ser Asn Pro Leu 
Gly Phe Phe Pro Asp His Gin Leu Asp Pro Ala Phe Arg Ala Asn Thr Asn Asn Pro 
Asp Trp Asp Phe Asn Pr036 
HBcE46 
Tie Ser Leu Pro Tie Pro Arg Gly Pro Asp Arg Pro Glu Gly Tie Glu Glu Glu Gly Gly 
Glu Arg Asp Arg Asp Arg 
Figure 5.2 
Electron Micrographs of Fusion Proteins 
All particles are shown at a magnification of 124 000x and all microscopy was 
performed by P. Highton. 
HBcpreSl(1-20) had been demonstrated previously by electron microscopy to form 
particles morphologically indistinguishable from those formed by wild-type HBcAg 
(Stahl and Murray, 1989). 
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extended air oxidation. 
All fusion proteins were incubated at the appropriate temperature for 10 minutes in 
the absence of reducing agent and immediately electrophoresed through a 15% SDS-
polyacrylamide gel. The same result was achieved when proteins were incubated at 
0, 20, 40, 60, 80 and 100°C prior to electrophoresis and a representative Coomassie-
stained gel is shown in Figure 5.3. 
HBcpreSl(1-20), which contains 4 cysteines, behaves in a manner analagous to CWT 
in not entering the gel. In contrast, HBcpreSl(1-36) which is of similar size to CWT 
but has a different COOH-terminal region containing no cysteine at its terminus, 
behaves in a manner analagous to freshly-prepared C183S (which also has only 
cysteines 48, 61 and 107) in running in the gel only as monomer. HBcE46, which has 
only three cysteines and a shorter fusion region, behaves in a manner analagous to the 
freshly-prepared wild-type truncated protein (EW1) in running in the gel as both 
monomer and dimer. These results are summarised in Figure 5.4. There were 
insufficient amounts of the fusion proteins available to be able to examine the samples 
after incubation with Cu", but as the samples had been prepared at least 12 months 
previously it would be expected that disulphide bond formation had proceeded 
significantly towards completion. (Full-length and truncated proteins, as described 
earlier, showed very similar disulphide bond complements after extended air oxidation 
and after incubation with Cu2 . Sections 4.2.7) 
5.3 Discussion 
From the behaviour of the full-length, truncated and fusion proteins in non-reducing 
SDS-PAGE, it is apparent that the nature of the carboxy-terminus of HBcAg, while 
dispensable for particle formation, influences the ease of disulphide bond formation, 
or even the ultimate disulphide bond complement of the particle. 
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Figure 5.3 
Non-reducing SIDS-Polyacrylamide gel electrophoresis of mutant and fusion proteins 
5ug of all proteins were incubated at 100°C for 5 minutes in the absence of 
reducing agent and immediately electrophoresed through a 15% SDS-
polyacrylamide gel which was subsequently stained with Coomassie Blue. 
Gels were dried between two sheets of cellophane membrane and analysed 
with a densitometer. The absorbance at 550nm was measured along each gel 
track and the areas under the peaks of the resulting graphs measured by the 
densitometer. These figures were then converted to % monomer and % dimer. 
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Summary of behaviour of mutant and fusion proteins during non-reducing SDS-
polyacrylamide gel electrophoresis 
Protein Cysteines Present Behaviour in Gel 
C183S 48 61 107 100% monomer 
CWT 48 61 107 	183 does not enter gel 
EWT 48 61 107 monomer and dimer 
HBcpreSl(1-20) 48 61 107 	C does not enter gel 
HBcpreSl(1-36) 48 61 107 100% monomer 
HBcE46 48 61 107 monomer and dimer 
While full-length and truncated proteins all formed the predicted disulphide bonds 
(Cys48-Cys48 and/or Cys6l-Cys6l) after extended air oxidation or Cu"-catalysed 
oxidation, only C183S had an absolute requirement for such oxidation as the other 
proteins all formed these bonds within a short time (less than five days) after 
liberation from the bacterium. As all proteins were in the same environment, with the 
same redox potential, the difference in ease of disulphide bond formation must be due 
to a difference in the conformation of the protein. However, the conformational 
difference must be only slight, as the disulphide bond(s) do ultimately form and this 
would not occur if the cysteine residues were kept permanently apart by the folded 
protein conformation. Where the COOH tail is absent (EWT) the bonds form 
immediately, and where the COOH- terminal is present but Cys183 is also present the 
bonds form immediately. It could therefore be imagined that the COOH-tail prevents 
the close contact required between Cys48-Cys48 and Cys61-Cys61 for disulphide 
bonds to form, but that if two COOH-tails are linked by a disulphide bond, such close 
contact is not prevented. However, while in no cases did Cys48-Cys48 and/or Cys61-
Cys6l bonds form in C183S particles immediately, only approximately 15% of these 
potential disulphide bonds were formed in EWT immediately and it cannot be 
predicted how many such bonds were formed in CWT as it can be said only that all 
molecules were in the form of multimers of at least 10 molecules (which do not enter 
the gel). However, this would require a minimum of 80% of Cys48-Cys48 or Cys61-
Cys6l bonds to have formed. Therefore, the presence of Cys183 may be more 
important in promoting tight/correct structure formation than the absence of the entire 
COOH tail. The function of the inner shell of the Tomato Bushy Stunt Virus capsid, 
formed from the internal domains of the component monomers, is thought to be to 
ensure that the viral shell closes around on itself correctly during assembly (Harrison, 
1985). If the HBV core particles have a similar inner shell, its function may also be 
similar. Removal of the carboxy-terminal cysteine, or of the entire carboxy-terminal 
region, may prevent or slow down correct formation of the inner shell, which may in 
turn prevent or slow down formation of the outer shell. 
The COOH-terminus of the wild-type full-length protein is thought to be inside the 
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core particle (Zhou et at., 1992) but the COOH-terminus of at least some of the fusion 
proteins is necessarily surface-accessible as the core fusion particles are bound by 
antibodies directed against the fusion section (Stahl and Murray, 1989). However, 
examination of the disulphide bond content of core fusion particles shows that the 
presence of the COOH-terminus on the surface of the particles also has an effect on 
disulphide bond formation. In addition, this effect is greater than that of the other 
mutants studied as the disulphide bond pattern is not that of wild-type, even after 
extended air oxidation. 
The behaviour of HBcpreSl(1-20) once again indicates that the presence of a cysteine 
at the COOH-terminus is important and results in at least 80% disulphide bond 
formation between Cys48-Cys48 and/or Cys6l-Cys6l. It is expected that the cysteines 
linked by disulphide bonds in the fusion proteins would be the same as those linked 
in the wild-type protein as the fusion proteins are known to react with anti-HBcAg 
antibodies to the same extent as wild-type HBcAg (Stahl and Murray, 1989). 
HBcpreSl(1-36), a protein with a tail of similar length but lacking a COOH-terminal 
cysteine existed only as monomer even after extended air oxidation. This was despite 
the tail being non-arginine-rich like that of the wild-type HBcAg. However, HBcE46, 
which has a tail slightly shorter than that of the wild-type does form a small 
proportion (6%) of dimer, and hence Cys48-Cys48 and/or Cys61-Cys61 bonds. 
However, this was the percentage formed after extended air oxidation and so it is not 
directly analagous to the situation with the wild-type truncated proteins. 
Thus, both the size of the COOR tail and its position in the particle are important with 
regard to disulphide bond formation in the remainder of the molecule. If dimers are 
not tightly linked by Cys183-Cys183 bonds but are more loosely associated, although 
still forming particles, this may prevent the remainder of the molecules from being in 
the correct position and/or conformation to form Cys48-Cys48 and/or Cys61-Cys61 
bonds with neighbouring molecules to create the approximately spherical particle. This 
effect is reduced as the length of the COOH-terminal tail is reduced, perhaps because 
it then causes less of an obstruction. 
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A COOH tail displayed on the surface of the particle also appears to be more 
disruptive than one present internally. It may be that as the mutations in the non-
fusion proteins are either subtle (C183S) or remove only a part of the protein known 
not to be essential for core particle formation, the overall effect of these mutations 
will be smaller than those in the fusion proteins. In the latter proteins the region 
known not to be important for particle formation is not merely removed but is 
substituted by a large number of foreign amino acids. This has been shown, 
previously, to alter the particle structure by presenting this region of the protein on the 
surface rather than the interior of the particle, in at least a proportion of the proteins 
(Stahl and Murray, 1989). 
The work presented here now demonstrates that there are further repercussions in the 
HBcAg-derived remainder of the fusion proteins in terms of disulphide bond 
formation, which reflects a difference in structure and stability. However, these 
differences can be compensated if a cysteine is present at the COOH-terminus of the 
fusion protein in which case the fusion region is still displayed, at least in part, on the 
particle surface, but the structure of the remainder of the particle is not affected and 
the particles are stable. As stability of recombinant vaccines is desirable, the inclusion 
of a cysteine residue at the COOH-terminus of the protein would be predicted to allow 
disulphide bond formation to occur to the extent of the wild-type HBcAg throughout 
the entire particle. This is likely to be true of most COOH-terminal fusion sequences 
as the highly-charged arginine-rich terminus of the wild-type protein, and the 
unremarkable preSl(1-20) sequences reacted in the same manner, with regard to 
disulphide bond formation, upon inclusion of a carboxy-terminal cysteine. Similarly, 
N-terminal fusions (Clarke et al., 1987; Beesley et al., 1990; Francis et al., 1990; 
Schoedel et al., 1992) and fusions within HBcAg (Borisova et al., 1989; Schoedel et 
al., 1992) may be made more stable by the retention of the native COOH tail with its 
cysteine residue. 
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CHAPTER 6: Conclusions 
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Work presented in this thesis has demonstrated that the amino- and carboxy-terminal 
regions of HBcAg and HBcAg-derived proteins are important for the structural 
integrity of the particles they form and that the disulphide bond pattern of HBcAg, 
determined during this work, is not essential for formation of core particles. 
The aim of the work presented in Chapter 3 of this thesis was to determine the reason 
for the low efficiency of interaction with antibody of the ammonium sulphate-
precipitated extract of the product of pRI-4 relative to the protein product of pRi-11, 
when the proteins differed by only two amino acids (amino acids 3 and 4 of HBcAg). 
The reasons for this were found to be two-fold. Firstly, the amount of each protein 
present differed and this is an example of the sensitivity of HBcAg to perturbation of 
its coding sequence, when expressed in E. coli, which has also been noted by others. 
Interestingly, a gradation of the amount of protein present was found in the panel of 
amino-terminus mutant proteins examined, from normal levels of protein to no 
detectable protein, with reduction in the levels of protein present having occurred only 
when amino acids 3, 4 or 5 were mutated. While mRNA was detected in all cases, 
even when protein was not detected, there may be different levels of core-specific 
mRNA present in cells transfected with different mutants as the PCR-based assay used 
is highly sensitive but not quantitative. Alternatively, there may be reduced efficiency 
of translation of certain mutants, possibly caused by unusual RNA structures. Finally, 
the protein products may be undesirable to the cell and consequently degraded. In 
summary, it is clear that levels of HBcAg-derived proteins produced in E. coli can 
vary enormously due to only minor alterations to the coding sequence. 
The role of the amino-terminus of HBcAg in core particle structure determination was 
also shown in Chapter 3. Proteins lacking amino acid 3 reacted less well with 
polyclonal anti-HBcAg/anti-HBeAg antibodies, relative to wild-type, while the other 
mutants examined reacted in a manner similar to wild-type. This may mean that 
deletion of amino acid 3 causes disruption of the structure of regions of HBcAg that 
react with antibody, either indirectly, or directly if amino acid 3 is contained within 
an antibody-binding site. In summary, the retention of amino acid 3 and possibly 
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amino acid 4, at least within the context of the proteins studied in this work, is not 
important for core particle formation but is important for the structure of these 
particles. 
Further investigation of the structure of core particles was presented in Chapter 4. The 
elucidation of the disulphide bond pattern of HBcAg during this work was used as a 
means of gaining information about the core particle structure, as cysteine residues 
between which a disulphide bond forms are necessarily very close. The following 
conclusions were drawn: 
100% of Cys 61 and at least 50% of Cys48 are at the interface between HBcAg 
subunits of core particles, as they form disulphide bonds with the equivalent cysteine 
residue on an adjacent molecule. 
HBcAg monomers appear to exist in at least two structural forms within the particle 
as approximately 50% of Cys48 is present in a disulphide bond while the remaining 
50% is not involved in a disulphide bond. Therefore each Cys48 is not in the same 
position in each molecule. 
Cys183 is also at an interface between HBcAg monomers but as it is thought to be 
inside the particle it may form an "inner shell" similar to that of the nucleocapsid of 
Tomato Bushy Stunt Virus. If this is indeed the case, it may also have the same 
function, in aiding correct formation of the "outer shell" of the nucleocapsid, as certain 
of the mutant proteins with an altered carboxy-terminus formed disulphide bonds in 
the remainder of the structure less readily than wild-type HBcAg. 
Cys107 may or may not be at an interface between HBcAg monomers. However, 
it can be said that it is not in the correct position relative to any other cysteines of the 
monomer or particle, to be able to form a disulphide bond with them. 
This work was taken further in the work presented in Chapter 5. Examination of the 
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disulphide bond pattern of core fusion proteins, once again using disulphide bond 
formation as an indicator of protein structure, showed that the nature of the carboxy-
terminal region of HBcAg has an effect on the fine structure of the remainder of the 
particle. While the reaction of anti-HBcAg antibodies with these proteins is not 
affected, relative to wild-type HBcAg (Stahl and Murray, 1989), fine structural 
alterations are apparent as there is a difference in disulphide bond formation. Thus, 
while particles of apparently normal morphology are formed by all fusion proteins 
examined, the structure of the particle is in fact affected by the nature of the carboxy-
terminus region. Possibly, in the fusion proteins in which the normal disulphide bond 
complement is not formed, the monomers have structure very similar to wild-type, and 
so react with antibody, but the monomers are held sufficiently apart by the abberrant 
carboxy-terminal region to prevent the close contact of the monomers in the core 
particle. 
In conclusion, the elucidation of the disulphide bond pattern of wild-type HBcAg has 
allowed more general conclusions concerning the particle structure to be drawn by 
investigation of disulphide bond formation in mutant proteins. While the stability of 
the structure is enhanced by the cysteine residues of HBcAg, the determination of the 
structure does not require these residues. As mutation of a cysteine codon to a serine 
codon requires only one nucleotide change, the fact that this has not occurred in vivo 
means that the presence of cysteine residues is essential for the virus. This work has 
excluded some possible reasons for this. Those that remain to be investigated include 
a role in the function of HBeAg, a role in infection of cells, or a role in maintaining 
the free energy of the particle at the optimum value for virus survival, which could 
be investigated only by examination of the viability of a virus lacking cysteines after 
very many rounds of infection. 
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Appendix: Nucleotide and amino acid sequence of the core gene of HBV subtype 
adyw 
The nucleotide sequence of the core gene of HBV subtype adyw (Pasek et al., 1979) 
is shown. Both strands of the DNA are shown, with the sense strand on top. 
Numbering is by the convention of Pasek et al. (1979) which sets number 1 at the 
start of the core ORF. The amino acid sequence of HBcAg is shown below the DNA 
sequence. 
AT6GACATTGACCCTTATAAAGAATTT6GA6CTACT6TGGTTACTCTC3TTTTTGCCT 
1 	 ----------------- oo 
MetAsp Ii eAspProlyrLysGl uPheGl yAl aThrVe.l 61 uLeuLeuSerPheLuPrQ - 
TCTGACTTCTTTCCTTCCSTACSAGATCTTCTAGATACCGCCGCAGCTCTGTATCGGGAT 




121 ---------+---------+--------+--------+---------+---------+ 180 
CSGAATCTCAGAGGACTCGTAACAAGTGGAGTGGTATGACGTGAGTCCSTTCGTTAAGAA 
Al aLuG1 uSrFrG1 uHi sCysSerProHi sHi s rhrAl aLeuArgGlnAl all eLeu - 





Cy.sTrpGl yAspLeuMetThrLeuAl aThrTrpVal 61 yThrAsrLeuG1 uAspProAl a - 
TCTAG6GACCTAGTAGTCAGTTATGTCAACACTAAT6T36GCCTAAAGTTCGACATTA.  
241 ---------+---------+---------+--------+---------+---------+ 00 
AGATCCCT6GATCATCAGTCAATACAGTTGTGATTAcACCC6GATTTCAAGTCTGTTAAT 
SerArAspLeuVa1 Val SerTyrVal AsnThrAsn Val 61 yLeuLysPheArgGl riLsu - 
TTGTGGTTTCACATTTCTTGTCTCACTTTTGGAAGA6AAAC6GTTCTAGAbTTTTSGT6  












481 ---------+---------+--------+---------+---------+---------+ 540 
GeI3AGCG6AGCGTCT6CTTCTAGAGTTAGCGGCGCP16CGTCTTCTAGAGTTAGAGCTT 
- 
TCTCPiATGT 
541 ---------549 
AGAGTTACA 
SerGlnCys - 
162 
